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Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor-β (TGF-β) family that signal via type I and type II serine/threonine kinase 
receptors and intracellular Smad transcription factors. BMPs are multifunctional 
regulators of development and tissue homeostasis and they were initially 
characterized as inducers of bone regeneration. Genetic studies in humans and 
mice showed that perturbations in BMP signaling lead to various diseases, such 
as skeletal diseases, vascular diseases and cancer. Mutations in BMP type II 
receptor and BMP type I receptor/activin receptor-like kinase 1 have been 
linked to pulmonary arterial hypertension and hereditary hemorrhagic 
telangiectasia, respectively. BMPs have also been implicated in promoting 
vascular calcification and tumor angiogenesis. In this review we discuss the role 
of BMP signaling in vascular diseases and the value of BMP signaling as a 
vascular disease marker or a therapeutic target. 
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Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor-β (TGF-β) family, which also includes TGF-βs, growth and 
differentiation factors (GDFs), anti-müllerian hormone (AMH), activins and 
nodal. BMPs were first identified as potent inducers of ectopic bone formation 
when implanted subcutaneously in rats (1, 2). Subsequent studies demonstrated 
that BMPs, as is the case for other TGF-β family members, are multifunctional 
regulators in development that regulate cell proliferation, differentiation, and 
apoptosis in different tissues (3, 4). BMPs exert their signals via type I and type 
II transmembrane serine/threonine kinase receptors. Inside the cell, Smad 
proteins play an important role in the transduction of the signal from the active 
receptor complex to the nucleus. Interestingly, misregulated BMP signaling has 
been shown to be involved in the pathogenesis of skeletal and (cardio) vascular 
disorders as well as cancer. Despite the recent advances in therapeutic 
interventions, cardiovascular disease remains the largest health problem 
worldwide causing morbidity and mortality. This review will focus on the role 




Among the 33 members of the TGF-β superfamily, over 20 molecules form the 
BMP subfamily. The BMP subfamily can be further subdivided into several 
subgroups, including BMP-2/4, BMP-5/6/7/8, GDF-5/6/7 and BMP-9/10 (4, 5). 
BMPs are synthesized as large precursor proteins consisting of an amino 
(N)-terminal signal peptide, a prodomain for folding and secretion, and a 
bioactive carboxy (C)-terminal mature peptide. BMP precursor proteins are 
produced in the cytoplasm as dimeric pro-protein complexes, which are cleaved 
by serine endoproteases (e. g. BMP-4 is cleaved by furin, PC6 and PC7 (6)) to 
generate N-terminal and C-terminal fragments, of which the latter is capable of 
binding to its receptor (7). Whereas the secretion of BMPs in a latent inactive 
form is not common (7), TGF-β is secreted as a latent form in which the 
N-terminal remnant, also known as latency associated peptide (LAP), sequesters 
and prevents the bioactive mature part from binding to its receptors. This 
complex is also associated with the latent TGF-β binding proteins (LTBP). Thus, 
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proteolytic cleavage of latent TGF-β by different activators is required for the 
release of the mature, active TGF-β (8). 
    BMP activity is also regulated by several intracellular and extracellular 
modulators. A large number of extracellular soluble antagonists bind BMPs and 
block their interaction with signaling receptors, thus dampening BMP signaling 
(9). These antagonists can be divided into three subgroups based on their 
structure similarity: the CAN (Cerberus/DAN) family, twisted gastrulation, 
chordin and noggin. The CAN family includes gremlin and cerberus, 
differential screening-selected gene aberrative in neuroblastoma (DAN), protein 
related to DAN and cerberus (PRDC), coco, uterine sensitization-associated 
gene-1 (USAG-1) and sclerostin (10). Several additional BMP regulators have 
been identified, such as cross-veinless 2 [CV2, also referred to as BMP 
endothelial cell precursor derived regulator (BMPER)], matrix GLA protein 
(MGP) and neogenin (11-14). MGP is a small, carboxyglutamic acid modified 
protein, which can bind and inhibit BMP-2 and BMP-4 by direct protein 
interaction (12, 15, 16). It is highly expressed in kidneys and lungs, where 
excessive MGP in MGP-transgenic mice altered pulmonary BMP-4 distribution 
and resulted in significant morphological defects in the pulmonary artery tree 
(17). Neogenin was identified as a receptor for netrins and proteins of the 
repulsive guidance molecule (RGM) family. The interaction of netrins-neogenin 
or RGM-neogenin stimulated or repelled neuronal axon guidance depending on 
the developmental context (18, 19). Recent research suggested that neogenin is 
a regulator of BMP signaling during chondrogenesis and skeletal development, 
since there is reduced expression levels of BMP target genes and intracellular 
BMP signaling mediators in chondrocytes from neogenin mutant mice, and the 
neogenin-deficient mice is retarded in digit/limb development and endochondral 
ossification (13). However, others reported that neogenin acts as a repressor of 
BMP signaling and knockdown of neogenin in C2C12 cells leads to increased 
BMP-2-induced phosphorylation of Smad1, Smad5, and Smad8 and osteoblast 
differentiation (14). The expression pattern of BMP antagonists is important for 
embryonic development, as an aberrant expression pattern can lead to defects in 
bone, limb and kidney formation (20). 
 
BMP receptors 
Like other members of the TGF-β family, BMPs bind to two types of 
serine-threonine kinase receptors, known as type I and type II receptors (21, 22). 
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Both receptors share a similar structure and are comprised of a short 
extracellular domain, a single transmembrane domain and an intracellular 
domain with serine-threonine kinase activity. The affinity of BMPs for type I 
receptors is higher than for type II receptors and its affinity is increased by the 
formation of a heterotetrameric receptor complex (23). The type II receptor 
kinase is constitutively active in the absence of ligand. BMP type II receptor 
(BMPR2) has a long C-terminal tail rich in serine and threonine residues (23). 
Besides BMPR2, BMPs can signal also via the activin type II receptors 
ACVR2A, and ACVR2B (4, 24), which are expressed in various tissues. 
Whereas BMPR2 is a specific receptor for BMPs, ACVR2A and ACVR2B also 
can be used by activins, myostatin and nodal. Based on the structural similarity, 
BMP type I receptors can be divided into two subgroups: activin receptor-like 
kinase 3 (ALK3, or BMPR-IA) and ALK6 (BMPR-IB) group, and the ALK1 
and ALK2 group. While ALK2 and ALK3/6 are widely expressed in various 
cell types, ALK1 has a more selective expression pattern being mainly restricted 





Fig. 1. Schematic overview of the BMP signaling pathway. BMPs interaction with 
surface receptors induces heteromeric complex formation between specific type II and 
type I receptors. This activity is regulated by extracellular regulators and type III 
receptors/Co-receptors. After being activated by type II receptors, the type I receptors 
phosphorylate Smad1/5/8 (R-Smads) to propagate the signal into the cell. Smad1/5/8 
form heteromeric complexes with Smad4 (Co-Smad) and translocate to the nucleus 
where, by interacting with other transcription factors, they regulate target gene 
expression (canonical Smad signaling pathway). I-Smads (Smad6/7) inhibit receptor 
activation of R-Smads. Besides Smad-depend signaling, non-Smad pathways are 
involved. Activated MAPKs can regulate R-Smad activation by a direct 
phosphorylation or through their downstream effectors molecules. Activated MAPKs 
can translocate to the nucleus to phosphorylate a number of transcription factors (TF), 
such as serum response factor (SRF), ternary complex factor (TCF) family members, 
activator protein 1 (AP1) complexes and activating transcription factor 2 (ATF2), 
thereby changing target gene transcription. 
 
    A number of BMP co-receptors have been identified. These co-receptors 
modulate the interactions between BMP ligands and receptors. There are two 
co-receptors, endoglin and betaglycan, which play important roles in vascular 
development and disease, although they lack a signaling domain (25). Endoglin 
and betaglycan can potentiate BMP signaling (26, 27). BMPs can also bind to 
the decoy receptor BMP and activin membrane-bound inhibitor (BAMBI). 
BAMBI resembles the type I receptors but lacks an active kinase domain and 
consequently sequesters ligands from the active receptors and inhibits BMP 
signaling (28). Family members of RGM, RGMa, RGMb (DRAGON) and 
RGMc, were shown to be implicated in BMP signaling (29-31). DRAGON was 
the first RGM family member identified as a BMP co-receptor (30). Cell 
surface GPI-anchored DRAGON directly binds to BMPs enhancing BMP 
signaling, but not TGF-β. Moreover, this effect can be reduced by noggin (30). 
Interestingly, DRAGON interacted directly with all BMP type I receptors as 
well as BMPR2, ActRII and ActRIIB (30). Furthermore a soluble form of 
DRAGON fused to Fc (DRAGON-Fc) inhibited BMP signaling in vitro (30, 32). 
It is possible that RGM proteins modulate the ability of cells responding to a 
low concentration of BMP ligands by altering the sensitivity of BMPR2 to BMP 
ligands. However, the precise mechanism by which RGM proteins regulate 




Smad and non-Smad signaling pathways 
After BMP ligand-induced heteromeric complex formation, the type II receptor 
kinase phosphorylates the type I receptor. Subsequently, the activated type I 
receptor initiates intracellular signaling by activating the Smad proteins. Smads 
can be divided into three groups: receptor-regulated Smads (R-Smads), 
inhibitory Smads (I-Smads), and a common mediator Smad (i.e. Smad4) (21). 
Upon type I receptor-mediated phosphorylation/activation of R-Smads, they 
form heteromeric complexes with Smad4. These heteromeric R-Smad/Smad4 
complexes translocate into the nucleus, where they regulate target gene 
expression by directly binding to Smad-binding elements (SBE), or indirectly 
through interactions with DNA-binding transcription factors, and by associating 
with co-activators/co-repressors and histone-modifying factors (34). Inhibitory 
Smads (I-Smad6 and 7) antagonize BMP and TGF-β receptor-initiated Smad 
signaling by mediating the degradation of receptors and R-Smads. Smad7 
inhibits all TGF-β family members, while Smad6 is more selective towards 
BMP family members. Smad ubiquitin ligases Smurf1 and Smurf2 are recruited 
by I-Smads to promote the proteasomal degradation of receptors and Smads 
(35-37).     
    Besides canonical BMP receptor/Smad signaling, activated BMP receptors 
can initiate non-Smad signaling pathways. MAP kinases (ERK, JNK and p38 
MAPK), phosphoinositide (PI) 3 kinase/Akt and protein kinase C (PKC) 
signaling pathways, and Rho-GTPases can also be activated by BMPs and 
TGF-βs in various cells (38). These non-Smad pathways are also important in 
creating diversity and fine-tuning of signals generated by the TGF-β family 
ligands (39, 40). Smad-independent pathways can also be involved in the 
pathogenesis of vascular diseases, such as in pulmonary arterial hypertension 
(PAH), which will be discussed later.  
 
BMP signaling during vessel development 
The establishment of the vascular system is an important event during 
embryonic development. Neovascularization involves two mechanisms: first the 
de novo formation of vessels termed vasculogenesis, and second, the sprouting 
and growth of new vessels from pre-existing ones, known as angiogenesis (41). 
Angiogenesis is a crucial process, which occurs primarily during embryonic 
development, and it is almost absent during adulthood besides wound healing, 
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inflammation and the female reproductive cycle. In healthy tissues, blood 
vessels are formed by a combination of several mechanisms, such as sprouting 
angiogenesis, bone-marrow derived and/or vascular-wall-resident endothelial 
progenitor cells (EPCs) differentiation, and vessel splitting (41). Main players 
in the process of angiogenesis are the endothelial cells (ECs) as well as smooth 
muscle cells (SMCs) and pericytes. EC proliferation, migration and tube 
formation are critical in the process of angiogenesis. Sprouting angiogenesis 
involves the selection of a leading migrating tip EC that invades the 
surrounding tissue by extending numerous filopodia. VEGF/VEGFR2 signaling 
triggers single EC to switch into a tip cell phenotype; these cells thereby express 
Delta-like 4 (Dll4), a Notch ligand, which instructs neighbor ECs to become 
so-called stalk cells (42). Stalk cells trail behind the tip cells proliferate and 
form tubes; stalk cell proliferation ensures elongation of sprouting vessel (43, 
44). Ultimately ECs stop proliferating, acquire a quiescent phenotype and 
become phalanx ECs. Finally, the new formed vessel is stabilized by deposition 
of basement membrane and recruitment of pericytes/SMCs (45). Interestingly, it 
has been reported that besides ECs, tumor cells can also contribute to 
angiogenesis. It has been suggested that cancer cells with stem cell features can 
dedifferentiate and acquire an EC-like phenotype. These cells can incorporate in 
the blood vessels and contribute to angiogenesis (41, 46).  
    The role of BMP signaling in vascular development has been illustrated by 
studies in knockout animal models (47). Table 1 (see below and references 
therein) shows a list of mouse knockout models for BMP signaling components, 
including ligands, receptors and Smads. Genetic deletion or misexpression of 
different components of BMP signaling leads to embryonic death due to 
cardiovascular malformations and defects in vascular remodeling. Moreover, 
proper BMP signaling in both ECs and mural/SMCs has been shown to be 
required for appropriate vasculogenesis and angiogenesis. Interestingly, deletion 
of the BMP target genes Id1 and Id3 in mice leads to impaired angiogenesis 
both in brain and tumor xenografts (48).  
    It has been reported that BMP-2, -4, -6 and -7 induce angiogenesis, EC 
proliferation and migration (49, 50). Capillary tube formation is increased upon 
activation of the BMP signaling pathway by overexpression of BMPs or Id1 (51, 
52). In contrast, BMP-9 inhibits basic fibroblast growth factor 
(bFGF)-stimulated proliferation and migration of bovine aortic endothelial cells 
(BAECs) and blocks VEGF-induced angiogenesis [36]. BMP-9 has also been 
CHAPTER 1 
16 
reported to inhibit the migration and growth of human dermal microvascular 
ECs [37]. Although (high dose) BMP-9 seems to have inhibitory effects on ECs, 
another report demonstrated that (low dose) BMP-9 induces proliferation of 
various types of ECs in vitro and promoted angiogenesis in matrigel plug assays 
and human pancreatic cancer xenografts in vivo (53). It is likely that BMP-9 has 
disparate effects on ECs depending on the cellular context and concentration of 
BMP-9. The effects of BMPs on ECs can be regulated by various BMP 
antagonists and modulators as well. For example, BMPER is an extracellular 
matrix protein expressed by ECs, which was shown to modulate BMP-4 activity 
in a concentration-dependent manner, and to exert proangiogenic effects in 
vascular ECs (54). Interestingly, MGP gene deletion in mice leads to 
misregulated BMP signaling and as a result in arteriovenous malformation 
(AVMs) in lungs and kidneys (55). Thus, selective BMP family members can 
stimulate and/or inhibit angiogenesis. Besides, BMP-induced signaling in ECs 
response can switch from stimulation to inhibition when co-stimulated with 
other signals, e. g. Notch (56). As mentioned earlier, Notch was shown to have 
an important role in stalk cell determination. Recently, Moya et al. reported that 
endothelium-specific inactivation of Smad1/Smad5 in mouse embryos 
decreased Notch signaling and increased numbers of tip cells. In HUVECs 
downregulation of Smad1/5 reduced the expression of Notch target genes Hes1 
and Hey1, and other stalk cell specific transcripts (57), In addition, Larrivée et 
al. showed that ALK1-dependent SMAD signaling collaborated with Notch 
signal to induce expression of HEY1 and HEY2 in stalk cells, which would 
limit the response of stalk cells to VEGF and thus reduce endothelial tip cell 
formation and sprouting (58). 
    A lot of research has focused on ECs due to their role in the formation of 
new vessels. However, research showed that SMCs are also involved in the 
maturation of the new-formed vessels, as well as in vascular diseases. In 
addition to their effects on EC function, BMPs were also shown to play key 
roles in SMC differentiation and function. BMPs have been shown to inhibit the 
proliferation of vascular SMC while enhancing the differentiation of these cells 
(59-61). BMP-2 inhibits the proliferation of cultured rat arterial SMCs in the 
presence of serum and injury-induced intimal hyperplasia in the in vivo rat 
carotid artery balloon injury model by inhibiting SMC proliferation without 
stimulating extracellular matrix synthesis (61). BMP-7 inhibits primary human 
aortic SMC proliferation in serum-stimulated conditions, as well as upon 
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induction with platelet-derived growth factor subunit BB (PDGF-BB) and 
TGF-β1, and maintains the expression of the vascular SMC phenotype. 
Furthermore, anti-inflammatory activities have been attributed to BMP-7 
suggesting that BMP-7 may play an important role in maintaining vascular 
integrity (59, 62). BMP-4, however, is expressed by ECs in response to hypoxia 
and it promotes vascular SMC proliferation (63). It has been demonstrated that 
vascular SMCs isolated from different parts of the pulmonary vasculature have 
different proliferation responses to BMP-4. Whereas the proliferation ability of 
human pulmonary arterial SMCs isolated from proximal pulmonary arteries is 
inhibited by BMP-4, the proliferation of human pulmonary artery SMCs from 
peripheral arteries is increased by BMP-4 (64). In summary, similarly to ECs, 
the effects of BMPs on vascular SMCs depend on the source of cells and the 
culture condition.  
 
BMP signaling pathway in vascular diseases 
The critical role of BMP signaling in vascular function was further corroborated 
by genetic studies in human (65). Genetic analysis revealed that mutations in 
genes of the BMP signaling or genes which affect BMP signaling function lead 
to vascular dysfunction and disease such as hereditary hemorrhagic 
telangiectasia (HHT) and pulmonary arterial hypertension (PAH), vascular 
calcification, and tumor angiogenesis. In addition, disturbance of vascular 
homeostasis due to vascular injury, hypertension or atherosclerosis was shown 
to affect the expression of BMPs, thereby suggesting a role of BMPs in 
abnormal vascular responses (65).  
 
1.1. Pulmonary arterial hypertension 
PAH is a disease characterized by elevated pulmonary artery pressure leading to 
heart failure. Processes underlying PAH include abnormal remodeling of small 
peripheral vessels in the lung, due to aberrant proliferation and migration of 
vascular SMCs, ECs and fibroblasts (66). Two types of PAH have been 
described: sporadic or idiopathic PAH (IPAH) and hereditary or familial PAH 
(FPAH). Heterozygous germ line mutations in BMPR2 are found in more than 
70% of patients with FPAH and 20% of patients with IPAH (67, 68). Mutations 
have been found in various regions of BMPR2, including the ligand-binding 
domain, the kinase domain, or the long cytoplasmic tail. Mice expressing a 
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BMPR2 tail domain mutation in pulmonary SMCs develop vascular lesions 
similar to PAH (69). Non-sense mutations in the C-terminal tail of BMPR2 were 
identified also in some FPAH patients, suggesting that this region might play an 
important role in BMP signaling (67, 68). Heterozygous and homozygous 
BMPR2 deletion specifically in pulmonary ECs and pulmonary SMCs 
mimicked the PAH phenotype (69, 70). Endothelial injury and enhanced 
inflammatory responses may contribute together with BMPR2 heterozygosity to 
the development of PAH (71). Interestingly it was shown that disruption of 
BMPR2 expression in PASMCs leads to reduced BMP-2 and BMP-4 signaling, 
while signaling by BMP-6 and BMP-7 is enhanced (72). It was shown that 
reduced BMP/Smad signaling resulted in activation of the p38 MAPK pathway, 
leading to aberrant PASMC proliferation (64, 73, 74). A recent report suggested 
that lack of endothelial nitric-oxide synthase (eNOS) due to BMPR2 mutations 
in pulmonary artery ECs (PAEC) may contribute to the pathogenesis of PAH. 
BMP-2 and BMP-4 cannot activate eNOS in BMPR2 knockdown cell lines or in 
PAEC from BMPR2 gene mutations patients and inhibition of NOS activity 
inhibited BMP-2 and BMP-4 stimulated PAEC migration (75). 
    Mutations in SMAD8 have also been reported in PAH patients (76). In 
addition, loss of Smad8 function in mice results in abnormal vascular 
remodeling and increased vascular inflammation (77). It was demonstrated that 
SMAD8 mutation leads to vascular cell proliferation in HPAH, due to decreased 
expression of specific micro RNAs (miR) miR-21 and miR-27a in pulmonary 
artery ECs and pulmonary artery SMCs from tissues of PAH patients (78). 
Additionally, overexpression of Smad8 resulted in increased expression of miRs 
and reversed the hyper-proliferative phenotype (78). Interestingly, certain 
HHT2 patients develop PPH-like syndromes, suggesting that ALK1 mutations 
can also be involved in PPH (79, 80). Moreover alk1
+/−
 mice display increased 
pulmonary vascular remodeling which may lead to signs of PAH. This was 
shown to be associated with eNOS-dependent reactive oxygen species (ROS) 











Animal model Human disease References 
 
Bmp-2 KO: Embryonic lethal with defect in cardiac 
development; 
Het: Susceptible to hypoxic pulmonary hypertension 
associated with reduced endothelial nitric oxide 
synthase (eNOS) expression 
unknown (82, 83) 
Bmp-4  Het : Less severe hypoxic pulmonary hypertension and 
vascular smooth muscle cell proliferation, impaired 
vascular remodeling 
unknown (63) 
Bmpr2 Het: Pulmonary hypertension PAH (69, 70, 84, 85) 
Alk1 KO: Embryonic lethal (E10.5), severe vascular 
abnormalities; Het: Models HHT type 2; EC 
conditional KO: Severe vascular malformations 
mimicking all pathologic features of HHT. 
HHT (86-89) 
Alk3 Mesoderm conditional KO: Embryonic lethal (E10.5- 
E11.5), hemorrhage, impaired vessel remodeling; 
SMC (embryo): Embryonic lethal (E11) due to vascular 
and pericardial hemorrhage, impaired vascular 
remodeling; 
SMC (adult): Impaired vascular remodeling 
unknown (90-92) 
Endoglin KO: Embryonic lethal (E10.5) due to impaired mature 
vessel formation;  
Conditional mutation: AVM 
HHT (93, 94) 
Smad1 KO: Embryonic lethal (E9.5) due to defects in allantois 
formation; with impaired embryonic circulation system 
unknown (95) 
Smad4 EC conditional KO: Embryonic lethal (E10.5) due to 
cardiovascular defects 
HHT (with or 
without JP) 
(96-98) 
Smad5 KO: Embryonic lethal (E9.5-E11.5) due to cardiac and 
angiogenesis defects 
unknown (99, 100) 
Smad6 KO: Cardiovascular defects, vascular calcification, 
hypertension 
CVM (101, 102)  
Smad7 KO: Embryonic lethal due to cardiovascular defects  unknown (103) 
Smad8 Smad8 mutation mice: Defective pulmonary vascular 
remodeling 
PAH (77) 
Abbreviations: KO, knockout; het, heterozygous; JP, juvenile polyposis; CVM, 
congenital cardiovascular malformation. 
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1.2. Hereditary hemorrhagic telangiectasia 
Mutations in the ALK1 gene have been reported in some PAH patients (79). 
ALK1 mediates both TGF-β and BMP-9 signaling in ECs. Interestingly, 
mutations in ALK1 lead to another vascular disease related to deregulated BMP 
signaling, HHT. HHT is an autosomal dominant disease and is associated with 
telangiectases in skin and mucosa, frequent epistaxis, and the presence of 
AVMs in the lung, liver or brain (104). HHT type 1 (HHT1) results from 
pathogenic mutations in ENG that lead to haploinsufficiency of endoglin (105), 
while HHT type 2 (HHT2) is caused by loss of function or dominant negative 
mutations in ALK1 (106, 107). Interestingly mice heterozygous for acvrl1 
(alk1), tβr1 (alk5), tβr2 and eng develop vascular abnormalities highly 
reminiscent of those described in patients with HHT (25, 50). Several studies 
have provided evidence that haploinsufficiency of the HHT genes both in ECs 
and SMCs leads to abnormal EC proliferation and SMC recruitment. As a result, 
vascular abnormalities and fragile leaky vessels occur, together with the 
generation of telangiectasias and AVMs (108, 109). In addition, disrupted 
Notch signaling has been reported to correlate with AVMs (110), and ChIP-seq 
analyses on human umbilical vein ECs (HUVECs) and pulmonary arterial 
SMCs pretreated with BMPs have demonstrated JAG1 as a direct target of 
Smad1/5 (111). Another report showed that human polymorphic variants of 
tyrosine-protein phosphatase non-receptor type 14 (PTPN14) influences the 
severity of pulmonary arteriovenous malformation acting via ALK1 and 
EphrinB2, which suggested that PTPN14 may also be involve in the 
pathogenesis of HHT (112).  
 
1.3. Atherosclerosis and vascular calcification 
Atherosclerosis is a chronic arterial wall disease that is characterized by chronic 
inflammation and the accumulation of atheromatous lesions in the inner layer of 
arteries. BMPs have been implicated in atherosclerosis progression by 
regulating endothelial inflammation and cell differentiation. BMP-2 and -4 have 
been shown to induce proinflammatory effects in the ECs (113, 114). Besides, 
inhibiting BMP signaling pathway by MGP resulted in reduced atherosclerotic 
lesions formation in apolipoprotein (Apo) E knockout mice, while enhanced 
BMP activity led to increased atherosclerotic lesions formation in Apo E 
knockout mice (113, 115). Atherosclerosis is the most common cause of aortic 
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aneurysms, a vascular disease which attributes to misregulation of TGF-β 
signaling (116, 117). However, Jones et al. showed that in 2-week post thoracic 
aortic aneurysms induction mice, the expression level of BMP signal 
components and BMP regulators were elevated in mRNA level, indicating that 
activation of BMP signaling may also be involved in the pathogenesis of aortic 
aneurysms (118). 
    One key histological and clinical event of atherosclerosis is vascular 
calcification, which is known as the abnormal deposition of calcium phosphate 
salts in blood vessels, myocardium, and cardiac valves. Vascular calcification is 
a tightly regulated process which leads to differentiation of cells such as SMCs 
or pericytes into osteoblast-like cells, and the mineralization of the extracellular 
matrix (119). It is speculated that the course of vascular calcification shares 
many similarities with that of bone mineralization (120). Pericytes, 
mesenchymal stem cells, multipotent cells from the adventitia, resident cells in 
the media or intima and trans-differentiated SMCs, are the possible cells which 
transdifferentiate into osteoblast-like cells in blood vessels (121-124). It has 
been suggested that vascular endothelial cells may contribute to osteogenic 
differentiation (125); ECs can transdifferentiate into mesenchymal stem cells 
through a process termed endothelial to mesenchymal transition (EndoMT) 
(126-128). Interestingly, in fibrodysplasia ossificans progressiva (FOP), a 
disease characterized by overactive osteoblasts and ectopic bone formation and 
linked to a point mutation in BMP type I receptor ALK2 (129), it was shown 
that ECs can acquire a progenitor-like phenotype and differentiate into bone 
forming osteoblastic cells (125).  
    BMPs expression is increased at vascular calcification sites; in addition 
BMPs can trigger the differentiation of multipotential cells into the osteogenic 
lineage. This raises the possibility that BMPs may be involved in the process of 
vascular calcification (130-134). Indeed it was shown that BMPs can direct 
osteogenic programming of vascular mesenchymal progenitors of the pericyte 
lineage (132) and that they can promote expression of osteoblast lineage 
markers such as alkaline phosphatase in cultured vascular SMCs (115, 119, 120, 
135-137). Cheng et al. showed that BMP-2 and the osteoblast homeoprotein 
Msx2 were expressed during the osteogenic process in the aorta of diabetic 
patients. The BMP-2-Msx2 signaling pathway may enhance vascular 
calcification by promoting the differentiation of myofibroblasts into the 
osteogenic lineage (138). In addition BMP-2 enhances the expression of Runx2, 
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a core transcription factor that is known to regulate osteoblast and chondrocyte 
differentiation and promote vascular SMCs calcification by increasing oxidative 
stress and endoplasmic reticulum (ER) stress in human coronary artery SMCs. 
Interestingly, the inhibition of oxidant stress or ER stress reversed this gene 
expression pattern and mineralization process (139). Moreover, recent research 
showed that BMPs are involved in vascular calcification in low-density 
lipoprotein (LDL) receptor-deficient (LDLR-/-) mice. Blockade of BMP type I 
receptor function by using either the small molecule inhibitor LDN-193189 or 
ALK3-Fc in LDLR-/- mice inhibited high-fat diet-induced vascular 
inflammation as well as osteogenic activity and calcification, thus suggesting 
BMP inhibition as a potential treatment for vascular calcification.  
    BMP signaling antagonists have been also implicated in vascular 
calcification. Research suggested that MGP might influence vascular 
calcification by modulating the effect of BMP-2. In C3H10T1/2 cells, MGP 
overexpression inhibited BMP-2 induced osteogenic and chondrogenic 
differentiation, whereas lack of MGP enhanced these differentiation processes 
(140). Notably, it was shown that transgenic expression of MGP in ApoE
−/−
 
mice results in diminished Smad1/5/8 signaling and reduced inflammation, 
lesion formation, and calcification after fat feeding (115). On the other hand 
MGP deficient ApoE
−/−
 mice displayed enhanced Smad1/5/8 signaling and 
extensive medial calcification (115). However, recent research showed that 
MGP can inhibit calcification in a BMP-2 independent manner in intact vessels 
and lack of GlaMGP (carboxylated MGP) was not the reason for medial 
calcification in rat renal failure model (141).  
As mentioned earlier the inhibitory Smad6 interferes specifically with the 
BMP pathway. Interestingly, perturbation of Smad6 expression was found to be 
associated with calcification of the aortic valve. In human aortic valve (AV), 
high levels of BMP antagonists (noggin and CV-2/BMPER) and Smad6 were 
detected in the ventricular endothelium, while low levels of such inhibitors were 
found in the fibrosa endothelium. This uneven distribution was shown to be 
responsible for the side-dependent calcification of human AVs (142). In 
addition, mutations in the Smad6 gene were found to predispose to congenital 
cardiovascular malformation. The capacity of Smad6 to inhibit BMP-induced 
osteogenic differentiation was significantly decreased by a C484F mutation in 
Smad6 (102). Thus, BMPs may be important in the pathology of vascular 
calcification, even though definitive evidence supporting this is still lacking. 
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1.4. Tumor angiogenesis 
Tumor growth beyond 2-3 mm in size makes diffusion insufficient to supply 
tumor cells with oxygen and nutrients and for the removal of the waste products 
(143). Angiogenesis, i.e. the formation of new blood vessels from pre-existing 
ones, is then needed for the tumors to grow. In addition, blood vessels provide 
the main route for metastatic spread (143). Several inhibitors of angiogenesis, 
such as bevacizumab (monoclonal antibody targeting VEGF) and sorafenib and 
sunitinib (tyrosine kinase inhibitors) have been used for the treatment of solid 
tumors (144, 145).  
BMPs have been found misexpressed in gastric, ovarian, prostate, 
pancreatic breast, lung and colon tumors (146-152). BMP-2 and BMP-4 were 
shown to favor angiogenesis by stimulating the secretion of pro-angiogenic 
growth factors, such as VEGF (52, 153). In the case of lung cancer, BMP-2 is 
highly expressed in the majority of patient-derived lung carcinomas (154) and 
recombinant BMP-2 potently increases the size and number of blood vessels in 
tumors formed by A549 cells in nude mice (155). Moreover, either recombinant 
noggin or an anti-BMP-2 antibody could inhibit the activity of BMP-2, resulting 
in a significant reduction in tumor growth (154). Besides BMP-2, other BMPs 
have also been reported to be involved in tumor angiogenesis. Rothhammer et 
al. showed that BMP-2 and BMP-4 are highly expressed in malignant 
melanomas, and they promoted cell invasion and migration of microvascular 
endothelial cells. Moreover, ECs have a reduced tube formation capacity when 
BMPs activities were inhibited (156). BMP antagonist chordin has been 
reported to inhibit in vitro BMP-4 induced tube formation in malignant 
melanoma cells (156).  
ALK1, a type I receptor for TGF-, BMP-9 and BMP-10 have received a 
lot of attention recently as an anti-angiogenesis target. A recent study indicated 
that ALK1 is widely expressed on prostate, skin, thyroid, kidney, ovary, lung, 
pancreas, and liver tumor blood vessels (157, 158). ALK1 is mainly expressed 
in developing arterial endothelial cells and is greatly reduced in adult arteries. 
However, ALK1 expression can be induced during tumor angiogenesis (158, 
159). It has been suggested that ALK1 signaling and function in ECs may 
depend on multiple proangiogenic factors (including VEGF and bFGF), and 
BMP-9-induced (tumor) angiogenesis can be specifically inhibited by an ALK1 
antibody (anti-ALK1) (157). Besides, anti-ALK1 can decrease tumor growth 
and angiogenesis when combined with VEGF receptor inhibitor in 
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human/mouse chimera tumor model (157). Other research described that a 
soluble chimeric protein (ALK1-Fc) which serves as BMP-9 (and -10) ligand 
trap, can inhibit (tumor) angiogenesis by interfering with ALK1 signaling both 
in vitro and in vivo (158, 160). Therefore, targeting ALK1 may effectively 
inhibit tumor angiogenesis and it is therefore a promising therapeutic strategy 
for cancer patients. 
    Endoglin plays a crucial role in EC function. Studies in mice revealed that 
tumor growth and angiogenesis is reduced in endoglin-haploinsufficient mice 
(161). In addition endoglin neutralizing antibodies have been used for vascular 
targeting and it was shown that they can inhibit both endothelial cell 
proliferation and tumor growth in mouse cancer models (25). It is known that a 
soluble form of endoglin (sol Eng) contributes to the pathogenesis of 
preeclampsia (25). Research showed that a fusion protein, which combined the 
endoglin extracellular domain (ECD) and immunoglobulin Fc domain, can 
significantly reduce VEGF induced angiogenesis in vitro and ex vivo (162), 
presumably by specifically binding to pro-angiogenic BMP-9 with a high 
affinity. These results suggest that endoglin-Fc may be used as a potential 
anti-angiogenesis therapeutic agent (163). Since the process of angiogenesis is 
tightly regulated by BMPs, a further understanding of their molecular 
mechanisms will provide opportunities for better diagnosis and development of 
new therapies targeting angiogenesis, tumor growth, and metastatic spread of 
disease. 
 
Conclusions and perspective 
BMP signaling plays a crucial role in cardiovascular homeostasis and disease. 
Genetic studies in mice indicate that components of BMP signaling are involved 
in EC and SMC interactions, EC function and angiogenesis. The knowledge 
regarding the role of BMP signaling in vascular diseases and cancer has mainly 
come from mouse models and clinical investigations. However, definitive 
evidences from functional studies in human tissues are still rare. Genetic mouse 
model studies showed that BMP function might depend on cell type and 
environment, but the availability of human tissues and the limited life span of 
patient-derived somatic cells limit the development of this research area. The 
use of induced pluripotent stem cells (iPSCs) technology could help to 
overcome these limitations (164-166). Generated iPSCs from human skin 
fibroblasts, keratinocytes, adipose stem cells and lymphocytes (167-169), can be 
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differentiated into various cell types (170), including ECs and SMCs (171). It is 
possible to utilize this new technology to generate ECs and SMCs from patients 
with vascular disorders (and from healthy volunteers) in order to investigate the 
pathology of vascular diseases and perhaps transplant cells to cure patients 
(172), or perform screens to identify small chemical compounds to rescue 
disease phenotypes. Of interest, the BMP receptor antagonist dorsomorphin and 
its more selective derivative LDN-193189 have recently been reported to inhibit 
BMP signaling (173, 174). Yu et al. found that dorsomorphin selectively 
inhibited the BMP type I receptors ALK2, ALK3 and ALK6 and blocked 
BMP-mediated SMAD1/5/8 phosphorylation (173). In addition, an optimized 
compound (LDN-193189 or DM-3189) with higher activity and specificity for 
BMP type I receptors has been developed from a structure-activity relationship 
study of dorsomorphin (174). The ongoing development of small molecule 
inhibitors/activators of BMP signaling will offer new opportunities for 
manipulating BMP signaling in therapeutic means. This will benefit future 
therapy of BMP related diseases caused by insufficient BMP signaling, such as 
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Part II: BMP signaling in fibrodysplasia ossificans progressiva 
(FOP) 
During embryonic development there are two mechanisms for creating bone 
tissues: endochondral ossification and intramembranous ossification (176). 
Bone undergoes constant remodeling by osteoclasts that degrade and by 
osteoblasts that form bone. This dynamic process is highly regulated by many 
regulators, especially by BMPs. For instance, BMP2 and BMP4 induce bone 
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and cartilage formation by stimulating osteoblast and chondrocyte 
differentiation.  
    The knowledge about this critical role of the BMP signaling pathway in 
bone and cartilage formation was initially mainly obtained from transgenic 
animal models. Overexpression of the negative BMP regulator Noggin in 
transgenic mice resulted in severe defects in cartilaginous components (177). 
Knockout of Bmp2 in chondrocytes showed defects in chondrocyte phenotypes 
(178), while overexpression of Bmp4 in the skeleton leaded to an increase of 
cartilage production and enhanced chondrocyte differentiation in mice (177). In 
addition, BMP receptors regulate bone formation (179). Furthermore, the 
downstream Smad pathway is involved in bone development; for instance, 
osteoblast-specific Smad1 knockout mice showed impaired osteoblast 
proliferation and differentiation (180). In addition, multiple human diseases 
with skeletal defects have been linked to mutations in BMP signaling 
components.  
Clarifying the role that the BMP signaling pathway plays in bone and 
cartilage formation helps us to understand the pathologies of BMP related bone 
diseases. Fibrodysplasia ossificans progressiva (FOP) is a rare disease known 
by its progressive heterotopic ossification (HO) in soft tissues, caused by 
gain-of-function mutations in ALK2 (181). In the first decade of life, most FOP 
patients develop painful and highly inflammatory soft tissue swellings, which 
transform the soft tissues into bone through endochondral ossification processes 
(182, 183). Most FOP patients have an R206H mutation in the GS domain of 
ALK2. The R206H mutation was shown to interferes with the binding of the 
negative regulator FKBP12 to ALK2 and leads to the leakage of BMP signaling 
in the absence of BMP ligands (184). The prevalence of FOP is about 1 in 2 
million. FOP patients appear normal at birth apart from malformation of the 
great toe (182).  
There is currently no cure for FOP. Surgical removal of the ectopic bone 
tissue is risky as the surgical trauma might induce the formation of new 
heterotopic bone. The recurrent mutations in ALK2 may provide a specific 
target to prevent HO in FOP patients. LDN-193189, a BMP type I receptor 
kinase inhibitor, was reported to reduce ectopic ossification in transgenic mice 
carrying an inducible constitutively active ALK2
Q207D
 gene (185). However, 
although LDN-193189 is a potent inhibitor of BMP signaling at higher dosages, 
it inhibits TGF-β signaling as well. The newer ALK2 inhibitor LDN-212854 
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showed selective inhibition towards the ALK2 receptor and had comparable 
inhibitory effects in vivo as LDN-193189 (186). Strategies to block ALK2 
activity by genetic tools, including antisense therapy and RNA interference 
were also reported (187-189). Identification of new therapeutic tools for FOP 
could also be useful for other situations, for instance, it may help to cure of 
nongenetic forms of HO which occur after deep burning or hip arthroplasty.  
 
Part III: Aims and outline of this thesis 
BMP signaling has been implicated in an enormous plethora of biological 
activities during embryonic development and in adult tissue homeostasis. 
Disruption of the BMP signaling pathway has been linked to various human 
diseases. In this thesis, two BMP related genetic diseases, FOP and PAH are 
studied. The main purpose of this thesis is to clarify the (dys)-regulation of 
BMP signaling in the disease context which may help to develop novel 
therapeutic approaches for these diseases. Furthermore, research on rare 
diseases like FOP might provide basic knowledge that can be used for the 
treatment of more common diseases, such as osteoporosis and non-junction 
fractures. 
    The first part of this thesis is predominantly about BMP signaling in FOP. 
A human iPSC model for FOP is introduced in chapter 2. Previous research on 
FOP was mainly conducted in murine cell lines; a human cell system was 
therefore expected to be more suitable for preclinical FOP studies. FOP iPSCs 
could recreate the disease phenotypes by differentiating into FOP bone-forming 
progenitors, ECs and pericytes. The approach to rescue the osteoblast 
differentiation phenotypes in FOP iPSCs derived cells might be used for drug 
development for FOP. 
    This thesis also presents a novel therapeutic approach for FOP. BMP 
receptor ALK2 antisense-oligonucleotide (AON)-mediated exon skipping was 
introduced in ECs and other cell types. The AON targeting the wild-type exon 
of ALK2 was found to downregulate Alk2 expression and represses 
BMP6-induced osteoblast differentiation (chapter 3).  
    The second part of this thesis analyses rescue of the insufficient BMP 
signaling in PAH by the US food and drug administration (FDA) approved drug 
FK506. Combined targeting of the BMP signaling pathway and inhibition of 
local inflammation could improve treatment of PAH. FK506 can induce 
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BMPR2 signaling both by acting as an inhibitor of the phosphatase calcineurin 
and by inhibiting the binding of the BMP signaling inhibitor FKBP12 to the 
BMP receptor. Importantly, FK506 can rescue the dysfunctional EC signaling 
and gene regulation in experimental PAH animal models to prevent and reverse 
PAH (chapter 4). 
    In chapter 5, we demonstrate that soluble endoglin regulates BMP9 
signaling through TGFβR2 and/or BMPR2. This regulation of BMP9 signaling 
by soluble endoglin provides another layer of regulation of TGF-β signaling 
pathway in ECs. It may also alter the inflammatory responses of ECs in 
different cellular contexts.  
Finally, the main findings reported in this thesis are summarized and 
discussed in chapter 6.  
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Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by 
progressive ossification of soft tissues, for which there is no effective treatment. 
Mutations in the bone morphogenetic protein (BMP) type I receptor activin 
receptor-like kinase 2 (ACVR1/ALK2) are the main cause of FOP. In this study 
we generated human induced pluripotent stem cells (hiPSCs) from FOP patients 
with the ALK2 R206H mutation. The mutant ALK2 gene changed 
differentiation efficiencies of hiPSCs into FOP bone-forming progenitors: 
endothelial cells (ECs) and pericytes. ECs from FOP hiPSCs showed reduced 
expression of vascular endothelial growth factor receptor 2 and could transform 
into mesenchymal cells through endothelial-mesenchymal transition. Increased 
mineralization of pericytes from FOP hiPSCs could be partly inhibited by the 
ALK2 kinase inhibitor LDN-212854. Thus, differentiated FOP hiPSCs 
recapitulate some aspects of the disease phenotype in vitro, and could be 
instrumental in further elucidating underlying mechanisms of FOP and 
development of therapeutic drug candidates. 
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INTRODUCTION 
Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant genetic 
disorder in which acute inflammation may trigger the formation of a second 
skeleton of heterotopic bone. Classic FOP is caused by gain of function 
mutation (617G > A; R206H) in the activin receptor-like kinase 2 
(ACVR1/ALK2) gene, encoding the bone morphogenetic protein (BMP) type I 
receptor (1). Enhanced BMP signaling in patients with the ALK2 R206H 
mutation has been attributed to loss of inhibitory activity of the 
ALK2-interacting protein FK506-binding protein-12 (FKBP12) (2, 3). Previous 
publications indicated that Tie2
+
 endothelial cells (ECs) and mesenchymal cells 
(MCs) contributed as progenitor cells to the episodic heterotopic ossification 
(HO) in FOP (4, 5). Other cells like circulating osteogenic precursors, skeletal 
myoblasts and vascular smooth muscle cells were also found in FOP lesions, 
and may contribute to HO in FOP (6-8). 
Despite recent advances of understanding of the disease (9), to date there is 
no cure or even treatment for HO in FOP. A comprehensive understanding of 
the molecular mechanisms underlying abnormal behavior of bone-forming 
progenitor cells in FOP could be one approach towards effective treatment for 
HO in FOP, and to other more prevalent situations with HO that for example 
may occur after traumatic accidents or deep tissue burns. The traditional way of 
obtaining human biopsy tissues from FOP patients is limited as physical and 
surgical injury can induce HO. New protocols to produce well characterized 
FOP bone-forming progenitor cells for research and therapeutic drug screening 
are needed. The ability to generate human induced pluripotent stem cells 
(hiPSCs) (10) from adult tissues provides new opportunities for research on 
FOP. If derived from patients with genetic disease, hiPSCs allow production of 
large numbers of diseased target cells for basic research and drug development 
since they are immortal and pluripotent (11). 
In this study, we generated FOP hiPSCs from kidney cells isolated from 
urine by episomal vectors. The expression of pluripotent markers and ability to 
form derivatives of the three germ layers were comparable in FOP and control 
hiPSCs. However, the mutation in ALK2 reduced the efficiency of 
differentiation of hiPSCs into ECs and affected the phenotypes of ECs and 
pericytes. hiPSCs derived ECs (hiPSC-ECs) from FOP patients exhibited 
reduced expression of vascular endothelial growth factor receptor 2 (VEGFR2) 
and could be transformed into MCs through endothelial-mesenchymal transition 
CHAPTER 2 
46 
(EndoMT). hiPSCs derived pericytes (hiPSC-pericytes) from the FOP group 
showed increased ability to mineralize compared with the control. Our 
experiments demonstrated that disease relevant cells differentiated from FOP 
hiPSCs possessed phenotypes reminiscent of the FOP disease.  
 
RESULTS 
Generation of FOP hiPSCs from Urine Cells 
We used a rapid and non-invasive procedure to isolate kidney cells in urine 
from FOP patients (12). The cells were isolated from 50-100 ml middle stream 
of the micturition from 2 male FOP patients (Dutch and Chinese, F2 and F3) 
diagnosed with the classic R206H mutation and 2 healthy male donors (Dutch 
and Chinese, C2 and C3) (Figure S1B). 
    A schematic representation of hiPSC generation is shown in Figure S1A. 
In summary, cultured cells from urine were electroporated with episomal 
vectors containing OCT4, SOX2, KLF4 and the pCEP4-miR-302-367 cluster 
(containing miR-302b, c, a, d and miR-367) (12). Transfected urine cells were 
maintained in serum-free mTesR1 medium supplemented with a cocktail of 
small molecule inhibitors to promote reprogramming: CHIR99021, PD0325901, 
A83-01 and thiazovivin (13). Small colonies of cells appeared that 
progressively adopted a human embryonic stem cell (hESC)-like morphology. 
Selected hiPSCs were picked manually and expanded at day 20; hiPSCs 
maintained their hESC-like morphology with prominent nuclei and little 
cytoplasm and stained positive for alkaline phosphatase (ALP) (Figure S1B).  
    hiPSCs from 1 healthy donor (C3) and from 2 FOP patients (F2 and F3) 
were characterized; the other control hiPSC line (UE017C1) was obtained from 
the Guangzhou Stem Cell Bank produced by the same method and was 
characterized previously (12). The presence of classical mutation in the ALK2 
gene was confirmed in FOP hiPSCs (Figure S1C). FOP and control hiPSCs 
karyotypes were checked before passage 10 and these were normal (Figure 
S1D). The loss of exogenous reprogramming factors and episomal backbones 
was demonstrated by genomic PCR that specifically amplifies exogenous 
factors (Figure S1E). Quantitative real-time PCR (qPCR) analysis revealed that 
compared to urine cells, FOP hiPSCs had upregulated expression of endogenous 
hESC transcriptional genes (endogenous OCT4, endogenous SOX2, NANOG, 
and REX1), and had expression levels comparable with established H1 hESC 
Induced pluripotent stem cells to model human fibrodysplasia ossificans progressiva                                                                    
47 
(Figure S1F). Immunofluorescence microscopy showed expression of 
pluripotency associated antigens OCT4, SSEA-4, TRA-1-60 and TRA-1-81 
(Figure S1G). In addition, hiPSCs formed teratomas in mice in vivo confirming 
the pluripotency of FOP iPSCs (Figure S1H). Therefore, hiPSCs from FOP 
patients corresponded phenotypically and functionally to hESCs. 
 
Impaired EC Differentiation of FOP hiPSCs 
A slight elevation of pSMAD1/5 signaling in FOP hiPSCs compared to control 
hiPSCs was observed when these cells were cultured for 24 hours in medium 
with low serum concentrations, but not in the undifferentiated FOP iPSCs 
(Figure 1A and S1I). We differentiated hiPSCs into ECs and pericytes to 
examine how minor changes in ALK2 R206H/SMAD signaling influenced the 
fate of two possible progenitor cells of FOP, i.e. ECs and pericytes. On day 10 
to 12 of differentiation, flow cytometry (FACS) analysis showed that two cell 
populations formed: CD31
+ 
ECs and platelet-derived growth factor receptor 
(PDGFR) β
+





cells was significantly impaired in FOP hiPSCs compared with controls, while 
general mesoderm induction was slightly enhanced in FOP hiPSCs (Figures 1B 
and 1C). To verify the FACs data, we examined the expression of early 
mesoderm and EC-specific genes (Figure 1D). Differentiation resulted in 
efficient downregulation of pluripotent markers (OCT4 and NANOG) in the 
control and FOP hiPSCs. Primitive streak/mesoderm lineage markers 
(Brachyury T and PDGFRα) were upregulated in FOP hiPSCs on day 4 of 
differentiation, which may due to the positive effect of the BMP signaling 
pathway on mesoderm formation. The induction of the early endothelial 
transcription factor (ETV2) on day 4 was similar between the 2 groups. 
However, consistent with the FACs data, we observed that endothelial-specific 
genes (CD31 and CD105) were downregulated in FOP hiPSCs on day 7 of 
differentiation. Early pericyte markers PDGFRβ and NG2 proteoglycan were 
expressed more abundantly in differentiating FOP hiPSCs. Overall, we 
observed that the EC differentiation efficiency was impaired while general 
mesoderm differentiation was enhanced in FOP hiPSCs; this difference may 
due to the elevated level of ALK2 R206H/SMAD signaling in FOP compared to 




Characterization of FOP hiPSC-ECs 
Differentiated cell populations were divided into CD31
+
 ECs and CD31
-
 cells 
by CD31 antibody coupled magnetic bead sorting (Figure 2A). The expression 
level of BMP type I receptors ALK1 and ALK2 were not different in control 
versus FOP CD31
+
 cells (Figure S2A). Sorted FOP hiPSC-ECs were more 
sensitive to low concentrations of BMP6 (5ng/ml) and the activated BMP 
signaling could be inhibited by BMP type I receptor kinase inhibitor 
LDN-193189 (14) (Figure 2B). FOP hiPSC-ECs exhibited poor viability and 
increased expression of senescence-associated β-galactosidase expression 
compared to controls (Figures S2B and S2C). As the VEGF signaling pathway 
is known to regulate survival and proliferation of ECs through VEGFR2 (15), 
we found that the expression of VEGFR2 was lower in FOP hiPSC-ECs 
compared with the control by FACs analysis, while the expression levels of 
other EC genes (CD31 and VE-cadherin) were unchanged (Figure 2C). The 
lower expression of VEGFR2 may be responsible for the failure of FOP 
hiPSC-ECs to propagate in vitro, and this may be related to the activated 
BMP/SMAD signaling in these cells (Figure 2B).  
    Moreover, we observed that ECs cultured in EGM-2 medium with 2% 
serum showed increased expression of EndoMT markers (SLUG, N-cadherin 
and TWIST; Figure 2D) and lost the expression of endothelial-specific markers 
confirmed by qPCR (VE-cadherin and VEGFR2; Figure 2D) and FACs analysis 
(CD31, VE-cadherin and VEGFR2; Figure S2D). ECs turned to 
mesenchymal-like cells (EC-MCs) in EGM2 medium and the expression of 
mesenchymal markers CD73, CD90 and CD105 were also induced (Figures 2E, 
2F and S2E). BMP signaling was also activated at an elevated level in FOP 
EC-MCs, as demonstrated by increased ID1 expression (Figure 2G), a direct 
BMP/SMAD target gene (16). Therefore, increased BMP signaling in FOP 
hiPSC-ECs correlates with impaired EC viability, increased senescence and 
increased EndoMT. 
 
Activated BMP Signaling in FOP hiPSC-pericytes 
The selected CD31
-
 cells were cultured in DMEM with 10% fetal bovine serum 
(FBS) or DMEM with 10% FBS supplemented with PDGF-BB and 
transforming growth factor (TGF) β3 for 1 day. The homogenous population 
expressed pericytes and MC markers (CD73, CD90, CD105, PDGFRβ, CD146, 
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NG2; Figures 3A, 3B and S3A). SMAD1/5 phosphorylation was increased in 
the FOP group in low serum conditions, and this could be inhibited by 
LDN-193189 (Figure 3C). The mRNA expression level of ALK2 was not 
different in control and FOP groups (Figure S3B). The SMAD1/5 downstream 
target gene ID1 was also significantly upregulated in the FOP group (Figure 





Figure 1. Differentiation of FOP hiPSCs into ECs and Pericytes. (A) Total SMAD1/5 
and phospho-SMAD1/5 (pSMAD1/5) level in control hiPSCs (C3-3, UE017C1) and FOP 
hiPSCs (F2-6, F3-8). Note that the antibodies used here may also recognize SMAD8 and 
pSMAD8 bands. (B) FACs analysis of EC markers (CD31, VE-cadherin) or pericyte 
marker (PDGFRβ) expression at differentiation day 10-12. (C) Quantification of the 
FACs analysis data for relative percentage of CD31 and VE-cadherin double positive 
ECs and PDGFRβ positive pericytes. All values were adjusted to the control colony C3-3, 
which is defined as 1. (D) Relative gene expression at different time points during the 
differentiation. ACTIN was used to normalize gene expression. Data are presented as 
mean and SD from 3 independent in (A), (C) and (D).  
 
 
Figure 2. ECs Derived from hiPSCs Undergo EndoMT. (A) Schematic representation 
of EC and pericyte derivation from hiPSCs. (B) Analysis of relative expression of ID1 in 
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hiPSC-ECs. (C) Left panel: Representative FACs analysis for EC markers in hiPSC-ECs. 
Blue, unstained cells; grey, antibody as indicated. Right panel: median fluorescence 
intensity of EC markers expression in hiPSC-ECs. (D) Relative gene expression analysis 
of EC and EndoMT markers in ECs and EC-MCs. (E) Bright field image of ECs and 
EC-MCs of the healthy donor (C3-3) and FOP patient (F3-8). Scale bar, 100μm. (F) 
Percentage of CD73, CD90 and CD105 positive cells in EC-MCs. Representative FACs 
plots of CD73, CD90 and CD105 are shown in Figure S2E. (G) Relative expression of 
ID1 in EC-MCs. Data are presented as mean and SD from 3 independent experiments in 
(B), (C), (D), (F) and (G). qPCR results in (B), (D) and (G) were normalized to ACTIN. 
See also Figure S2. 
 
 
Figure 3. Activated BMP Signaling in FOP hiPSC-pericytes. (A) Percentage of CD73, 
CD90, CD105, PDGFRβ, CD146 and NG2 positive cells in hiPSC-pericytes. 
Representative FACs plots of CD73, CD90 and CD105 are shown in Figure S3A. (B) 
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Bright field images of pericytes from healthy donor (UE017C1) and FOP patient (F3-8). 
Scale bar, 100 μm. (C) Western blots results showing SMAD1/5 phosphorylation in the 
hiPSC-pericytes. GAPDH was used as loading control. (D) Relative expression of ID1. 
All experiments were normalized to ACTIN. Data are presented as mean and SD from 3 
independent experiments in (C) and (D); average of 4 independent experiments is shown 
in (A). See also Figure S3. 
 
FOP hiPSC-pericyte Mineralization as an Assay to Identify New ALK2 
Inhibitors 
Heterotopic bone formation in FOP follows the progressive heterotopic 
endochondral ossification in soft connective tissues, a process in which 
condensing mesenchymal progenitor cells differentiate into chondrocytes, and 
are eventually mineralized into osteoblasts and bone (17). We examined the 
effect of ALK2 R206H mutation on chondrogenic differentiation by 
differentiating hiPSC-pericytes in the two-dimensional micromass culture 
system without the addition of growth factors. hiPSC-pericytes were stained 
with Alcian blue for early differentiation and extracellular matrix production 
such as glycosaminoglycans (GAGs) and sulfated glycosaminoglycans. After 3 
days of chondrocytic differentiation, Alcian blue staining indicated that FOP 
hiPSC-pericytes have more GAGs expression than control hiPSC-pericytes 
(Figure 4A and 4B). 
We further assessed the mineralization capability of FOP hiPSC-pericytes 
when grown in osteogenic medium. The osteoblast differentiation of pericytes 
was measured by determining ALP activity, an early marker of osteoblast 
differentiation. Histochemical staining revealed that ALP activity in the FOP 
group was enhanced (Figure 4C), F2-6 hiPSC-pericytes showed higher 
pSMAD1/5 signaling compared to F3-8 (Figure 3C and 3D), which may explain 
the stronger ALP activity in F2-6. Furthermore, we analyzed osteoblast 
differentiation by alizarin red S staining to detect calcium deposition. On day 21 
and day 28 of differentiation, we detected higher mineralization in the FOP 
group (Figures 4D and 4E). Consistent with the ALP activity and alizarin red S 
staining, qPCR analysis confirmed that expression of osteoblast markers ALP 
and OSTEOCALCIN (OSC) (Figure 4F) was increased in the FOP group, but we 
did not detect altered expression of COLLAGEN type I alpha 1 (COL1α) in FOP 
and control cells (Figure 4F). Together these data indicated that FOP 
hiPSC-pericytes were prone to mineralization, which may due to activated 
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BMP/SMAD signal in these cells. After pretreating pericytes with LDN-212854, 
a BMP type I receptor kinase inhibitor that is more selective for ALK2 
compared with other BMP type I receptors (18), we observed that the ALP 
activity of FOP hiPSC-pericytes was partly inhibited (Figure 4G). 
 
 
Figure 4. Increased Mineralization of FOP hiPSC-pericytes. (A) Representative 
Alcian blue staining of the micromass for 3 days chondrogenic differentiation. Scale bar, 
2 mm. (B) Alcian blue staining of micromasses was quantified by stain extraction and 
absorbance reading at 595 nm. (C) ALP staining was performed 14 days (D14) after 
maintaining in α-MEM with 10% FBS (Ctrl) and osteogenic medium (OM). Results are 
shown as representative scanned images (4C, left panel) and images taken at 4× 
magnification (4C, right panel). Scale bar, 200 μm. (D) The mineralization was visualized 
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by 2% alizarin red S staining on day 21(D21) and day 28 (D28). Results are shown as 
representative scanned images (4D, left panel) and images taken at 4× magnification (4D, 
right panel). Scale bar, 200 μm. (E) Alizarin red S staining on D21 and D28 were 
quantified by stain extraction and absorbance reading at 570 nm. (F) Relative gene 
expression analysis of ALP, COL1α and OSC on day 14 and day 28 of osteoblast 
differentiation. All experiments were normalized to ACTIN. Control, the average of the 
results from C3-3 and UE017C1; FOP, the average of the results from F2-6 and F3-8. (G) 
ALP assay on day 7 of F3-8 after maintaining in osteogenic medium pretreated with 
LDN-212854. Data are presented as mean and SD from 4 times independent experiments 
in (E) and 3 times in (B) and (G).  
 
DISCUSSION 
Our results demonstrated that hiPSCs could be used as an in vitro disease model 
for FOP. hiPSC-ECs and hiPSC-pericytes can be applied to investigate the 
molecular mechanisms underlying the pathology of FOP, as well as to identify 
new therapeutic drugs. 
We have shown that FOP hiPSCs could be established from cells in urine 
using non-integrating episomal vectors. BMP signaling contributes to the initial 
stage of iPSC reprogramming in mouse (19), but induces differentiation of 
hESCs (20). Consistent with prior research (21), our FOP hiPSCs were 
generated without addition of exogenous BMP inhibitors during the 
reprogramming process. We did not observe activated SMAD1/5 signaling in 
FOP hiPSCs maintained in hESC medium mTeSR1 unless these cells were 
placed in differentiation culture conditions. This may explain why FOP hiPSCs 
could be maintained and passaged in defined medium. Besides, we observed 
heterogeneous of BMP/SMAD signaling and mineralization in FOP hiPSCs and 
derivative cells, indicating that intrinsic genetic and/or epigenetic features of 
donor cells may influence properties of hiPSCs and the progeny. In order to 
eliminate the heterogeneity, the isogenic correction FOP hiPSCs can help to 
facilitate more stringent screening for effects arising from clonal variations in 
hiPSCs (22). 
We found that the generation and maintenance of ECs from FOP hiPSCs 
were impaired. One explanation is the elevated BMP signaling in FOP 
hiPSC-ECs, which resulted in downregulation of VEGFR2 expression that 
mediated VEGF-induced proliferation and survival of ECs; this may have 
caused the decrease in EC viability. We do not know the underlying mechanism 
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of VEGFR2 downregulation, e.g. whether it occurs at the transcriptional or the 
protein level. Inhibition of BMP receptor kinase activity by LDN-212854 
during the vascular specification stage (from day 3 of hiPSCs differentiation) 
did not rescue the impaired FOP hiPSC-EC phenotypes (unpublished data). 
BMPs are indispensable for the formation of mesoderm where ECs originate, 
but they may function as a context-dependent regulator in vascular 
morphogenesis (23). In addition, a recent publication indicated activin A signals 
through the mutant ALK2 R206H to stimulate HO in a FOP conditional-on 
knock-in mice (9). Of note, in our EC differentiation protocol, we used activin 
A and BMP4, both of which were shown to induce SMAD1/5 signaling through 
mutant ALK2 R206H (9). These ligands may thus combine with the SMAD1/5 
signal to contribute to the FOP hiPSC-EC phenotypes that we observed. The 
other explanation of low yields of ECs is the increased EndoMT in ALK2 
mutated ECs. Consistent with a previous publication (4), FOP EC-MCs showed 
higher expression of EndoMT markers (N-cadherin, TWIST), which might be 
due to the interaction of mutant ALK2 R206H and VEGF signaling in these 
cells. Further investigation of the crosstalk between BMP signaling and VEGF 
signaling might contribute to the better understanding of the EndoMT 
mechanism in FOP lesions and also help in identifying new druggable targets to 
prevent HO in FOP patients. 
Lastly, we demonstrated that the mutant ALK2 R206H contributed to the 
increased mineralization of FOP hiPSC-pericytes and as such is a useful human 
in vitro disease model for identifying and evaluating the bioactivity of ALK2 
inhibitors. More evidence indicates that MCs are the major contributors of HO 
(5), while ECs indirectly contribute to osteogenic differentiation by acting in a 
paracrine manner via crosstalk between ECs and MCs (24, 25). Even though 
Matsumoto et al. partly exhibited FOP phenotypes by directly differentiating 
hiPSCs into osteoblast cells (21), they provided little evidence of how the 
specific cell types contributed to the increased mineralization. To further clarify 
the mineralization capacity of FOP hiPSCs in vitro, we differentiated hiPSCs 
into pericytes. ALP activity of FOP hiPSC-pericytes can be inhibited by 
pretreating with BMP inhibitor LDN-212854. As the ALP assay has been used 
as an HTS readout for screening regulators in osteogenic differentiation (26), 
our platform could be used for drug screening and further verifying the 
bioactivity of ALK2 inhibitors in the future. 
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Even though in this study we only studied ECs and pericytes, the two most 
well-known HO progenitor cells in FOP, it is possible other unidentified cells 
types may also be involved in the HO process in FOP. Due to the pluripotent 
characterization of hiPSCs, FOP hiPSCs can be differentiated into other 
(unknown) progenitor cells to discover the underlying molecular mechanisms of 
HO in the future. 
 
EXPERIMENTAL PROCEDURES 
Primary human cells were obtained with informed consent. The generation and 
differentiation of hiPSCs were previously described (12, 27). Differences 
between the control group and the FOP group were evaluated by t-test or 
one-way ANOVA with Tukey's multiple comparison tests. ns, not significant; *, 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. For further information, see 
the Supplemental Experimental Procedures. 
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Figure S1. Characterization of hiPSCs from FOP Patients and Healthy Donor 
(A) Schematic represented the reprogramming of hiPSCs from urine cells. (B) Left 
panel, bright field image of cultured patient F2 urine cells. Middle panel, bright field 
image of cultured human FOP hiPSCs. Right panel: ALP staining of FOP hiPSCs. 
Scale bars, 250 μm. (C) Sequencing results of the G→A mutation site in the FOP 
hiPSCs. (D) Normal karyotypes of FOP hiPSCs and control hiPSCs. (E) Lack of 
vector DNA in expanded hiPSCs that have been passaged for ˃10 times.  PCR 
analysis on total DNA extracted from control and FOP hiPSCs was performed by 
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using primers that specifically recognize exogenous transgenes (exo genes, OCT4, 
SOX2, KLF4, SV40L, oriP and EBNA1). Endogenous OCT4 (endoOCT4) is used for 
the detection of OCT4 expression and GAPDH was used as the loading control. 
Positive control, genome DNA extracted from urine cells that were transfected with 
related episome vectors. Negative control, water. (F) qPCR analysis of endogenous 
OCT4, SOX2, NANOG, and REX1 mRNA expression in FOP hiPSCs and H1 ESCs. 
H1 ESCs were used as positive control. ACTIN was used to normalize gene 
expression. Each value is the means ± SD. All the values were adjusted to urine cells 
value, which is defined as 1. The values represent the average level of 3 independent 
samples. (G) Immunofluorescence staining of hiPSCs specific cell markers. Green: 
antibody indicated in the figure; blue: DAPI. Scale bars, 50 μm. (H) 
Hematoxylin/eosin staining of teratoma derived from FOP hiPSCs (F2-6). Scale bars, 
100 μm. (I) Western blot in FOP and control hiPSCs. After serum starvation for 6 
hours, hiPSCs were stimulated with or without BMP6 (5ng/ml) for 1 hour. Protein 
was isolated and western blotting was performed to check the SMAD1/5 
phosphorylation. GAPDH was used as loading control; all the experiments 





Figure S2: hiPSCs-ECs and EC-MCs Characterization. Related to Figure 2. (A) 
The mRNA expression level of ALK1 and ALK2 in CD31
+
 ECs. Each value is the 
means ± SD. All the experiments represented 3 independent biological replicates and 
were normalized to ACTIN. (B) Bright field image of ECs on passage 3 after cell 
sorting. Scale bars, 100 μm. (C) Upper panel: Numbers of β-galactosidase positive 
cells per microscopic field. Lower panel: Bright field image of β-galactosidase 
staining of ECs. Scale bars, 100 μm. All the experiments were repeated 3 times, and 
one of the representative results is shown. Values are presented as mean and SD from 
3 technique replicates. (D) FACs analysis for ECs markers in EC-MCs. Blue, 
unstained cells; grey, antibody as indicated. (E) Upper panel: FACs gates illustrating 
percentage of CD73, CD90 and CD105 positive cells. Lower panel: Histogram of 
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CD73, CD90 and CD105 positive cells analyzed in this study from 3 batches of 
experiments, the average data from 3 batches of experiments showed in Figure 2F. 
 
 
Figure S3: hiPSC-pericytes Characterization. Related to Figure 3. (A) Upper part: 
FACs gates illustrating percentage of CD73, CD90, CD105, PDGFRβ, CD146 and 
NG2 positive cells. Lower part: Histogram of CD73, CD90, CD105, PDGFRβ, 
CD146 and NG2 positive cells analyzed in this study from 4 batches of experiments, 
the average data from 4 batches of experiments showed in Figure 3A. (B) The mRNA 
expression level of ALK2 in CD31
-
 pericytes. Each value is the means ± SD. All the 
experiments represented 3 independent biological replicates and were normalized to 
ACTIN.  
 




The participants in this manuscript have signed written informed consent for 
donating human urine cells for stem cell generation. Experiments involved 
with human subjects was approved by IRB GIBH-IRB02-2009002 at 
Guangzhou Institutes of Biomedicine and Health (GIBH), and 12/467 (2013 
January) at VU university medical center. The animal research was approved 
by IRB at GIBH (NO. 2010012). 
 
Urine Cell Culture and hiPSCs Generation 
Urine cells were collected and maintained as previously publication (Zhou et 
al., 2011). Urine cells within 5 passages were used for iPS cells generation. 




urine cells which was 
electroporated with episomal vectors (3.5 µg pEP4EO2SET2K 
(contains OCT4, SOX2, SV40LT and KLF4) and pCEP4-miR-302-367 
cluster (contains miR-302b, c, a, d and miR-367) by Amaxa™ Basic 
Nucleofector™ kit for primary mammalian epithelial cells, program T-020 
(LONZA). The transfected urine cells were immediately seeded onto 
matrigel (BD Biosciences, 354230) pre-coated 6-well plates. Refreshed the 
medium with defined medium mTeSR1 (StemCell Technologies, 05852) 
with TGF-β/Activin/Nodal receptor inhibitor A-83-01 (Sigma, SML0788), 
MEK inhibitor PD0325901, GSK3b inhibitor CHIR99021 and ROCK 
inhibitor thiazovivin (gifts from Dr. Ke Ding) the next day and changed 
medium every other day. The appeared hiPSCs were passaged by 
mechanical picking and replated in matrigel pre-coated plates between day 
20 and day 30 after induction. The hiPSCs were routinely maintained in 
mTesR1 medium and passaged by dispase (1 mg/ml in DMEM/F12, Gibco, 
17105-041) or by 0.5 mM EDTA (Invitrogen, AM9260G). H1 human 
embryonic stem cells brought from WiCell Research Institute (Madison, WI). 
UE017C1 (uiPSC-015 C1 in the paper) was obtained from the Guangzhou 
Stem Cell Bank and was previously characterized (Xue et al., 2013). 
 
hiPSCs Characterization 
qPCR, transgene integration, immunofluorescence (OCT-3/4 Antibody, 
Santa Cruz Biotechnology sc-5279; Human NANOG Affinity Purified 
Polyclonal Ab, R&D AF1997; Anti-SSEA4 antibody, Abcam AB16287; 
Anti-TRA-1-60, Millipore MAB 4360; Anti-TRA-1-81, Millipore MAB 
Supplemental                                                                   
65 
4381) and karyotyping were done as described (Xue et al., 2013); the 
primers used for transgene integration and qPCR also published before (Xue 
et al., 2013). For teratomas, hiPSCs were resuspended with 30% matrigel 
and then injected subcutaneously and intramuscularly into the flanks of 
SCID mice. Tumors were sectioned after 7 weeks and stained with 
hematoxylin/eosin. 
 
ALK2 Mutational Analysis 
Genomic DNA of hiPSCs was isolated by using Wizard® Genomic DNA 
Purification Kit (Promega, A1120), PCR reaction was conducted as previous 
publication using primers as following (Kaplan et al., 2008): Forward primer: 
5‘-CCAGTCCTTCTTCCTTCTTCC-3‘, Reverse primer: 
5‘-AGCAGATTTTCCAAGTTCCATC-3‘. PCR products were sequenced to 
identify the mutation sites. 
 
Differentiation hiPSCs into ECs and Pericytes 
ECs and pericytes differentiation was initiated by culture hiPSCs in basal 
medium BEPL and growth factors Activin A (25ng/ml, R&D, 338-AC-010), 
BMP4 (30ng/ml, R&D, 314-BP-010/CF), VEGF (30ng/ml, R&D Systems, 
293-VE) and the small molecule inhibitor CHIR99021 (1.5μM, Tocris, 4423) 
for 3 days. The medium was refreshed with BPEL with VEGF and SB43152 
(10μM, Tocris, 1614) from day 4 to day 10 of differentiation. ECs were 
isolated by CD31
- 
labeled Dynabeads (Life Technologies, 11155D). Sorted 
CD31
+
 ECs were maintained in human endothelial growth (serum free) 
medium (hEC-SFM) (Life Technologies, 11111) supplemented with 1% 
platelet poor plasma (BTI, BT-214), 30ng/ml VEGF and basic fibroblast 
growth factor (bFGF) (20ng/ml, R&D, 100-18B) on 0.1% gelatin 
(Sigma-Aldrich, G1890) coated plates, and passaged every 3-4 days by 
TrypLE Select (Gibco, 12563-011). CD31
- 
cells were plated in EGM-2 
media (Lonza, CC-3162). Medium changed to DMEM+10% FBS (Gibco, 
10270), supplemented with or without TGF-β3 (1ng/ml, a generous gift of 
Kenneth K. Iwata, OSI Pharmaceuticals) and PDGF-BB (4ng/ml, Peprotech, 
100-14B) for 1 day when cells were confluent. Afterwards, the hiPSCs 





Flow Cytometry (FACs) Analysis 
Cells were dissociated by TrypLE Select and washed with the FACs buffer 
with 10% FBS, followed the other time of washing by the FACs buffer. The 
following antibodies was used for the FACs staining: VE-cadherin-A488 
(eBiosciences, 53-1449-41, 1:100), CD31-APC (eBiosciences, 17-0319, 
1:200), KDR-PE (R&D Systems, FAB357P, 1:50), PDGFRβ-PE (BD 
Pharmingen, 558821, 1:50), CD73-PE (BD Pharmingen, 550257, 1:50), 
CD105-PE (Life Technologies, MHCD10504, 1:200), CD90-PE (1:400), 
NG2-PE (R&D, FAB2585P, 1:50), CD146-FITC (BD, P1H12, 1:50). 
Samples were analyzed with the MACSQuant VYB (Miltenyi) with the 
following instrument settings Blue/488 FITC, A488: 525/50, Yellow/561 PE: 
586/15, APC: 661/20. Unstained cells were used as negative controls for 
FACS gating. FACS data were analyzed using FlowJo 10.1 software. 
 
Cell senescence assay 
β-galactosidase (β-gal) activity was performed using a senescence detection 
kit (Cell Signaling, 9860S) according to the manufacturer‘s instructions. The 
number of β-gal positive cells was counted in randomly selected microscopic 
fields (magnification ×10). 
 
Alkaline Phosphatase (ALP) Assay  
Pericytes were seeded in 96 well plate pre-coated with 0.1% gelatin. After 
pretreating LDN-212854 (gift from Paul Yu) for 1 day, differentiation of 
pericytes was initiated in osteogenic medium, which is comprised of α-MEM 
(Gibco, 32561-029) supplemented with 10% FBS, 0.2 mM ascorbic acid 
(Sigma, A8960), dexamethasone (Sigma, D4902) and 10 mM of 
β-glycerophosphate (Sigma, G6251), medium refreshed every 3-4 days. 
Histochemical examination of ALP activity was performed using naphtol 
AS-MX phosphate (Sigma, N4875) and fast blue RR salt (Sigma, F0500), as 
described previously (Shi et al., 2013).  
 
Chondrogenic Differentiation 
Chondrocytes differentiation was performed according to previous 
publication (Greco et al., 2011). Briefly, hiPSC-pericytes were suspended in 
growth medium at a density of 1.5×10
7
/ml, micromasses were seeded in 
48-well plates by pipetting 10 μl of cell suspension into each wells. The 
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droplets were leave in the incubator for 3 hours for attachment, after that the 
growth medium was added. The growth medium was changed to 
chondrogenic medium (Dulbecco‘s modified Eagle‘s medium/F-12 
(Invitrogen), 1% (v/v) ITS+ Premix (Corning), 50 μg/ml ascorbic acid, 40 
μg/ml L-Proline (Sigma), 0.1 mM dexamethasone, 100 μg/ml sodium 
pyruvate) 24 hours later and culture for another 3 days before stained with 1% 
(w/v) Alcian Blue (pH 1.0, Sigma). The quantification of Alcian blue 
staining was performed by incubated stained micromass with 125 μl 6 M 
guanidine hydrochloride overnight. The absorbance of the Alcian blue 
solution was measured at 595 nm to determine the relative amount of bound 
GAGs in the micromass. 
 
Mineralization assay 
The mineralization assay was performed after subsequent 3 weeks of 
culturing in osteogenic medium. To visualize mineralization, cells were 
stained with 2% alizarin red S solution (Sigma, A5533). 
 
Western Blotting  
Cell lysate was isolated from subconfluent cells cultured for 24 hours in 
α-MEM+1% FBS. Western blotting was performed as previously described 
using standard techniques (Shi et al., 2013). The antibodies used for 
immunoblotting were phosphorylated SMAD1/5 antibody (1:1000, Cell 
signaling Technology, Danvers, MA, USA, 9511), SMAD1/5 antibody 
(1:1000, Santa Cruz, SC-6031) and GAPDH antibody (1:40,000, Sigma). 
Protein expression was quantification of by ImageJ software (NIH). GAPDH 
was used as the loading control. 
 
Statistical Analyses  
Error bars indicated standard deviation of the mean. We treated each cell line 
as an individual biological replicate and pooled our results into control group 
(C3-3 and UE017C1) or FOP group (F2-6 and F3-8). At least three replicates 
of each of the two control or two FOP hiPSCs or derived cells were 
performed. Differences between the control group and the FOP group were 
evaluated by t-test or one-way ANOVA with Tukey's multiple comparison 
tests by using the Prism Software (6.01 version; GraphPad Software). 




qPCR primers used in this study 





































































PCR Transgene primers     
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Markers     (5'-3') 
OCT4 Oct4-SF1 AGTGAGAGGCAACCTGGAGA 
 IRES2-SR AGGAACTGCTTCCTTCACGA 
SOX2 Sox2-SF1 ACCAGCTCGCAGACCTACAT 
 SV40pA-R CCCCCTGAACCTGAAACATA 
KLF4 Klf4-SF1 CCCACACAGGTGAGAAACCT 
 SV40pA-R CCCCCTGAACCTGAAACATA 
SV40L SV40T-SF1 TGGGGAGAAGAACATGGAAG 
 IRES2-SR AGGAACTGCTTCCTTCACGA 
oriP pEP4-SF1 TTCCACGAGGGTAGTGAACC 
 pEP4-SR1 TCGGGGGTGTTAGAGACAAC 
EBNA1 pEP4-SF2 ATCGTCAAAGCTGCACACAG 
 pEP4-SR2 CCCAGGAGTCCCAGTAGTCA 
endoOCT4 endoOct4-F2 AGTTTGTGCCAGGGTTTTTG 
 endoOct4-R2 ACTTCACCTTCCCTCCAACC 
GAPDH GAPDH-F GTGGACCTGACCTGCCGTCT 
 GAPDH-R GGAGGAGTGGGTGTCGCTGT 
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Fibrodysplasia ossificans progressiva (FOP) is a rare heritable disease 
characterized by progressive heterotopic ossification of connective tissues, for 
which there is presently no definite treatment. A recurrent activating mutation 
(c.617G→A; R206H) of activin receptor-like kinase 2 (ACVR1/ALK2), a BMP 
type I receptor, has been shown as the main cause of FOP. This mutation 
constitutively activates the BMP signaling pathway and initiates the formation 
of heterotopic bone. In this study, we have designed antisense oligonucleotides 
(AONs) to knockdown mouse ALK2 expression by means of exon skipping. 
The ALK2 AON could induce exon skipping in cells, which was accompanied 
by decreased ALK2 mRNA levels and impaired BMP signaling. In addition, the 
ALK2 AON potentiated muscle differentiation and repressed BMP6-induced 
osteoblast differentiation. Our results therefore provide a potential therapeutic 
approach for the treatment of FOP disease by reducing the excessive ALK2 
activity in FOP patients.  
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Introduction 
BMPs are multifunctional growth factors that play key roles in bone formation, 
and heart and liver development (1-3). The activity of the BMP pathway is 
precisely regulated to elicit its function in different cellular contexts. 
Perturbation of BMP pathways can lead to multiple diseases, including 
fibrodysplasia ossificans progressiva (FOP), a genetic disease caused by 
constitutively activated BMP signaling (4-7). 
    FOP is a rare disease in which acute inflammation results in progressively 
ossified fibrous tissue. Minor traumas such as intramuscular immunization, 
muscle fatigue or muscle trauma from bumps or bruises can initiate the 
formation of heterotopic bones in the soft tissue (6). Since surgical trauma also 
induces ectopic bone formation, surgery to remove ectopic bone is not an option 
for FOP patients. In the past decade, a variety of gene mutations in the activin 
receptor type IA/activin-like kinase 2 (ACVR1/ALK2) gene, encoding one of 
the type I BMP receptors, were found in most FOP patients (4). The most 
common ALK2 FOP mutation is a change of guanine (G) into adenine (A) 
causing an arginine to histidine substitution (R206H) in the ALK2 GS domain 
(4). Due to this mutation, the FOP ALK2 shows a lower binding affinity for its 
negative regulator FKBP12, which results in elevated BMP signaling in cells, 
both in the presence and absence of exogenous BMP ligands (5, 8, 9). 
    The recurrent ALK2 mutation in FOP patients provides a specific target for 
drug development. Plausible therapeutic approaches for inhibiting the excessive 
BMP signaling in FOP include ALK2 inhibitory RNA technology, anti-ALK2 
monoclonal antibodies, and ALK2 small molecule inhibitors (10, 11). Several 
small molecules already have been developed that efficiently inhibit ALK2 
activity, such as dorsomorphin and LDN-193189 (LDN) (12, 13). However, 
these compounds in addition also inhibit the activity of BMPR1 (ALK3), 
another type I BMP receptor (12, 13). Other studies have suggested that 
dorsomorphin and LDN are not specific for BMP signaling as the inhibitors 
could block TGF-β-induced activity at higher concentrations (14). The ideal 
BMP inhibitor for FOP patients would be an agent that normalizes the 
(excessive) ALK2 activity without affecting the functions of other kinases. 
Using the allele specific siRNA technique, two separate research groups have 
successfully obtained siRNAs that target the disease-causing ALK2, without 
affecting normal ALK2 expression (15, 16). The siRNAs were used in cells 
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from FOP patients to restore BMP activity and osteogenic differentiation (15, 
16).  
    In addition to siRNAs, antisense oligonucleotides (AONs) mediated exon 
skipping might be a potential tool to modulate ALK2 activity. AONs are short 
synthetic, chemically modified single-stranded oligonucleotides between 20-30 
base pairs in length. AONs can be used to modify splicing by specifically 
binding pre-mRNA sequences to block the access of spliceosome and other 
splicing factors, thereby excluding the target exon from the mature mRNA (17). 
AON-mediated exon skipping has enabled the successful reframing of the 
mutated dystrophin mRNA and the restoration of dystrophin protein synthesis 
in skeletal muscle of Duchenne muscular dystrophy (DMD) patients (18, 19). 
Systemic delivery of AONs is less challenging than for siRNAs, since AONs 
are single stranded, which is pharmacokinetically advantageous, allowing 
uptake by many tissues at significant levels after subcutaneous and intravenous 
administration without the need for specific formulations (20). Therefore, 
adjustment of aberrant gene expression via exon skipping or RNaseH 
knockdown might be an attractive therapeutic option for genetic diseases.  
    In this study, ALK2 AON was designed to selectively modulate 
pre-mRNA splicing of mouse ALK2 to inhibit Alk2 expression. The effects of 
ALK2 knockdown on ALK2-mediated BMP functions were assessed by 
analyzing myogenic differentiation and osteoblast differentiation. In line with 
the fact that BMP represses myogenic differentiation and potentiates osteoblast 
differentiation, we found ALK2 AON to potentiate myogenic differentiation of 
C2C12 myoblasts and inhibit osteoblast differentiation in mouse endothelial 
cells, suggesting that the endogenous BMP signaling in C2C12 cells and mouse 
endothelial cells were repressed by the ALK2 AON.  
 
Results  
Design of AON for ALK2 exon skipping in mouse cells 
The classic FOP mutation, a G-A substitution in exon 7 of the human ALK2 
gene, leads to a R206H substitution in the GS domain of ALK2 protein, causing 
elevated BMP signaling in FOP patients (4, 5). The mutated ALK2 exon 
sequence is highly conserved between mouse and human, and the exon 7 in 
human corresponds to exon 8 in mouse (21). In an attempt to modulate 
ALK2-mediated BMP signaling, an ALK2 AON was designed to specifically 
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target exon 8 encoding the GS domain of mouse ALK2 and the sequence of 
ALK2 AON overlapped with the location of hot spot mutation in FOP (Figure 
1). Upon transfection and entry into the cell nucleus, the AON was anticipated 
to modulate mouse ALK2 pre-mRNA splicing by masking and subsequent 
skipping of exon 8, which disrupts the reading frame (exon 8 is 100 base pairs, 
not dividable by three) (Figure 1). We have chosen AON against exon internal 
site as we demonstrated previously that they outperform AONs targeting splice 
sites (22). The truncated ALK2 mRNA without exon 8 may be degraded via 
nonsense-mediated decay due to the introduction of a premature stop codon. 
The locations of primers to detect the skipped exon are indicated as black 
arrows in Figure 1.  
    To test whether the designed ALK2 AON could induce exon skipping and 
decrease full-length ALK2 expression and/or ALK2 activity in cultured cells we 
applied ALK2 AON in various cell types. These cells were shown to be 
transfected with AONs with high efficiency (>70%) as visualized by the 
5‘-fluorescein (FAM)-labeled control AON (Figure 2A). RT-PCR on RNA 
harvested 2 days after transfection showed a skipped band representing the 
transcript without exon 8 upon transfection of the ALK2 and not the control 
AON (Figure2B). qPCR analysis showed that Alk2 expression was decreased 
about 70-80% in the cells treated with ALK2 AON (Figure 2C).  
 
 
Figure 1. Schematic overview of ALK2 exon skipping. Left panel: The ALK2 protein 
structural domains include ligand binding domain (LBD), transmembrane domain (TM), 
GS domain (GS), and kinase domain (KD). The position of each exon relative to each 
domain is denoted by broken lines. Right panel: The FOP mutation hot spot (c.617G→A; 
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R206H) is in exon 8 (*). ALK2 AON (red bars, the sequence covered the FOP mutation 
hot spot) hybridizes and hides exon 8 from the splicing machinery, resulting in skipping 
exon 8 upon mRNA splicing. This out-of-frame mutation will lead to non-sense mediated 
decay of Alk2 mRNA. qPCR primers to detect Alk2 expression are indicated by green 
arrows; The primers for detecting of skipped band are indicated by blue arrows. While we 
targeted exon 8 for exon skipping, we do not exclude that other AONs targeting other 
exons can be designed that also inhibit ALK2 expression.  
 
 
Figure 2. AON-induced ALK2 exon 8 skipping in various cell types. (A) C2C12 cells 
were transfected with 500 nM non-targeting, fluorescently-labeled AONs fluorescent 
AON in differentiation medium and fluorescent images were taken 2 days after 
transfection. (B) Various of cells were transfected with indicated control AON or ALK2 
AON. RNA was isolated 2 days after transfection, and RT-PCR was performed to 
visualize the full length Alk2 (composed of exon 7, 8 and 9); and skipped Alk2 
(composed of exon 7 and exon 9). (C) MEECs cells were transfected with 100nM control 
AON or 100nM ALK2 AON, RNA was isolated 1 day after transfection. C2C12 cells and 
KS483 cells were transfected with AONs in proliferation medium; RNA was isolated 2 
days post transfection. cDNA was synthesized using random hexamer primers and used 
for the quantification of Alk2 expression. The relative full length ALK2 mRNA 
expression was analyzed. Alk2 RNA level was normalized to Gapdh; the level of 
expression for untreated sample was defined as 1. Values and error bars represent the 
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means ± SD of triplicates. Statistical analysis was performed using Student‘s t-test. 
*P<0.05, **P < 0.005 
 
Exon-skipping in ALK2 reduced Alk2 expression and potentiated muscle 
differentiation 
BMP signaling is known to repress myogenic differentiation, and BMP 
inhibitors have been shown to potentiate the differentiation of myoblasts into 
myotubes (23, 24). We therefore examined whether the ALK2 AON can 
decrease BMP signaling and function as a BMP inhibitor to potentiate 
myogenic differentiation of C2C12 myoblasts. Seven days after transfection, 
cells were fixed and immunostained for myosin to visualize the differentiated 
myotubes. The degree of differentiation was measured by determining the 
differentiation and the fusion indexes. The differentiation index was calculated 
as the percentage of myosin-positive cells out of all myogenic (desmin-positive) 
cells. The fusion index was calculated as the average number of nuclei in the 
differentiated myotubes. The ALK2 AON was found to enhance both the 
differentiation index and the fusion index in C2C12 cells (Figure 3), suggesting 
that AON-mediated ALK2 knockdown can potentiate myoblast differentiation 
via repression of endogenous BMP signaling. 
 
 
Figure 3. ALK2 AON enhanced myogenic differentiation in C2C12 cells. C2C12 
cells were transfected with 200 nM control AON or 200 nM ALK2 AON in 
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differentiation medium for 7 days. Then cells were immunostained with myosin and 
desmin. Myosin (green) was used to label the differentiated cells while desmin (red) was 
used to label myogenic cells. The values for the percentage of myosin positive cells or for 
the fusion index represent the average levels of two independent samples. Values and 
error bars represent the means ± SD. Statistical analysis was performed using Student‘s 
t-test, using the untransfected samples as reference. *P<0.05 
 
ALK2 AON-mediated exon skipping decreased BMP signaling and 
mineralization in endothelial cells 
Recently, endothelial cells were reported as potential osteoprecursor cells for 
ectopic bone formation in FOP patients (25, 26). Therefore, our next step was to 
test whether the ALK2 AON can repress BMP signaling and osteoblast 
differentiation in endothelial cells. The ALK2 AON (and not a control AON) 
decreased BMP-induced BMP-responsive element (BRE)-driven luciferase 
reporter activity (Figure 4A). BMP6-induced Smad1/5 phosphorylation was 
also inhibited by the ALK2 AON, albeit weakly (Figure 4B). We next evaluated 
the therapeutic potential of the ALK2 AON in the treatment of excessive bone 
formation such as occurring in FOP patients. For this purpose we investigated 
the effect of the ALK2 AON on endothelial to osteoblast transdifferentiation by 
using MEECs cultured under osteogenic conditions. MEECs were chose due to 
the short transdifferentiation period. Transfected MEECs were treated with 
TGF-β3 for 2 days and then refreshed with osteogenic medium with or without 
BMP6 for several days (Figure 5A). The osteoblast differentiation can be 
measured by determining alkaline phosphatase (ALP) activity, an early marker 
for osteoblast differentiation. Histochemical staining revealed that ALP activity 
in ALK2 AON treated cells was significantly decreased (Figure 5B). Compared 
to LDN-193189 treated sample in which most of the ALP activity was blocked, 
ALP activity in ALK2 AON treated cells was only partly blocked (Figure 5B). 
Furthermore, we analyzed the effect of ALK2 AON on osteoblast 
differentiation by alizarin red S staining, a staining to detect calcium 
mineralization. BMP6 induced mineralization was significantly decreased by 
exon skipping of ALK2 (Figure 5C). Consistent with the ALP activity and 
alizarin red S staining results, qPCR analysis confirmed that exon skipping in 
ALK2 can decrease the expression of Runx2, bone sialoprotein (BSP) and 
osteocalcin (OSC) (Figure 5D). Together these data indicate that ALK2 AON 
can decrease BMP-induced osteoblast differentiation.  
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Figure 4. ALK2 AON-induced exon skipping decreased BMP signaling in 2H11 
endothelial cells. (A) 2H11 cells were cotransfected with 100nM of the indicated AON 
and the BMP reporter construct BRE-Luc for 16 hours. Subsequently, cells were starved 
for 8 hours, and then stimulated with 50 ng/ml BMP6 overnight. Luciferase reporter 
activity was measured after stimulation and normalized with β-gal activity. (B) 2H11 
cells were transfected with 100 nM control AON or 100 nM ALK2 AON in proliferation 
medium. One day after transfection, the cells were serum starved for overnight and 
stimulated with 5 ng/ml BMP6 for 1 hour. Protein was isolated and western blotting was 
performed to check the Smad1/5/8 phosphorylation. GAPDH was used as loading control. 
Data are means ± SD from three independent experiments. Statistical analysis was 
performed using Student‘s t-test, using the untransfected samples as reference. *P<0.05, 
**P < 0.005 
 
The ALK2 AON decreased BMP6-induced osteoblast differentiation in 
KS483 osteoprogenitor cells 
In addition to endothelial cells, mesenchymal stem cells are considered as 
another source of osteoprecursors responsible for BMP induced ectopic bone 
formation in mice (6, 27). In FOP patients, the mesenchymal stem cell-like cells 
derived from endothelial cells are considered to be in part responsible for 
heterotopic ossification (26). Multipotent mesenchymal stem cells KS483 cells 
can be differentiated into osteoblasts, chondrocytes and adipocytes in vitro (28, 
29). Two days after transfection, KS483 cells were maintained in proliferation 
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medium with or without BMP6 for 2 days before measuring ALP activity. For 
alizarin red S staining, transfected cells were cultured in proliferation medium 
for 4 days and then refreshed with osteogenic medium with or without BMP6 
for 12 days (Figure 6A). The ALK2 AON also efficiently repressed 
BMP6-induced osteoblast differentiation in KS483 cells, as visualized by the 
ALP activity (Figure 6B) and the mineralization assay (Figure 6C). qPCR 
analysis confirmed that exon skipping in ALK2 can decrease the expression of 
BMP6-induced osteogenic gene expression (data not shown). 
 
 
Figure 5. BMP-induced osteoblast differentiation was impaired by ALK2 
AON-induced exon skipping in MEECs. (A) As a mineralization assay, MEECs were 
seeded into a 24-wells or 48-wells plate. One day after transfection, cells were stimulated 
with 5ng/ml TGF-β3 for 2 days and switched to osteogenic medium with or without 
100ng/ml BMP6 for several days (with medium refreshment after 4 days). ALP staining 
was performed 2 days after maintaining in osteogenic medium. After 4 days in osteogenic 
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medium, the cells were fixed and stained with 2% alizarin red S solution for 
mineralization staining. (B) MEECs were transfected with 200 nM control AON or 200 
nM ALK2 AON, and stimulated with osteogenic medium indicated in figure 4A. The 
LDN sample indicates LDN-193189 was present during the whole experiment. 
Representative microscopic pictures of staining (upper panel) are shown; ALP activity 
was represented as the average of three independent samples, and was normalized by 
protein concentration. (C) MEECs were transfected with 100 nM control AON or 100 nM 
ALK2 AON in grow medium and treated as in panel 4A. The mineralization was 
visualized by alizarin red S staining. The plate was scanned (4C, left panel), and scanned 
under a microscope (4x, 4C, middle panel). Alizarin red S staining was quantified by 
stain extraction and absorbance reading at 570 nm (4C, right panel). (D) RNA was 
collected in experiment 4C. mRNA expression of Runx2, OSC and BSP was measured by 
qPCR. All the experiments were performed for three times and were normalized to 
Gapdh. Each value is the means ± SD. Statistical analysis was performed using Student‘s 
t-test, using the untransfected samples as reference. *P<0.05, **P < 0.005 
 
 
Figure 6. ALK2 AON reduced BMP-induced osteogenic differentiation in KS483. 
(A) Confluent KS483 cells were transfected for 2 days in a 96-wells or 24-wells plate. 
Two days after AON transfection, cells were stimulated with 100 ng/ml BMP6 (R&D, 
MN, USA) for 2 additional days and ALP assay was performed. For mineralization assay, 
after stimulation with 100 ng/ml BMP6 (R&D, MN, USA) for 4 days, cells then switched 
to osteogenic medium for subsequent 14 days. Medium was refreshed every 3-4 days. (B) 
Confluent KS483 cells were transfected with 200 nM control AON, or 200 nM ALK2 
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AON for 2 days in proliferation medium. Then cells were stimulated with 100 ng/ml 
BMP6 for another 2 days in proliferation medium. Cells lysates were harvested and ALP 
activity was measured. Data are presented as means ±SD. (C) Confluent KS483 cells 
were transfected with 200 nM control AON, or 200 nM mouse ALK2 AON for 2 days in 
proliferation medium. The cells were then stimulated with 100 ng/ml BMP6 in 
proliferation medium for 4 days. Then cells were maintained in osteogenic medium for 
another 12 days. Medium was refreshed every 3-4 days. The cells were finally stained 
with alizarin red S solution to visualize the mineralized area in KS483 cells. Statistical 
analysis was performed using Student‘s t-test, using the untransfected samples as 
reference. **P < 0.005 
 
Discussion 
In this study, an ALK2 exon-skipping AON was designed based on previous 
published guidelines (30). The mouse ALK2 AON we designed can specifically 
induce skipping of exon 8 in different cell types, including C2C12 myoblasts, 
KS483 osteoprogenitor cells, and two types of endothelial cells (2H11 and 
MEECs). The removal of exon 8 might cause the transcripts to be degraded via 
nonsense-mediated decay. We observed a weak skip product in the RT-PCR 
analysis, which suggested that the transcript with premature stop codon might 
not be stable. Potentially, the truncated protein, if stably produced, could have 
dominant negative receptor activity. However, high amounts of kinase inactive 
ALK2 are required to achieve dominant negative effects in cultured cells, while 
the accumulated mutant ALK2 in AON transfected cells may be readily 
degraded. From studies examining the effect of mismatches on efficiency, we 
know that AONs with 1 mismatch at the 5' of 3' end of the AON can still work, 
but these AONs may show a reduced efficiency. More mismatches leads to poor 
or inefficient AONs (31). As there is no complete overlap of ALK2 AON with 
another region in the genome as determined by blasting the ALK2 AON 
sequence with the full genome, and ALK2 AON did not inhibit the expression 
of other related type I receptors, such as ALK3 and ALK1 (or housing keeping 
genes) (data not shown), we conferred that ALK2 AON specifically targets 
ALK2 in vitro. 
    Importantly, the ALK2 AON also can downregulate ALK2 and 
BMP-induced osteoblast differentiation in endothelial cells, which has recently 
been reported to be the major bone progenitor cell population in FOP patients 
(26). Endothelial cells were first found to dedifferentiate into a mesenchymal 
stem cell-like phenotype by endothelial-to-mesenchymal transition, and 
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subsequently to differentiate into cartilage and bone (26). The ALK2 AON 
downregulated the levels of ALK2 mRNA and significantly reduced 
BMP-induced signaling responses and osteogenic differentiation in MEECs and 
more mature 2H11 cells. The effect of the ALK2 AON on BMP-induced 
Smad1/5 phosphorylation was relatively weak compared to other responses. 
This could be because of the different thresholds required for BMP-induced 
responses; BMP6-induced Smad1/5 phosphorylation as measured in a total cell 
lysate at the time point examined may need more efficient knockdown to 
observe a strong effect.  
    BMPs transmit signals through induction of heterotetrameric complexes 
consisting with type I receptors and type II receptors (7). Utilization of type I 
receptors differs depending on BMP ligands; BMP-6 binds principally to ALK2, 
but also ALK3, ALK6 (32). The role of ALK2 played in BMP6 induced 
osteoblast differentiation may be different depending on the cell types (9, 33). 
While LDN can strongly block the BMP signal pathway and osteoblast 
differentiation (Figure 5B), ALK2 AON has a slightly lower inhibitory effect, 
which may explained by the minor role ALK2 played in BMP signal pathway in 
endothelial cells. Alternatively, as AON-mediated depletion of ALK2 does not 
affect the expression ALK3, the cells with ALK2 knockdown may still partly 
respond to BMP6 by signaling via ALK3 or other BMP type I receptors. 
    Our research provides a new approach for the therapy of FOP. The next 
step is to test whether the ALK2 AON can efficiently decrease ALK2 
expression and ALK2-mediated BMP signaling in vivo. In this respect, it will be 
of great interest to test whether the ALK2 AON can inhibit the heterotopic 
ossification in ALK2 R206H knock-in mice that have recently been developed 
(34). The specific chemistry of the type of AONs used in this study 
(2‘-O-methyl phosphorothioate RNA) enhances nuclease resistance and stability 
of the AON-target RNA duplex (35). The phosphorothioate backbones of AONs 
also prevent renal clearance (35), resulting in a long serum half-life and uptake 
by most of tissues. Phase 3 clinical trials are currently ongoing for DMD (36). 
The research of applying AON to DMD holds a promise for the application of 
AON in FOP. The final goal would be to examine whether ALK2 AON can 
counteract the excessive BMP activity in tissues from FOP patients. We have 
attempted to specifically target the ALK2 R206H allele with AON-mediated 
strategies by human ALK2 AON, but so far this has not been successful. Taken 
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together, the results presented here underscore that AONs have potential for the 
treatment of FOP, although more studies should be performed in this sense. 
 
Materials and Methods  
Antisense oligonucleotides  
ALK2 AON was specifically designed to target exon 8 of wild type mouse Alk2; 
AONs with full length phosphorothioate backbones and 2‘-O-methyl-modified 
ribose molecules were obtained from Prosensa Therapeutics B.V. (Leiden, the 
Netherlands). AONs sequences are listed in Table 1. 
 
Cell culture  
Mouse C2C12 myoblast cells were maintained in DMEM medium (Gibco, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, 
Carlsbad, CA), and penicillin/streptomycin (Invitrogen). For myogenic 
differentiation, C2C12 cells were cultured in DMEM (Gibco) supplemented 
with 2% FBS (Invitrogen). Mouse endothelial cells (MEECs (37) and 2H11 
(38)) and mouse osteoprogenitor cells KS483 (39) were cultured in α-MEM 
(Gibco) and 10% FBS (Invitrogen), and penicillin/streptomycin (Invitrogen), 
the plates were pretreated with 0.1% gelatin (Sigma, St Louis, MO, USA). All 
of the cells were grown at 37 ºC in a humidified incubator with 5% CO2.  
Table 1. Antisense oligonucleotides used in this study 
AON Sequences (5’-3’) Targeting 
ALK2 AON GGGUUAUCUGGCGAGCCACCG
UUCU 





AON transfection  
ExGen 500, the linear 22 kDa form of polyethyleneimine (PEI, MBI Fermentas, 
St.Leon-Rot, Germany), was used as a transfection reagent for KS483, MEECs 
and 2H11; DharmaFECT Duo (Thermo Scientific, Pittsburgh, PA, USA) was 
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used as transfection reagent for C2C12 cells. Transfection was performed 
according to the manufacturer‘s instructions.  
 
RNA isolation and quantitative real-time PCR analysis  
Total RNA was isolated using the RNAII isolation kit (Machery Nagel, Düren, 
Germany) according to the manufacturer‘s instructions. The RNA quantity and 
integrity were measured using RNA 6000 Nanochip in the Agilent 2100 
bioanalyzer (Agilent Technologies, Amstelveen, the Netherlands). Reverse 
transcriptase-polymerase chain reaction was performed using the RevertAid H 
Minus First strand cDNA synthesis kit (Fermentas, St.Leon-Rot, Germany) 
according to manufactures instructions. Quantitative real-time PCR (qPCR) 
analysis was performed using the Roche LightCycler 480 and the relative 
expression levels of the genes of interest were determined in triplicate for each 
sample using the 2
-CT
 method. Values were normalized to Gapdh expression, 
qPCR primers are listed in Table 2.  
 
Immunofluorescence  
Antibodies used for immunofluorescence were Desmin (Santa Cruz, Santa Cruz, 
CA, USA) and Myosin heavy chain (MF20; Developmental Studies hybridoma 
Bank, USA). The immunofluorescence procedure was performed as described 
previously (23).  
Table 2. Primers used in this study 
Primers Sequences(5’-3’) Used for 
mouse ALK2 E7 FW AAGTTGGCCTTATCATCC ALK2 exon 8 skip PCR 
mouse ALK2 E9 RV GTACAATTCCGTCTCCCT  
mouse ALK2 FW TGGCTCCGGTCTTCCTTT ALK2 qPCR 
mouse ALK2 RV AGCGACATTTTCGCCTTG  
mouse GAPDH FW AACTTTGGCATTGTGGAAGG GAPDH qPCR 
mouse GAPDH RV ACACATTGGGGGTAGGAAC
A 
 






Alkaline phosphatase (ALP) assay 
2×10
4
 MEECs cells were seeded in a 48-well plate. One day after AON 
transfection, cells were stimulated with TGF-β3 (kindly provided by Dr. K 
Iwata, OSI Pharmaceuticals, Melville, NY, USA) for 2 days. The ALP activity 
assay was performed after treatment with BMP6 in proliferation medium for 
another 2 days. KS483 cells were seeded in a 96-well plate with 5×10
3
 cells per 
well. Two days after AON transfection, cells were stimulated with 100 ng/ml 
BMP6 (R&D, Minneapolis, MN, USA) for further 2 days. Histochemical 
examination of ALP activity was performed using naphtol AS-MX phosphate 
(Sigma) and fast blue RR salt (Sigma), as described previously (5). To quantify 
the data, the histochemically stained cell material was solubilized in 50mM 
NaOH in ethanol, and absorbance was measured at 550 nm. 
 
Mineralization Assay  
AON-transfected MEECs were stimulated with 5 ng/ml of TGF-β3 for 2 days in 
growth medium. Mineralization assay was performed after the cells were 
cultured in osteogenic medium, which is comprised of α-MEM supplemented 
with 5% FBS, 0.2 mM of ascorbic acid (Sigma), dexamethasone (Sigma) and 10 
mM of β-glycerolphosphate (Sigma), containing 100 ng/ml of BMP6 for 
another 4 days. Confluent KS483 cells were transfected for 2 days, then 
stimulated with 100 ng/ml BMP6 for 4 days in growth medium. The 
mineralization assay was performed after subsequent 14 days of culturing in 
osteogenic medium, medium refreshed every 3-4 days. To visualize 
mineralization, cells were stained with 2% alizarin red S solution (Sigma). 
 
Transcription Reporter Assays 
mouse BSP RV ACACATTGGGGGTAGGAAC
A 
 
mouse OSC FW AGACTCCGGCGCTACCT OSC qPCR 
mouse OSC RV CTCGTCACAAGCAGGGTTAA  
mouse RunX2 FW GAATGCTTCATTCGCCTCAC Runx2 qPCR 
mouse RunX2 RV GTGACCTGCAGAGATTAACC  
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2H11 cells were seeded in 24-well plates, and then transfected with the BMP 
Responsive Element (BRE)-Luc reporter construct using PEI (Fermentas) as 
described previously (23). After overnight serum starvation, the cells were 
stimulated with BMP6 (50ng/ml) for 8 hours. Harvested cells were assayed for 
luciferase activity with a Perkin Elmer luminometer. Each experiment was 
performed in triplicate and data represent the mean ± SD of three independent 
experiments with normalization to β-galactosidase activity. 
 
Western Blotting  
Western blotting was performed as previously described using standard 
techniques (14). The antibodies used for immunoblotting were phosphorylated 
Smad1/5/8 antibody (1:1000, Cell signaling Technology, Danvers, MA, USA) 




We would like to acknowledge Midory Thorikay for expert technical assistance, 
Prosensa B.V. for their generous supply of antisense oligonucleotides, and 
thank Hans van Dam for critical reading of the manuscript. 
 
References 
1. Schlange T, Andree B, Arnold HH, and Brand T. BMP2 is required for early heart 
development during a distinct time period. Mech Dev. 2000;91(1-2):259-70. 
2. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, and Roth MP. 
Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat 
Genet. 2009;41(4):478-81. 
3. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, 
Tabin CJ, and Rosen V. BMP2 activity, although dispensable for bone formation, 
is required for the initiation of fracture healing. Nat Genet. 2006;38(12):1424-9. 
4. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, 
Delai P, Glaser DL, LeMerrer M, et al. A recurrent mutation in the BMP type I 
receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans 
progressiva. Nat Genet. 2006;38(5):525-7. 
5. van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, and ten 
Dijke P. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva 
confers constitutive activity to the BMP type I receptor and sensitizes 
mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. 
CHAPTER 3 
88 
Journal of bone and mineral research : the official journal of the American Society 
for Bone and Mineral Research. 2010;25(6):1208-15. 
6. Shi S, de Gorter DJ, Hoogaars WM, t Hoen PA, and Ten Dijke P. Overactive bone 
morphogenetic protein signaling in heterotopic ossification and Duchenne 
muscular dystrophy. Cell Mol Life Sci. 2012. 
7. Cai J, Pardali E, Sanchez-Duffhues G, and ten Dijke P. BMP signaling in vascular 
diseases. FEBS letters. 2012;586(14):1993-2002. 
8. Groppe JC, Wu J, Shore EM, and Kaplan FS. In vitro analyses of the dysregulated 
R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification 
in FOP. Cells Tissues Organs. 2011;194(2-4):291-5. 
9. Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY, and Ryoo HM. 
Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia 
ossificans progressiva. J Biol Chem. 2010;285(29):22542-53. 
10. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, 
Groppe J, and Shore EM. Fibrodysplasia ossificans progressiva. Best practice & 
research Clinical rheumatology. 2008;22(1):191-205. 
11. de Gorter DJ, Jankipersadsing V, and Ten Dijke P. Deregulated bone 
morphogenetic protein receptor signaling underlies fibrodysplasia ossificans 
progressiva. Curr Pharm Des. 2012;18(27):4087-92. 
12. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, 
McManus PM, Katagiri T, Sachidanandan C, et al. BMP type I receptor inhibition 
reduces heterotopic [corrected] ossification. Nat Med. 2008;14(12):1363-9. 
13. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, 
Bloch KD, and Peterson RT. Dorsomorphin inhibits BMP signals required for 
embryogenesis and iron metabolism. Nat Chem Biol. 2008;4(1):33-41. 
14. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, Kawai N, and Bloch KD. 
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated 
growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol 
Chem. 2008;283(7):3877-88. 
15. Kaplan J, Kaplan FS, and Shore EM. Restoration of normal BMP signaling levels 
and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant 
allele-specific targeting. Gene therapy. 2012;19(7):786-90. 
16. Takahashi M, Katagiri T, Furuya H, and Hohjoh H. Disease-causing allele-specific 
silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia 
ossificans progressiva. Gene Ther. 2012;19(7):781-5. 
17. Aartsma-Rus A, and van Ommen GJ. Antisense-mediated exon skipping: a 
versatile tool with therapeutic and research applications. RNA. 
2007;13(10):1609-24. 
18. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, 
Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, et al. 
Local dystrophin restoration with antisense oligonucleotide PRO051. The New 
England journal of medicine. 2007;357(26):2677-86. 
19. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans 
N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, et al. Systemic 
administration of PRO051 in Duchenne's muscular dystrophy. The New England 
journal of medicine. 2011;364(16):1513-22. 
20. Spitali P, and Aartsma-Rus A. Splice modulating therapies for human disease. Cell. 
2012;148(6):1085-8. 
AON mediated exon skipping in Alk2: inhibiting the receptor that is overactive in FOP 
89 
21. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, 
Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, et al. Classic and atypical 
fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in 
the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 
2009;30(3):379-90. 
22. Aartsma-Rus A, Houlleberghs H, van Deutekom JC, van Ommen GJ, and t Hoen 
PA. Exonic sequences provide better targets for antisense oligonucleotides than 
splice site sequences in the modulation of Duchenne muscular dystrophy splicing. 
Oligonucleotides. 2010;20(2):69-77. 
23. Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY, Hong CC, 
Kemaladewi DU, Aartsma-Rus A, ten Dijke P, and t Hoen PA. BMP antagonists 
enhance myogenic differentiation and ameliorate the dystrophic phenotype in a 
DMD mouse model. Neurobiol Dis. 2011;41(2):353-60. 
24. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, 
Wozney JM, Fujisawa-Sehara A, and Suda T. Bone morphogenetic protein-2 
converts the differentiation pathway of C2C12 myoblasts into the osteoblast 
lineage. J Cell Biol. 1994;127(6 Pt 1):1755-66. 
25. Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment AD, 
Shore EM, Glaser DL, Goldhamer DJ, and Kaplan FS. Identification of progenitor 
cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am. 
2009;91(3):652-63. 
26. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, and Olsen BR. 
Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 
2010;16(12):1400-6. 
27. Leblanc E, Trensz F, Haroun S, Drouin G, Bergeron E, Penton CM, Montanaro F, 
Roux S, Faucheux N, and Grenier G. BMP-9-induced muscle heterotopic 
ossification requires changes to the skeletal muscle microenvironment. Journal of 
bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research. 2011;26(6):1166-77. 
28. Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, and Lowik CW. 
Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits 
adipogenesis. J Bone Miner Res. 2002;17(3):394-405. 
29. de Gorter DJ, van Dinther M, Korchynskyi O, and ten Dijke P. Biphasic effects of 
transforming growth factor beta on bone morphogenetic protein-induced osteoblast 
differentiation. J Bone Miner Res. 2011;26(6):1178-87. 
30. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, 
de Kimpe S, van Deutekom JC, t Hoen PA, and van Ommen GJ. Guidelines for 
antisense oligonucleotide design and insight into splice-modulating mechanisms. 
Mol Ther. 2009;17(3):548-53. 
31. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van 
Ommen GJ, and van Deutekom JC. Comparative analysis of antisense 
oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene 
Ther. 2004;11(18):1391-8. 
32. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M, Miyazono K, 
and Imamura T. Characterization of bone morphogenetic protein-6 signaling 
pathways in osteoblast differentiation. J Cell Sci. 1999;112 ( Pt 20)(3519-27. 
33. Lavery K, Swain P, Falb D, and Alaoui-Ismaili MH. BMP-2/4 and BMP-6/7 
differentially utilize cell surface receptors to induce osteoblastic differentiation of 
CHAPTER 3 
90 
human bone marrow-derived mesenchymal stem cells. J Biol Chem. 
2008;283(30):20948-58. 
34. Chakkalakal SA, Zhang D, Culbert AL, Convente MR, Caron RJ, Wright AC, 
Maidment AD, Kaplan FS, and Shore EM. An Acvr1 R206H knock-in mouse has 
fibrodysplasia ossificans progressiva. Journal of bone and mineral research : the 
official journal of the American Society for Bone and Mineral Research. 
2012;27(8):1746-56. 
35. Oberbauer R, Schreiner GF, and Meyer TW. Renal uptake of an 18-mer 
phosphorothioate oligonucleotide. Kidney Int. 1995;48(4):1226-32. 
36. Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, 
and van Deutekom JC. Targeted exon skipping as a potential gene correction 
therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 2002;12 Suppl 
1(S71-7. 
37. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, Xu X, 
ten Dijke P, Mummery CL, and Karlsson S. Abnormal angiogenesis but intact 
hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J. 
2001;20(7):1663-73. 
38. Walter-Yohrling J, Morgenbesser S, Rouleau C, Bagley R, Callahan M, Weber W, 
and Teicher BA. Murine endothelial cell lines as models of tumor endothelial cells. 
Clin Cancer Res. 2004;10(6):2179-89. 
39. Yamashita T, Ishii H, Shimoda K, Sampath TK, Katagiri T, Wada M, Osawa T, 
and Suda T. Subcloning of three osteoblastic cell lines with distinct differentiation 




FK506 activates BMPR2, rescues endothelial dysfunction, 










































 Thomas J. Wandless,
8







The Vera Moulton Wall Center for Pulmonary Vascular Disease, 
2
Department 
of Medicine, and 
3
Cardiovascular Institute, Stanford University School of 
Medicine, Stanford, California, USA. 
4
Department of Molecular Cell Biology, 
Cancer Genomics Center and Center for Biomedical Genetics, Leiden 
University Medical Center, Leiden, Netherlands. 
5
Department of Pediatrics, 
6
High-Throughput Bioscience Center, 
7
Department of Biochemistry, and 
8
Department of Chemical and Systems Biology, Stanford University School of 
Medicine, Stanford, California, USA. 
 
J Clin Invest. 2013;123(8):3600–3613. 
 
Contribution statement 
In the chapter 4 of this thesis, “FK506 activates BMPR2, rescues endothelial 
dysfunction, and reverses pulmonary hypertension”, Jie Cai worked on the 
molecular mechanism by which FK506 activates BMP/SMAD signaling in vitro, 
her work is mainly represented in Figure 2, Supplement Figure 1 and 




Dysfunctional bone morphogenetic protein receptor-2 (BMPR2) signaling is 
implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We 
used a transcriptional high-throughput luciferase reporter assay to screen 3,756 
FDA-approved drugs and bioactive compounds for induction of BMPR2 
signaling. The best response was achieved with FK506 (tacrolimus), via a dual 
mechanism of action as a calcineurin inhibitor that also binds FK-binding 
protein-12 (FKBP12), a repressor of BMP signaling. FK506 released FKBP12 
from type I receptors activin receptor-like kinase 1 (ALK1), ALK2, and ALK3 
and activated downstream SMAD1/5 and MAPK signaling and ID1 gene 
regulation in a manner superior to the calcineurin inhibitor cyclosporine and the 
FKBP12 ligand rapamycin. In pulmonary artery endothelial cells (ECs) from 
patients with idiopathic PAH, low-dose FK506 reversed dysfunctional BMPR2 
signaling. In mice with conditional Bmpr2 deletion in ECs, low-dose FK506 
prevented exaggerated chronic hypoxic PAH associated with induction of EC 
targets of BMP signaling, such as apelin. Low-dose FK506 also reversed severe 
PAH in rats with medial hypertrophy following monocrotaline and in rats with 
neointima formation following VEGF receptor blockade and chronic hypoxia. 
Our studies indicate that low-dose FK506 could be useful in the treatment of 
PAH. 
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Introduction 
Idiopathic pulmonary arterial hypertension (IPAH) is a rare disorder thought to 
develop following a genetic and/or environmental insult that triggers endothelial 
cell (EC) apoptosis, loss of distal vessels, and occlusive vascular remodeling (1). 
These pathological changes increase resistance to pulmonary flow and cause 
progressive right heart failure. Current therapies mainly include drugs with 
vasodilatory properties that improve cardiopulmonary function (2). However, 
the obliterative vascular pathology usually continues to progress (3), leaving 
heart-lung transplantation as the only option for many patients. Therefore, new 
approaches are needed that focus on activating cellular mechanisms to reverse 
vascular remodeling. One strategy could be to improve function of the bone 
morphogenetic protein receptor-2 (BMPR2) signaling pathway. Germline 
mutations causing loss of BMPR2 function are found in >80% of familial and 
approximately 20% of sporadic cases of IPAH (4, 5). Acquired somatic 
chromosomal abnormalities in the BMPR2 signaling pathway have also been 
described (6). The low penetrance of pulmonary arterial hypertension (PAH) 
found in nonaffected family members with a BMPR2 mutation has been 
attributed to a higher level of BMPR2 expression from the normal allele (7). In 
addition, patients with IPAH without a BMPR2 mutation or with PAH 
associated with other conditions have reduced expression of BMPR2 in 
pulmonary arteries (8). Furthermore, estrogen can reduce BMPR2 expression, 
perhaps explaining the propensity of females to develop PAH (9). IL-6, a 
cytokine increased in the blood of patients with IPAH, can reduce BMPR2 
expression via a STAT3-miR17/92–mediated mechanism (10). Furthermore, 
patients with a BMPR2 mutation have worse pulmonary vascular remodeling 
(3). The importance of BMPR2 dysfunction in PAH is supported by studies in 
transgenic mice. Mice with deletion of BMPR2 in ECs (11) develop PAH, as do 
mice expressing a dominant-negative Bmpr2 gene after birth in vascular SMCs 
(12). Mice heterozygous for BMPR2 develop exaggerated PAH in response to 
hypoxia and serotonin (13). Reduced BMPR2 expression also occurs in 
monocrotaline (14) and chronic hypoxic (15) rat models of PAH, and delivery 
of BMPR2 by intravenous gene therapy attenuates the disease in both models 
(16, 17). Moreover reconstitution of athymic rats with regulatory T cells also 
prevents PAH resulting from blockade of the VEGF receptor, coincident with 
an increase in BMPR2 expression in ECs (18).  
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    Since clinical application of BMPR2 gene therapy poses challenges, we 
sought to identify an FDA-approved drug with a known pharmacokinetic and 
toxicity profile that increases signaling through the BMPR2 pathway. We 
applied a high-throughput assay to screen available libraries, and agents that 
appeared to activate the receptor were further tested in human pulmonary 
arterial ECs (PAECs), including those from patients with dysfunctional BMPR2 
signaling. The mechanism of BMPR2 activation by the most effective 
compound was investigated. Then the compound was tested in experimental 
PAH animal models for its efficacy in rescuing dysfunctional EC signaling and 
gene regulation and in preventing and reversing PAH. 
 
Results 
High-throughput screen yields activators of BMPR2 signaling. Like other 
members of the TGF-β family, BMPs elicit their effects through activation of 
receptor complexes,  composed of a type II receptor (BMPR2, ActivinR2A, or 
ActivinR2B) and a type I receptor (ALK3 [also known as BMPR1A], ALK6 
[also known as BMPR1B], ALK2, or ALK1). This results in activation of 
multiple signaling pathways, such as MAPK, PI3K (pAKT), and pSMAD, and 
downstream transcription factors, such as PPARγ (19) and inhibitor of 
differentiation 1 (ID1) (20). The latter is a basic helix-loop-helix (HLH) 
transcription factor that binds other HLH transcription factors and acts as a 
dominant-negative antagonist (21). As substrates of the ubiquitin/ 26S 
proteasome system that regulate protein stability, ID proteins are short-lived, 
with a half-life of 30 minutes (22). As an early response gene (23), ID1 is 
transcribed in a pSMAD1/5-dependent manner (24) and thus is used commonly 
as a read out for BMPR2 signaling in vascular cells (20, 25, 26). Furthermore, 
ectopic ID1 expression induces EC migration and tube formation (26). 
In developing the high-throughput assay to assess activation of BMPR2 
signaling, we used the C2C12 mouse myoblastoma cell line stably transfected 
with a construct in which the BMP/SMAD elements of the ID1 promoter were 
linked to luciferase (BRE-luc). We optimized conditions to improve the 
luciferase signal related to varying the cell number, adding test compounds and 
the luciferase substrate. Plating 1,500 cells in 384-well plates without 
exogenous ligand permitted the assessment of activators of BMPR2 signaling in 
the presence of only endogenous ligand produced by the cells. Adding 250 pM 
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BMP4, the concentration resulting in 20% of maximal response (EC-20), 
allowed distinction of activators requiring the presence of exogenous ligand 
(Figure 1A). Although BRE-luc C2C12 cells respond to all BMP ligands 
(BMP2, BMP4, BMP6, BMP7, and BMP9), we chose BMP4 for this assay 
because of excellent assay sensitivity. The following libraries available at the 
Stanford High-Throughput Bioscience Center were screened: NIH-CC, LOPAC, 
Biomol ICCB Known Bioactives, Microsource spectrum, and Biomol 
FDA-approved drug library. 
Figure 1. High-dose FK506, the main activator of BMP signaling found in the 
high-throughput screen, recapitulates BMP4 signaling and function. (A) BRE-luciferase 
activity in different numbers of C2C12 cells at different concentrations of BMP4. 
BMP4 at the EC-20 concentration of 250 pM for 1,500 cells per 60 μl per well 
permitted identification of coactivators. (B) Percentage BRE-luc activation, compared 
with 250 pM BMP4, in 6-point serial dilution for FK506 and rapamycin. (C) 
BRE-luciferase activity in C2C12 cells comparing FK506 (FK; 2 μg/ml), rapamycin 
(Rapa; 4 μg/ml), cyclosporine (Cyclo; 2 μg/ml), and Shield-1 (1 μg/ml) (n = 8; ***P < 
0.001 vs. CON, ###P < 0.001 vs. FK506, §§§P < 0.001 vs. cyclosporine, 1-way 
ANOVA, Bonferroni multiple-comparison test). (D) In human PAECs, ID1 expression 
relative to B2M mRNA 24 hours after stimulation with vehicle (CON), FK506 (15 
ng/ml), or rapamycin (10 ng/ml) (n = 3; **P < 0.01 vs. vehicle, 1-way ANOVA, 
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Dunnett‘s post test). (E and F) Representative Western immunoblot and relative 
densitometric analysis of PAECs showing (E) pSMAD1/5/8 and (F) ID1 relative to 
β-actin following stimulation with BMP4 (10 ng/ml) or FK506 (15 ng/ml) (n = 3; *P < 
0.05; **P < 0.01 vs. CON, 2-way ANOVA). (G) Assessment of apoptosis with 
measurement of caspase-3/7 luminescence 24 hours after serum starvation and treatment 
with BMP4 (10 ng/ml) or FK506 (15 ng/ml). (n = 5; *P < 0.05; **P < 0.01 vs. CON, 
1-way ANOVA, Dunnett‘s post test). (H) Representative images from a Matrigel tube 
formation assay. Tube number and length were assessed after 8 hours in unstimulated 
cells (CON) or following stimulation with VEGF (20 ng/ml), BMP4 (10 ng/ml), or 
FK506 (15 ng/ml). (n = 6; *P < 0.05; **P < 0.01 vs. CON,1-way ANOVA, Dunnett‘s 
post test). Scale bar: 100 μm. Mean ± SEM. 
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Activators of ID1 expression without and with exogenous BMP4 ligand found in 
high-throughput screen of 3,756 FDA- approved drugs and bioactive compounds (20 μM 
each). 100% of activation is defined as BRE-luc activity relative to the EC-20 dose of 250 
pM BMP4. Only activators that increase BRE-luc activity >10% are shown. CML, 
chronic myelogenous leukemia. 
 
   The major activators of BMPR2 signaling identified, with and without 
additional ligand, are listed in Table 1. Values of percentage of activation were 
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defined as luminescence relative to the EC-20 dose of BMP4, and agents that 
increased BRE-luc reporter activity greater than 10% are shown. Tacrolimus 
(FK506) was the main activator of BRE-luc (113%). A similar response was 
seen with a less commonly used immunosuppressive agent, ascomycin (FK520). 
This compound, like FK506, interacts with FK-binding protein-12 (FKBP12) to 
inhibit calcineurin and NF-ATc–mediated IL-2 expression in T cells. 
Rapamycin, a third immunosuppressant that also interacts with FKBP12 and 
inhibits the mTOR pathway, but does not inhibit calcineurin, was a much 
weaker activator of signaling. Other agents included the TGF-β receptor blocker 
SB431542. The promising ―hits‖ were tested in a 6-point serial dilution assay 
(Figure 1B), and the superiority of FK506 over rapamycin was shown with 
respect to the magnitude of BREluc activity reflecting BMPR2-mediated ID1 
expression. FK506 induced ID1 at low doses, and a high plateau of activation 
was rapidly achieved. We then compared the effect of FK506 and rapamycin to 
another calcineurin inhibitor, cyclosporine, that does not interact with FKBP12 
but binds the immunophilin, cyclophilin A, as well as shield-1 (27). Shield-1 
binds FKBP12 but does not have any immunosuppressive properties (Figure 
1C). We showed that the effect of FK506 on increasing BMP signaling could 
only partially be replicated by an agent that binds FKBP12 or that inhibits 
calcineurin. Furthermore, we showed that FK506 is selective in increasing BMP 
signaling in a dose-dependent fashion (Supplemental Figure 1A; supplemental 
material available online with this article; doi:10.1172/JCI65592DS1), without 
inducing TGF-β signaling (Supplemental Figure 1B).  
    FK506, like BMP4, induces ID1 and pSMAD1/5 in PAECs. We also 
compared FK506 with rapamycin-mediated BMPR2 signaling in human PAECs. 
These cells have higher BMPR2 expression than other pulmonary artery 
vascular cells (8), and PAEC dysfunction has been implicated in the 
pathogenesis of PAH (11, 19, 28). Rapamycin attenuates chronic hypoxic PAH 
(29), but its effect on monocrotaline-induced PAH in rats is not unequivocal (30, 
31). FK506 had not been previously tested in experimental PAH. We stimulated 
PAECs with 15 ng/ml FK506 or 10 ng/ml rapamycin, concentrations used to 
induce immunosuppression in the clinical setting. Consistent with the 
BMP/SMAD transcriptional luciferase assay, we confirmed a significant 
increase in ID1 mRNA 24 hours after stimulation with FK506, but only a trend 
was evident with rapamycin (Figure 1D). We then compared BMPR2 signaling 
induced by FK506 with that induced by the natural ligand BMP4. Both agents 
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resulted in similar induction of pSMAD1/5 at 15 minutes and ID1 at 1 hour 
(Figure 1E), consistent with the fact that ID1 is an early target gene of 
SMAD1/5-dependent and -independent BMP signaling (23, 32). ID1 levels 
returned to control values 6 hours after BMP4 stimulation but remained 
elevated following FK506 stimulation (Figure 1F). We then showed that FK506 
was similar to BMP4 in promoting PAEC survival following serum withdrawal, 
as judged by the Caspase-Glo 3/7 apoptosis assay (Figure 1G). In addition, 
BMP4 and FK506 were comparable to VEGF (20 ng/ml) in inducing formation 
of PAEC tubular networks in Matrigel (Figure 1H).  
FK506 binds to and removes FKBP12 from BMP type I receptors. 
Previous data suggested that a low subimmunosuppressive dose of FK506 can 
prevent neointima formation in a carotid artery injury model in Apoe
–/–
 mice (33, 
34). We confirmed in microvessel PAECs (mvPAECs) that FK506, in 
concentrations as low as 0.2 ng/ml, increased Id1 mRNA and protein (Figure 2, 
A and B, respectively). The mechanism of action of FK506 was then 
investigated.  
 
Figure 2. Low-dose FK506 induces pSMAD1/5/8 and ID1 in human mvPAECs 
related to FKBP12 interaction. (A) Id1 mRNA, normalized to 18S mRNA, in human 
unstimulated mvPAECs (CON) or 1 hour after the addition of BMP4 (10 ng/ml) or 
FK506 (0.2 ng/ml and 2.0 ng/ml). (B) Representative immunoblot and densitometric 
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analysis of ID1 protein relative to β-actin at time points and doses indicated in A. (A 
and B) (n = 3; *P < 0.05; **P < 0.01 vs. CON, 1-way ANOVA, Dunnett‘s post test). (C) 
BRE-luciferase activity in C2C12 cells after stimulation with the BMPR2 ligand BMP6 
(50 ng/ml) and FK506 (1 μg/ml) for 24 hours, with or without preincubation for 30 
minutes with kinase inhibitor LDN-193189 (120 nM) (n = 6; ***P < 0.001 vs. CON; 
§§§P < 0.001 vs. BMP6, 1-way ANOVA, Bonferroni‘s multiple-comparison test). (D) 
BRE-luciferase activity in C2C12 cells treated with nontargeting siRNA (NTsi), 
BMPR2 siRNA (BMPR2si), BMPR2si plus Activin2A siRNA (ActA2si), and BMPR2si 
plus Activin2B siRNA (ActBsi) and stimulated with FK506 (1 μg/ml) (n = 6; §§P < 
0.01 vs. BMPR2si and FK treatment; ##P < 0.01 vs. BMPR2si-Act2Asi, 1-way 
ANOVA, Bonferroni‘s multiple-comparison test). (E) Immunoprecipitation with an 
antibody to FLAG and immunoblot for HA and FLAG in 293T cells transfected with 
plasmids HA-ALK1, HA-ALK2, and HA-ALK3 as well as FKBP12-FLAG and 
stimulated with FK506 (100 ng/ml for 30 minutes). (F–H). BRE-luciferase activity in 
C2C12 cells treated with NTsi, ALK1 siRNA (ALK1si), ALK2si, and ALK3si and 
stimulated with (F) BMP4 (250 pM), (G) FK506 (2 μg/ml), and (H) rapamycin (n = 8; 
##P < 0.01 vs. NTsi plus BMP4, NTsi plus FK506, NTsi plus rapamycin, 1-way 
ANOVA, Bonferroni‘s multiple-comparison test). Mean ± SEM. 
 
Previous studies have shown that a BMP ligand (BMP2, BMP4, BMP6, 
BMP7, and BMP9) can initiate the interaction of a type II receptor with 
serine/threonine kinase activity (BMPR2, ActivinR2A, or ActivinR2B) with a 
type I receptor (ALK1, ALK2, ALK3, and ALK6), resulting in its 
phosphorylation (35). We therefore determined whether FK506 requires the 
kinase activity to induce BMP signaling. When we pretreated C2C12 BRE-luc 
cells with a BMP type I receptor kinase inhibitor, LDN-193189, FK506 failed 
to induce BMP signaling, as judged by BRE-luciferase (ID1 expression) (Figure 
2C) as well as pSMAD1/5 (Supplemental Figure 2A). These features were 
replicated by LDN-193189 inhibition of BMP6 activation of BMP signaling 
(BRE-luciferase) as a positive control. When BMPR2 was reduced by siRNA 
(documented in Supplemental Figure 2B), there was only a partial decrease in 
ID1 expression (Figure 2D), suggesting that another type II receptor such as 
Activin R2A could substitute. In fact, we were able to show that reducing both 
ActivinR2A and BMPR2 by siRNA caused an additive decrease in ID1 
expression (Figure 2D), consistent with previous reports (36).  
    FKBP12 interacts with TGF-β type I family receptors and blocks signaling 
by occupying the phosphorylation site at its glycine-serine–rich region (37). We 
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hypothesized that FK506-mediated BMP signaling was related to its interaction 
with and removal of FKBP12 (38) from type I receptors involved in BMP 
signaling, in addition to its known function as an inhibitor of the phosphatase 
calcineurin (39). By coimmunoprecipitation of 293T cell lysates transfected 
with plasmids containing FLAG-tagged FKBP12 as well as HA-tagged ALK1, 
ALK2, or ALK3, we showed that FKBP12 binds to type I receptors involved in 
BMP signaling and that FK506 releases FKBP12 from all 3 tested (Figure 2E). 
We then assessed which of the type I receptors was predominantly involved in 
FK506-mediated BMP signaling. We knocked down ALK1, ALK2, and ALK3 
by siRNA in BRE-luc cells and assessed whether the loss of any one of the 
above receptors would compromise BMP4- or FK506-induced BRE luciferase 
activity. While BMP4 predominantly signaled via ALK3 and, to a lesser extent, 
ALK1 (Figure 2F), FK506 was able to interact with all 3 receptors (Figure 2G). 
Rapamycin exclusively recruited ALK2 (Figure 2H), a receptor that is not 
involved in BMP4-induced BMP signaling and therefore does not appear to 
preferentially interact with BMPR2. We confirmed that cyclosporine did not 
interact with type I receptors (Supplemental Figure 2C).  
    FK506 binds and removes FKBP12 from multiple type I receptors that 
interact with BMPR2 or ActivinR2A, whereas rapamycin only engages 
FKBP12 bound to ALK2. This explains, perhaps, why BRE-luc activity is 
greater with FK506 than with rapamycin combined with the calcineurin 
inhibitor cyclosporine (Supplemental Figure 2D). We furthermore tested 
whether removing FKBP12 by siRNA would mimic FK506 function, allowing 
for an increase in ID1 expression. However, reducing levels of FKBP12 to 30% 
of control values (Supplemental Figure 2B) did not enhance baseline 
BRE-luciferase (Supplemental Figure 2E). This suggests that incomplete 
depletion of FKBP12 is either not sufficient to activate type I BMP receptors 
(BRE-luc) or that engaging FKBP12 bound to the receptor and then removing it 
by FK506 may be required to activate the signaling machinery. We also 
assessed whether other FKBPs could inhibit ligand-independent type I receptor 
activation. However, reducing levels of 6 other FKBPs (FKBP12.6, FKBP13, 
FKBP25, FKBP52, FKBP54, and FKBP38) by siRNA, one at a time, did not 
induce BRE-luciferase activity (Supplemental Figure 2, F and G). These data 
are consistent with a redundancy in FKBPs as binding partners of type I 
receptors. We confirmed FK506 activation of pSMAD1/5 as one read out for 
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BMP signaling as well as others, such as pERK, pAKT, and p-c-JUN 
(Supplemental Figure 2, H–J).  
     
 
Figure 3. Low-dose FK506 rescues IPAH mvPAEC dysfunction. (A) Representative 
immunoblot and densitometry showing BMPR2 and ID1/β-actin in human PAECs 
stimulated with BMP4 (10 ng/ml) or FK506 (15 ng/ml) following knockdown of 
BMPR2 with BMPR2si compared with NTsi as control (n = 3; *P < 0.05 vs. CON, 
2-way ANOVA). (B)  Representative immunoblot and densitometry of mvPAECs 
from 3 patients with IPAH showing ID1/β-actin at baseline (CON) or at various time 
points after stimulation with BMP4 (10 ng/ml) or FK506 (15 ng/ml) (n = 3; *P < 0.05 
vs. CON, 2-way ANOVA). (C) ID1/18S mRNA 4 hours after and apelin/18S mRNA 8 
hours after stimulation with BMP4 (10 ng/ml) and low-dose FK506 (0.2 ng/ml) in the 
same IPAH mvPAECs as in B (n = 3; *P < 0.05; **P < 0.01, vs. CON, 1-way ANOVA, 
Dunnett‘s post test). (D) Representative images and quantitative analysis of tube 
number and length of tubes formed in Matrigel with mvPAECs from a patient with 
IPAH 4 hours after unstimulated CON, VEGF (10 ng/ml), BMP4 (10 ng/ml), and 
FK506 (0.2 ng/ml) (n = 6; ***P < 0.001; **P < 0.01 vs. CON, 1-way ANOVA, 
Dunnett‘s post test; scale bar: 100 μm). (E) Proposed model of activation of BMPR2 in 
the presence of a subactivating dose of BMPs and an activating dose of BMPs and 
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mutated or dysfunctional BMPR2 receptor with an activating dose of BMPs or with a 
subactivating dose of BMPs and FK506. Mean ± SEM.  
 
FK506 rescues endothelial dysfunction in PAECs from patients with IPAH. To 
determine whether FK506 could rescue BMPR2 dysfunction in PAECs, we 
reduced BMPR2 protein levels to 50% of control values using RNAi (Figure 
3A). As expected, these cells were unresponsive to BMP4 (10 ng/ml), but 
FK506 (15 ng/ml) increased ID1 in keeping with its ability to engage another 
type II receptor, specifically ActivinR2A (40). We then screened mvPAECs 
cultured from lungs harvested at transplant from 6 patients with IPAH that were 
obtained through the Pulmonary Hypertension Breakthrough Initiative Network. 
We found that mvPAECS from 3 out of the 6 patients did not increase 
pSMAD1/5 or ID1 in response to normally activating doses of BMP4 (10 
ng/ml). One of these patients had a documented mutation in BMPR2 
(c.961C>CT; p.321R>R/X). In contrast, all mvPAEC cultures that did not 
respond to BMP4 showed an increase in pSMAD1/5 and ID1 1 hour after 
stimulation with FK506 (15 ng/ml) (Figure 3B). Interestingly, 4 hours after 
low-dose FK506 (0.2 ng/ml), ID1 mRNA was elevated, and at 8 hours, apelin 
mRNA was increased (Figure 3C). Apelin is regulated by BMPR2-mediated 
signaling (19) and is important in endothelial homeostasis. We further 
documented that FK506 (0.2 ng/ml) rescued dysfunction of IPAH PAECs by 
reversing their previously described impaired ability to form tubular networks 
in Matrigel (41). FK506 induced tube formation 4 hours after stimulation, in a 
manner comparable to that of VEGF (20 ng/ml), whereas BMP4 failed to do so 
(Figure 3D). 
Taken together, we propose the following mechanism by which FK506 
activates BMP signaling (see schema in Figure 3E). In the presence of BMPs at 
a subactivating dose, FKBP12 acts as inhibitor of BMP signaling. An activating 
dose of BMP ligand initiates removal of FKBP12 from the type I receptor and 
allows for normal SMAD- and non-SMAD–dependent signaling. When BMPR2 
is mutated or dysfunctional, FK506 restores normal signaling by the dual action 
of removing FKBP12 from the type I receptor and inhibiting calcineurin.  
Low-dose FK506 prevents hypoxic PAH in mice with deletion of BMPR2 in 
ECs. Next, we asked whether FK506 would prevent PAH in a mouse with 
BMPR2 deleted in ECs to show — as proof of concept — that FK506 could 
rescue downstream BMP signaling, even in the absence of a functional BMPR2 
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receptor. We crossed SCL-CreERTM, R26 LacZfl/fl, and Bmpr2fl/fl mice and 
created an CLCreERTM+/R26R/Bmpr2–/–(EC-Bmpr2–/–) mouse by 
administering 2 mg tamoxifen per day intraperitoneally for 10 days when the 
mice were 8–12 weeks of age. We documented BMPR2 deletion by positive 
LacZ staining in lung ECs (Figure 4, A and B) and in ECs of other tissues (data 
not shown). Whole lung lysates of EC-Bmpr2–/–mice showed reduced BMPR2 
protein expression compared with those of Cre–/– mice and Cre+/+ mice 
without tamoxifen treatment (Figure 4C). ECs harvested from the lungs of 
EC-Bmpr2–/– mice using CD31 antibody-coated beads showed no BMPR2 
expression in contrast to PAECs from littermate controls (Figure 4D).  
Male animals generally have a greater chronic hypoxia-induced pulmonary 
hypertensive response (42), so we used them exclusively in our study. 
EC-Bmpr2–/– and littermate control mice were housed in room air or in 10% 
oxygen (chronic hypoxia) for 3 weeks, during which time half the mice of each 
genotype were given a continuous s.c. infusion of low-dose FK506 (0.05 mg/ 
kg/day) by mini-osmotic pump and the other half were given vehicle. 
EC-Bmpr2–/– mice and littermate controls maintained in room air had similar 
values for right ventricular systolic pressure (RVSP), and FK506 had no effect 
on this measurement. The elevation in RVSP in chronic hypoxia-exposed mice, 
as a measure of PAH, was more severe in the EC-Bmpr2–/– group than in 
controls (Figure 4E), although there was no further increase in right ventricular 
hypertrophy (RVH) (Figure 4F) or in vascular changes, including 
muscularization of distal arteries (Figure 4G, vessels marked by arrows, and 
Figure 4H) and loss of peripheral arteries (Figure 4I). Administration of 
low-dose FK506 prevented chronic hypoxic PAH in both EC-Bmpr2–/– mice 
and in littermate controls, as judged by lack of elevated RVSP, RVH, and 
reduced vascular changes. Cardiac output decreased slightly in both genotypes 
after chronic hypoxia independent of FK506 treatment (Supplemental Table 1). 
A 3-week treatment with low-dose FK506 did not increase the systemic blood 
pressure (Supplemental Figure 3). Despite its immunosuppressive properties, 
FK506, in the dose used, did not reduce total white blood cells, neutrophils, or 
lymphocytes (Supplemental Table 1). To address whether FK506 rescued EC 
dysfunction related to loss of BMPR2, we exposed PAECs from the 
EC-Bmpr2–/– mice to 1% O2 for 24 hours and treated the cells with low-dose 
FK506 (0.2 ng/ml) or BMP4 (10 ng/ml) for another 8 hours under the same 
conditions. An increase in apelin mRNA, an EC gene normally regulated by 
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BMP signaling, and in endothelial nitric oxide synthase (eNOS), a gene 
regulated by apelin (43) and a marker of EC homeostasis were observed with 
FK506, but not with BMP4 (Figure 4, J and K). The same was true for cells 
under normoxic conditions (data not shown).  
Low-dose FK506 reverses monocrotaline-induced PAH in rats, inhibits 
proliferation, and induces apoptosis in pulmonary artery SMCs. As patients 
with PAH present late in the course of their disease, we assessed whether 
FK506 could also reverse severe PAH and vascular pathology in an 
experimental model without a deletion in BMPR2. PAH was induced in adult 
male Sprague Dawley rats, weighing between 180 and 220 g, with a single s.c. 
dose of monocrotaline (60 mg). PAH was verified in a subset of animals after 
day 21, and a 3-week treatment with vehicle or low-dose FK506 (0.05 mg/kg/d) 
was initiated via s.c. mini-osmotic pump. While vehicle-treated rats showed 
severe PAH at day 42, FK506 treatment significantly reduced the PAH, 
measured by the RVSP (Figure 5A) as well as RVH (Figure 5B). The 
monocrotaline animal model of PAH is characterized by increased muscularity, 
and FK506-treated animals showed reduced muscularization compared with 
vehicle- treated animals (Figure 5C). 
We had previously shown that FK506 could increase apelin in pulmonary 
artery SMCs (PASMCs). Apelin has beneficial autocrine effects on PAEC 
function and, by a paracrine mechanism, suppresses PASMC proliferation and 
can induce apoptosis (19). However, we also showed a direct effect of FK506 in 
inhibiting PDGF-induced PASMC proliferation (Figure 5D) and in inducing 
apoptosis, as judged by the caspase luminescence assay (Figure 5E). 
Interestingly, the latter effect of FK506 on SMCs was lost at higher 
immunosuppressive doses of 15 ng/ml. The mechanism appears to be 
pSMAD1/5 and ID1 independent (Supplemental Figure 4, A and B) and 
suggests an alternative pathway, possibly via PPARγ and ApoE (44) or via 
suppression of NF-ATc, as has been previously shown (31).  
Using an NFAT reporter assay in PASMCs, we confirmed mild NFAT 
inhibition at low doses of FK506 (0.2–0.5 ng/ml) and a more pronounced effect 
at doses clinically used to induce immunosuppression (5–15 ng/ml) (Figure 5F). 
However, FK506 showed only a trend in reducing expression of IL-2, a major 
downstream target of NFAT signaling, when assessed in whole lung tissue of 
vehicle- and monocrotaline-treated rats (Figure 5G), and no effect on IFN-γ, 
another NFAT target (Supplemental Figure 4C). This suggests that inhibition of 
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NFAT activation is not the major mechanism of action by which low-dose 
FK506 reverses PAH. 
 
 
Figure 4. Low-dose FK506 prevents the development of PAH in mice with a 
deletion of BMPR2 in ECs. (A and B) LacZ staining documenting BMPR2 deletion in 
(A) distal PAECs and (B) capillary ECs in EC-Bmpr2–/– mice. Scale bar: 100 μm. (C) 
Reduced BMPR2 in whole lung lysates by Western immunoblot comparing wild-type 
mice with tamoxifen (TAM) with floxed Bmpr2 Cre-ERT mice with or without 
tamoxifen. (D) Absence of Bmpr2 mRNA in ECs harvested from EC-Bmpr2–/– (KO) 
vs. wild-type mice (n = 3; ***P < 0.001 WT vs. EC-Bmpr2–/–, 1-way ANOVA, 
Dunnett‘s). (E) RVSP in wild-type and EC-Bmpr2–/– mice treated with vehicle or 
FK506 (0.05 mg/kg/d) in normoxia or hypoxia (10% O2) for 3 weeks (n = 8 per group; 
**P < 0.01 compared with vehicle normoxia; §§P < 0.01 vehicle hypoxia wild-type vs. 
EC-Bmpr2–/–, 2-way ANOVA, Dunnett‘s). (F) RVH (Fulton index, weight of RV/LV 
and septum) in same groups as in E. (G) Representative histology of barium-injected 
lungs of wild-type and EC-Bmpr2–/– mice after normoxia/hypoxia with or without 
vehicle or FK506. The decreased number of vessels in hypoxia is ameliorated by FK506 
(arrows). Scale bar: 100 μm. (H) Percentage muscularized alveolar wall and alveolar 
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duct arteries per total arteries in wild-type and EC-Bmpr2–/– mice after 
normoxia/hypoxia with or without vehicle or FK506 (n = 8 mice;mean of 5 ×20 fields 
per mouse; **P < 0.01; ***P < 0.001 vs. normoxia wild-type and EC-Bmpr2–/–, 2-way 
ANOVA, Dunnett‘s). (I) Arteries per 100 alveoli in same animals as in H. (J) 
Apelin/18S mRNA and (K) eNOS/18S mRNA in mvPAECs from EC-Bmpr2–/– mice, 
preconditioned in 1% hypoxia and harvested 8 hours after BMP4 (10 ng/ml) or FK506 
(0.2 ng/ml) vs. vehicle (CON) (n = 3; *P < 0.05 vs. CON, 1-way ANOVA, Dunnett‘s). 
Mean ± SEM. 
 
We had previously shown that FK506 could increase apelin in pulmonary 
artery SMCs (PASMCs). Apelin has beneficial autocrine effects on PAEC 
function and, by a paracrine mechanism, suppresses PASMC proliferation and 
can induce apoptosis (19). However, we also showed a direct effect of FK506 in 
inhibiting PDGF-induced PASMC proliferation (Figure 5D) and in inducing 
apoptosis, as judged by the caspase luminescence assay (Figure 5E). 
Interestingly, the latter effect of FK506 on SMCs was lost at higher 
immunosuppressive doses of 15 ng/ml. The mechanism appears to be 
pSMAD1/5 and ID1 independent (Supplemental Figure 4, A and B) and 
suggests an alternative pathway, possibly via PPARγ and ApoE (44) or via 
suppression of NF-ATc, as has been previously shown (31). Using an NFAT 
reporter assay in PASMCs, we confirmed mild NFAT inhibition at low doses of 
FK506 (0.2–0.5 ng/ml) and a more pronounced effect at doses clinically used to 
induce immunosuppression (5–15 ng/ml) (Figure 5F). However, FK506 showed 
only a trend in reducing expression of IL-2, a major downstream target of 
NFAT signaling, when assessed in whole lung tissue of vehicle- and 
monocrotaline-treated rats (Figure 5G), and no effect on IFN-γ, another NFAT 
target (Supplemental Figure 4C). This suggests that inhibition of NFAT 
activation is not the major mechanism of action by which low-dose FK506 
reverses PAH. 
Low-dose FK506 reverses PAH related to neointima formation. Given that 
the monocrotaline rat model does not replicate the pathology in humans with 
PAH (45), we also assessed whether FK506 could reverse severe obliterative 
pulmonary vascular lesions characterized by neointima formation in distal 
pulmonary arteries. This pathology is seen in rats treated with the VEGF 
receptor blocker SUGEN 5416 and exposed to chronic hypoxia (46, 47). Adult 
male Sprague Dawley rats at 8 weeks of age, weighing between 180 and 220 g, 
were given a single s.c. dose of SUGEN 5416 (20 mg/kg), exposed to chronic 
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hypoxia for 3 weeks, and then kept in normoxia for another 5 weeks (Figure 
6A). This experimental protocol induces severe and progressive PAH, with 
extensive loss and obliteration of distal arteries associated with neointimal 
lesions (46). Beginning at 8 weeks, we initiated a 3-week treatment with either 
vehicle or low-dose FK506, by continuous s.c. infusion via mini-osmotic pump 
(0.05 mg/kg/d). Vehicle-treated rats showed severe PAH, but FK506 reversed 
the elevation in RVSP and RVH, resulting in values not significantly different 
from those of controls (Figure 6B). Cardiac output was lower after 
administration of SUGEN 5416 and hypoxia and increased with FK506 
treatment (Supplemental Table 2). The percentage of vessels with a neointima 
was reduced from 60% in vehicle-treated rats to less than 20% in those 
administered FK506 (Figure 6C). Consistent with previous studies, we 
documented mild emphysema in rats treated with SUGEN 5416 and hypoxia 
(48, 49), reflected in a 25% decrease in the number of alveoli and a comparable 
reduction in the number of arteries (Figure 6D). FK506 preferentially restored 
arterial number so the ratio of arteries per 100 alveoli increased (Figure 6E). As 
in the murine chronic hypoxia experiments, FK506 also restored endothelial 
function, as judged by an increase in apelin (Figure 6F) in whole lung tissue. 
Although we cannot exclude a contribution of NFAT inhibition in 
FK506-mediated reversal of PAH, we found no significant reduction in targets 
of NFAT activation, i.e., IL-2 (Figure 6G) and IFN-γ (Supplemental Figure 5).  
 
Discussion 
We report the first high-throughput screen of known pharmaceuticals to 
determine whether any of these agents would increase BMPR2 signaling. Our 
study design permitted evaluation of strong activators (without exogenous BMP 
ligand), weaker acti-vators (with exogenous BMP ligand), and potential 
inhibitors of BMP signaling. The top 3 activators of BMP-mediated signaling 
and ID1 target gene expression, FK506 (tacrolimus), FK520 (ascomycin), and 
rapamycin, are potent immunosuppressants that prevent T cell proliferation by 
interacting with the immunophilin FKBP12 (50). FK506 appears superior to 
rapamycin in potentiating BMP signaling because it also inhibits the 
phosphatase calcineurin (51). In addition, FK506 interacts with FKBP12 
associated with all 3 BMPR type 1 receptors (ALK1, ALK2, and ALK3), 
including those preferred by BMPR2 (ALK1 and ALK3), whereas rapamycin 
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only interacts with ALK2.  Cyclosporine shares the calcineurin inhibitory 
properties of FK506 (52), but as it does not bind FKBP12, it is a weak activator 
of BMP signaling in PAECs. 
 
Figure 5. Low-dose FK506 reverses monocrotaline-induced PAH in rats, inhibits 
proliferation, and induces apoptosis in PASMCs. (A) RVSP (mmHg) in rats 21 days 
after monocrotaline (MCT) treatment (60 mg s.c. once), with or without 3-week 
treatment with vehicle (VEH) or low-dose FK506 (n = 6–8; **P < 0.01 compared with 
VEH treated; #P < 0.05 compared with day 21 monocrotaline; §§§P < 0.001 compared 
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with day 42 monocrotaline vehicle, 1-way ANOVA, Bonferroni post test). (B) RVH 
(Fulton index) in same group as above (***P < 0.001 compared with vehicle treated; §P 
< 0.05 compared with day 42 monocrotaline vehicle, 1-way ANOVA, Bonferroni post 
test). (C) Represented lung histology (Movat stain) (scale bar: 100 μm). (D) MTT 
proliferation assay with PASMCs in the presence or absence of PDGF (20 ng/ml) 72 
hours after stimulation with vehicle (CON), BMP4 (10 ng/ml), or FK506 (0.2 and 2.0 
ng/ml) (n = 5; **P < 0.01, ***P < 0.001, BMP4 vs. CON [in the presence of PDGF], 
1-way ANOVA, Dunnett‘s). (E) Assessment of apoptosis with measurement of 
caspase-3/7 luminescence under 24-hour serum starvation or treatment with BMP4 (10 
ng/ml) or FK506 (0.2, 1.0, 2.0, and 15 ng/ml) (n = 5; *P < 0.05 1-way ANOVA, 
Dunnett‘s post test). (F) Luciferase NFAT reporter activation assay in PASMCs 
stimulated with PDGF (30 ng/ml) and doses of FK506 between 0.2 and 15 ng/ml. (##P 
< 0.01 and ###P < 0.001, vs. stimulation by PDGF alone, 1-way ANOVA with 
Bonferroni‘s multiple pairs test). (G) Il2/Gapdh mRNA expression in whole lungs of 
rats 21 days after monocrotaline treatment (60 mg s.c. once), with or without 3-week 
treatment with vehicle or low-dose FK506 (n = 6–8; nonsignificant, 2-way ANOVA). 
Mean ± SEM.  
 
Also on the list of BMPR2 signaling activators is the TGF-β receptor 
blocker, SB431542, which could antagonize the enhanced TGF-β signaling that 
occurs when BMPR2 is deficient (53). Our libraries contained pharmaceuticals 
currently used to treat PAH, including bosentan, iloprost, and imatinib. None 
activated BRE-luciferase, although iloprost can induce ID1 by a 
pSMAD1/5-independent, cAMP-mediated mechanism (54). Recent data suggest 
that other medications approved and effective for PAH, such as the vasodilator 
and phosphodiesterase inhibitor sildenafil, can partially restore BMPR2 
defective signaling (55), underscoring the importance of this pathway in PAH.  
 Both at immunosuppressive and at low doses, FK506 not only mimics BMP4 
signaling in PAECs but also promotes PAEC survival and increases tube 
formation, functions essential for preventing loss of vessels and inducing vessel 
regeneration in PAH (56). In addition, we have evidence of both paracrine (via 
apelin) (57) and autocrine effects of FK506 in reducing proliferation and 
mediating apoptosis in SMCs. 
TGF-β type I family receptors (including ALK3) share a common 
glycine-serine–rich sequence, identified as the site of phosphorylation by type 2 
receptors as well as the FKBP12 binding site (58). FKBP12 has multiple 
functions, including Ca
++
 channel gating and protein folding (37). By serving as 
CHAPTER 4 
110 
a docking protein for the phosphatase calcineurin (39), FKBP12 also modulates 
the phosphorylation status of TGF-β type I and other receptors, e.g., EGF-R and 
inositol trisphosphate receptors (50), providing a safeguard against leaky 
constitutive signaling (37). We showed that FK506 interacts with FKBP12 and 
is able to dissociate it from type I receptors, e.g., ALK1, ALK2, and ALK3 that 
form heterodimers with BMPR2. This is a novel finding, although the concept 
that FK506 can release bound FKBP12 from TGF-β type I receptors or EGF-R 
(59) has been described previously. Furthermore FK506, even at low doses, 
inhibits calcineurin activity, which, in concert with removing FKBP12, results 
in phosphorylation of ALK1, ALK2, and ALK3 and in downstream 
pSMAD1/5-dependent and -independent signaling. Phosphorylation of the type 
I receptor induced by FK506 requires kinase activity from a type 2 BMP 
receptor, and the type I receptor likely co-opts ActivinR2A when BMPR2 is 
reduced or dysfunctional. Thus, signaling is transduced in mice with deletion of 
BMPR2 in ECs and in human PAECs with mutant BMPR2. 
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Figure 6. Low-dose FK506 reverses established PAH and neointima formation in 
rats. (A) Timeline of experiments. (B) RVSP and RVH (Fulton index) in rats in 
normoxia with or without vehicle (VEH) or FK506 and in rats after SUGEN with 3 
weeks hypoxia and 5 weeks normoxia, sacrificed at 8 weeks and at 11 weeks following 
treatment with vehicle or FK506 (n = 8; *P < 0.05; ***P < 0.001 vs. same condition in 
normoxia, 2-way ANOVA, Bonferroni post test). (C) Representative images (scale bar: 
100 μm) and percentage vessels with neointima in hypoxia/SUGEN/normoxia rats at 8 
and 11 weeks treated with vehicle or FK506 (n = 8; **P < 0.01 vs. vehicle, 1-way 
ANOVA, Bonferroni post test). (D) Number of alveoli per mm2 in normoxia (with or 
without vehicle or FK506) and in rats after hypoxia/SUGEN/normoxia, sacrificed at 11 
weeks (with or without 3-week treatment of vehicle or FK506) (n = 8; *P < 0.05 vs. 
untreated normoxia condition, 2-way ANOVA, Dunnett‘s post test). (E) Mean number 
of arteries per 100 alveoli (5 fields ×20) in same groups as in D (n = 8, #P < 0.05, 1-way 
ANOVA, selected pairs post test, vehicle vs. FK506). (F) Apelin/β-actin mRNA 
expression in total lung lysate in same group as in D (n = 8; *P < 0.05, 1-wayANOVA, 
Dunnett‘s post test). (G) Il2/Gapdh mRNA expression in whole lungs of rats in 
normoxia (with or without vehicle or FK506) and in rats after 
hypoxia/SUGEN/normoxia, sacrificed at 11 weeks (with or without 3-week treatment of 
vehicle or FK506) (n = 8; *P < 0.05 vs. vehicle normoxia, #P < 0.05 vs. FK normoxia, 
nonsignificant trend in decrease of IL-2 with FK506 treatment, 2-way ANOVA, 
Bonferroni multiple-comparison test). Mean ± SEM. 
 
FK506 also increases EC expression of ALK1 and endoglin (60). As 
loss-of-function mutations in these genes are observed in PAH associated with 
hemorrhagic telangiectasia (HHT), FK506 could also be of potential benefit in 
patients with this disorder. In fact, FK506 was given following liver transplant 
in a patient with HHT who had multiple arteriovenous malformations, and it 
was noted that internal and external telangiectases, epistaxes, and anemia 
disappeared, suggesting that the mechanism of action of FK506 involved partial 
correction of endoglin and ALK1 haploinsufficiency (60).  
    Binding and removing FKBP12 from the type I receptors by FK506 is 
dynamic and varies with different FK506 concentrations at different time points 
(data not shown), so the effect, particularly, of low-dose FK506 is unlikely to 
induce the same constitutive activation of BMP signaling that is observed in 
fibrodysplasia ossificans progressiva. This is a condition characterized by a 
mutation in ALK2 that permanently reduces binding of FKBP12 (61). 
    Low-dose FK506 reverses the impaired ability of PAECs from patients 
with IPAH to form tubular networks (41, 62), consistent with its induction of 
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apelin, a pSMAD-independent target of BMPR2 signaling (19). Apelin (63), a 
ligand for the G protein–coupled receptor APJ, is highly expressed in 
endothelial but not in other vascular cells (64). It is proangiogenic (65) and 
induces eNOS (57). Apelin-null mice develop more severe hypoxia-induced 
PAH than controls. Patients with IPAH have reduced apelin plasma levels (43), 
and their PAECs have decreased apelin mRNA and protein (19). Furthermore, 
the role of apelin in raising levels of a miRNA that represses FGF production is 
thought to be responsible for the paracrine effect of apelin in suppressing SMC 
proliferation and inducing SMC apoptosis. This may be the mechanism causing 
reversal of PAH in both the monocrotaline and the SUGEN hypoxia rat models 
(66), but we also showed that low-dose FK506 represses cultured PASMC 
proliferation and induces apoptosis independent of endothelial apelin. 
Our studies show efficacy of low-dose FK506 in activating the BMPR2 
pathway. Interestingly, it was this dose in contrast to a higher dose that inhibited 
atherosclerotic plaque development and progression in Apoe
–/–
 mice (33, 34). 
Moreover, high doses of FK506 (>10 fold of those used in our study) caused 
systemic hypertension and transplant vasculopathy in animal models, 
presumably mediated by a paradoxical decrease in eNOS and increase in 
endothelin production (67). In contrast, the low-dose FK506 used in our studies 
did not induce systemic hypertension, even after a 3-week treatment.  
We chose mice with deletion of BMPR2 in ECs to determine whether 
FK506 could prevent hypoxia-induced PAH in the absence of endothelial 
BMPR2 and found that it was effective in both EC-Bmpr2
–/–
 and wild-type 
genotypes. The latter may be related to reversal of hypoxia-mediated 
suppression of BMPR2 signaling (68). 
Our study is one of few to show that an agent can reverse severe 
established PAH and neointima formation in the SUGEN5416/ hypoxia rat 
model (46, 66). We suggest that FK506 was able to do so both by upregulating 
apelin and, to a lesser extent, by suppressing NF-ATc–mediated gene regulation. 
The effect of inhibiting NFAT activation, in addition to increasing BMPR2 
signaling, would be beneficial in treating PAH. Previous studies have shown 
that inhibition of NF-ATc with rapamycin reverses monocrotaline-induced PAH 
(31) by restoring Kv1.5 channel expression, decreasing proliferation, and 
inducing apoptosis of SMCs. 
Treatment with FK506 increases cardiac output in the 
SUGEN5416/hypoxia rat model, perhaps because the interaction of FK506 with 
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FKBPs modulates calcium cycling in the heart. In a mouse model of left heart 
failure, characterized by increased expression of FKBP12.6 in the heart, FK506 
restored contractile function of isolated cardiomyocytes by inhibiting the 
association with FKBP12.6 and the ryanodine receptor (69). 
 
Methods 
High-throughput screen. Libraries of FDA-approved drugs and bioactive 
compounds, containing 3,756 unique compounds (NIH-CC, LOPAC, Biomol 
ICCB Known Bioactives, Microsource spectrum, Biomol FDA-approved drug 
library), were available from the High-Throughput Bioscience Center at 
Stanford University. The C2C12 mouse myoblast cell line that stably expresses 
a BMP response element from the ID1 promoter linked to luciferase (BRE-luc) 
(25) was used as a reporter cell line for BMP activation. The bioassay can detect 
luciferase activity after stimulation with a dose as low as 3 pM BMP4 (our 
ligand of choice, due to the excellent assay sensitivity) (see Supplemental 
Figure for details). 
    Reagents. FK506 (Cayman Chemicals), rapamycin (Cayman Chemicals), 
cyclosporine (Sigma-Aldrich), shield-1 (a gift from T.J. Wandless, Stanford 
University), SUGEN5416 (Cayman Chemicals), BMP4 (Sigma-Aldrich), and 
monocrotaline (Sigma-Aldrich) were used.  
    Plasmids. FKBP12-Flag plasmid was a gift from Takeshi Imamura (JFCR 
Cancer Institute, Tokyo, Japan). HA-ALK1, HA-ALK2, HA-ALK3 have been 
previously described (72). Transcription reporter assays. C2C12 cells were 
seeded in 24-well plates and then transfected with Polyethylenimine (PEI, 
Fermentas) with the indicated plasmids. For CAGA-Luc, the luciferase activity 
was analyzed 24 hours after stimulation with TGF-β3 (5 ng/ml) or FK506 with 
indicated concentrations. For BRE-luc, the transfected cells were pretreated 
with LDN-193189 (120 nM) for 30 minutes before stimulation with FK506 (1 
μg/ml) for 24 hours. Each experiment was performed in triplicate at least, with 
normalization to β-galactosidase activity.  
    Cell culture. C2C12 mouse myoblastoma cell line was stably transfected 
with a construct in which the BMP/SMAD elements of the ID1 promoter were 
linked to luciferase (BRE-luc) (a gift from Peter ten Dijke). C2C12 and 293T 
were maintained in DMEM supplemented with 10% FBS, penicillin/ 
streptomycin, and Glutamine (Gibco). Human large PAECs (ScienCell) and 
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human and mouse mvPAECs were grown in commercial EC media (ScienCell). 
Cells were subcultured at a 1:3 ratio in gelatin-coated dishes. Human PASMCs 
(Lonza) were grown in commercial SMC media (Lonza) and subcultured at a 
1:5 ratio. Only passages 3–8 were used.  
    Immunoprecipitation and immunoblotting. 293T cells were transfected 
with indicated plasmids, medium was changed 12 hours after transfection, and, 
48 hours after transfection, cells were stimulated with FK506 (100 ng/ml) for 30 
minutes (see the Supplemental Methods for details).  
    Isolation of human and mvPAECs. Human and murine mvPAECs were 
isolated from digested whole lung tissue using CD31 antibody–coated magnetic 
beads (Dynabeads; Invitrogen) as previously described (19). mRNA expression 
by qRT-PCR. Total RNA was extracted and purified from whole lung tissue and 
cells with the RNAeasy Plus Kit (Qiagen) and then reverse transcribed using 
SuperScript III (Invitrogen) per the manufacturer‘s instructions. Expression 
levels of selected genes were quantified using preverified Assays-on-Demand 
TaqMan primer/probe sets (Applied Biosystems) and normalized to ribosomal 
RNA 18S and B2M (mice and humans) and β-actin and Gapdh (rats). The 
housekeeping gene that was chosen was most consistent throughout the 
experimental conditions. 
    Western immunoblotting. Western immunoblotting was done as previously 
described (41). 
    Apoptosis assay and proliferation assays. PAEC, mvPAEC, and PASMC 
survival and proliferation were assessed by cell counts and MTT assays. 
Caspase-3/7 (Promega) was used to detect apoptosis as previously shown (19, 
41). 
    RNAi. siRNAs for BMPR2 (Dharmacon) were transfected into PAECs 
using RNAi Max (Invitrogen) as described previously (73). The knockdown 
efficiency for BMPR2 was determined by Western immunoblotting. siRNAs for 
BMPR2, ActivinR2A, Activin R2B, ALK1, ALK2, ALK3, and FKBP12 were 
transfected into C2C12 BRE-luc cells using DharmaFect3, and knockdown 
efficiency was determined by qRT-PCR. Nontargeting siRNA (Dharmacon) 
was used as a control. 
    Tube formation assay. PAECs were starved for 12 hours in 0.2% FBS, and 
10,000 cells were seeded on Matrigel (Trevigen) in serum-free medium with or 
without stimuli. The number of tubes and tube length were assessed after 8 
hours in large PAECs and after 4 hours in mvPAECs. 
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Creation of cell-specific inducible EC-Bmpr2–/– mice. Endothelial SCL-CRE 
ERT mice, with a 5′-endothelial SCL enhancer (–7 to 0.9 kb) that directs 
expression to endothelium (74), were crossed with Rosa26R mice and crossed 
with Bmpr2fl/fl mice created previously in our laboratory. Tamoxifen was 
given at 2 mg per day i.p. for 10 days; after another 14 days, CRE activation led 
to a deletion in BMPR2 in ECs in lungs as well as all other vascularized tissues. 
Littermates were used as controls. 
Hypoxia/SUGEN/normoxia and monocrotaline rat models. Adult male Sprague 
Dawley rats at 8 weeks of age, weighing between 180 and 220 g, were given a 
single s.c. dose of SUGEN5416 (20 mg/kg) and then placed in chronic hypoxia 
for 3 weeks, followed by a period of 5 weeks normoxia, as previously described 
(46). The monocrotaline experiments in rats were carried out as previously 
described (75). 
Statistics. All data are presented as mean ± SEM. We performed the statistical 
analyses using 1-way ANOVA when more than 2 groups of data were compared 
and 2-way ANOVA when 2 conditions were involved. We considered 
differences to be statistically significant at P < 0.05.  
Study approval. All animal experiments were reviewed and approved by the 
Stanford University IACUC in accordance with the guidelines of the NIH. The 
studies on human primary cells were approved by the appropriate Institutional 
Review Board on human subjects and IACUC at Stanford University. 
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High Throughput Screen: Libraries of FDA approved drugs and bioactive 
compounds containing 3756 unique compounds (NIHCC, LOPAC, Biomol 
ICCB Known Bioactives, Microsource spectrum, Biomol FDA approved drug 
library) were available from the High-Throughput-Bioscience-Center at 
Stanford University. Some compounds were present in more than one drug 
library. The C2C12 mouse myoblast cell line that stably expresses a BMP 
Response Element from the Id1 promoter linked to luciferase (BRE-luc) (1) 
was used as a reporter cell line for BMP activation. The bioassay can detect 
luciferase activity after stimulation with as low as 3 pM BMP4 (our ligand of 
choice due to the excellent assay sensitivity) and has been validated for BMP2, 
BMP6 and BMP7; however, other members of the TGF-β family, i.e., TGF-β 1, 
2, 3 or TGF-β unrelated growth factors such as FGF-2 and VEGF, do not induce 
luciferase activity. We optimized a number of conditions (cell number, BMP4 
concentration, time-course of plating cells, adding stimulus, adding luciferase 
substrate Brightglo® (Promega) and the library of interest). C2C12 BRE-luc 
cells were grown in DMEM (4.5 g/L D-Glucose, L-Glutamine, 10% FBS, 1% 
Penicillin/Streptomycin) up to 80% confluency. Cells were trypsinized, 
centrifuged and resuspended in complete medium. Cells were counted in a 
Coulter counter (size range 11-21 m) and 1500 cells/60 l were plated in each 
well of a 384-well plate (EK-30098, clear bottom plate, E&K Scientific) using 
the Matrix Wellmate. Cells were placed in the Liconix automated incubator at 
37°C for 24 h. Ten microliters of the stimulant BMP4 was added to columns 
1-22 of every other plate by the multidrop (250 pM final concentration) on the 
Staccato system and 100 nL of the compounds were added (in duplicate +/- 
BMP4) to plates using the Pin Tool on the SciClone ALH3000. The plates were 
incubated for an additional 24 hours and 10 l Bright-Glow (Promega) was 
added to each well and the plates were read immediately afterwards in the 
AnalystGT (0.2 second read per well). Hits were determined as compounds that 
either increase the BMP4 induced signal (weak activators) or increase the 
un-induced signal (strong activators) without exogenous BMP4 and only 
endogenously produced BMP4 around. The intra-plate and inter-plate 
variability in a pilot screen using 10 x 384 well plates showed a coefficient of 
variance of 4.7% and 7.1% respectively. The Z‘ of the screen was above 0.5 
showing a robust and reproducible response from BMP4 activation. ―Hits‖ were 
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validated with respect to their potential to activate luciferase to detect false 
positive signals and promising hits were tested in 6 serial dilutions. 
Immunoprecipitation: To determine the interaction between TGF-β type I 
receptors and FKBP12, 293T cells were transfected with low amounts of 
Flag-tagged FKBP12 and/or BMP type I receptor (ALK1, -2 or -3)-HA tagged 
plasmid. Medium was changed 12 hour after transfection, and 48h after 
transfection cells were stimulated with FK506 (100ng/ml) or vehicle for 30 min. 
prior to harvest. Cells were then washed with PBS and lysed with 1ml lysis 
buffer (10mM Tris–HCl at pH 7.5, 1mM EDTA, 150mM NaCl and 0.5% NP-40) 
plus protease inhibitors (Sigma) for 10min at 4°C. Lysates were clarified by 
centrifugation and equal amounts of lysate were incubated with anti-Flag 
agarose beads (A2220,Sigma) for 1 hour at 4°C before the beads were washed 
three times with washing buffer (50mM Tris–HCl at pH8.0, 150mM NaCl, 0.5% 
Nonidet P-40, 0.5%sodium deoxycholate and 0.1%SDS) and resuspended in 
lysis buffer. Total protein expression was detected by immunoblotting with 
anti-Flag (M2, Sigma) or anti-HA (Y-11, SC-805, Santa Cruz biotechnology) 
antibodies. The immune complexes were eluted with sample buffer containing 1% 
SDS for 5min at 95°C, and separated by SDS–PAGE. Western blotting was 
performed with indicated antibodies and secondary anti-mouse or anti-rabbit 
antibodies conjugated with horseradish peroxidase (Amersham Biosciences). 
Visualization was obtained with chemiluminescence detection. While upon 
co-expression FKBP12 and BMP type I receptor were readily detected by 
Western blot analysis, when expressed alone, FKBP12 or BMP type I receptor 
expression levels were below the detection limit. A possibility for the higher 
expression of FKBP12 and BMP type I receptor, when coexpressed, is that 
FKBP12 stabilizes the complex via its chaperone activity. FK506 short-term 






Supplementary Table 1: Characterization of mice with a conditional endothelial 
specific deletion in BMPR2 in Normoxia and Hypoxia ± Vehicle (VEH) or FK-506 in 
terms of echocardiographic as well as laboratory parameters. (2-way ANOVA and 
Bonferroni‘s post test, N=8, *p<0.05 vs Normoxia VEH. ns=No significant difference 






Supplementary Table 2: Echocardiographic cardiac output measurements in control 
versus SUGEN/Hypoxia treated rats with and without treatment with FK506. (N=8, 





Supplement Figure 1: FK506 in a dose dependent manner induces BMP but not 
TGF- signaling (A) BRE-luciferase activity in C2C12 cells at different concentrations 
of FK506 (0.01 and 3.5 g/ml) (N=6,**p<0.01 vs CON, one-way ANOVA, Dunnett‘s 
post-test). (B) Luciferase activity in CAGA-Luc cells with TGF- (5ng/ml) and 
different concentrations of FK506 (0.01 and 3.5 g/ml) (N=6, **p<0.01 vs CON, 




Supplement Figure 2: Mechanism of FK506 induced BMP signaling related to FKBP12 
release from type I receptors. (A) Representative immunoblot showing expression of 
phospho Smad1/5/8 and GAPDH in C2C12cells, pretreated with LDN-193189 (120 nM) 
for 30 min and stimulated with BMP6 (50ng/ml) and FK506 (1g/ml) for 15 min, 30 
min and 1 h. (B) Panels showing knockdown efficiency of, BMPR2si, ActivinR 2Asi as 
well as ActivinR 2Bsi FKBP12si in C2C12 BRE-luc cells. (C) BRE-luciferase activity 
in C2C12 cells treated with nontargeting(NT)si, ALK1si, ALK2si and ALK3si and 
stimulated with Cyclosporine (2 g/ml) (N=8, NS vs. NTsi with cyclosporine, One-way 
ANOVA). (D) BRE-luciferase activity in C2C12 cells after FK506 (2 
g/ml),Rapamycin (4 g/ml), Cyclosporine (2 g/ml) and Rapamycin combined with 
Cyclosporine (same conc. as above)(N=8, ***p<0.001 vs. FK; ###p<0.01 vs. Rapa; and 
§§§p<0.001 vs. Cyclo one-way ANOVA, Bonferroni‘s Multiple Comparison Test). (E) 
BRE-luciferase activity in C2C12 cells after knocking down FKBP12 by siRNA and 
stimulation with FK506 (2 g/ml) and BMP4 (250 pM) (N=16, **p<0.01 NTsi + FK vs 
FLBP12 si + FK, two-way ANOVA, Bonferroni‘s Multiple Comparison Test). (F and G) 
BRE-luciferase activity in C2C12 cells after knocking down different FK Binding 
Proteins (FKBPS) by siRNA and no stimulation or stimulation with BMP4(250 pM) or 
FK506 (2 g/ml): FKBP1A (=FKBP12), FKBP1B (=FKBP12.6), FKBP2 (=FKBP13), 
FKBP3(=FKBP25), FKBP8 (=FKBP38), FKBP4 (=FKBP52), FKBP5 (=FKBP54). (H) 
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Representative immunoblot showing phospho p38, phospho ERK, Phospho Smad1/5 
and Smad1 in PAECs stimulated with BMP6 (50 ng/ml)and FK506 (15 ng/ml) for 15 
min and 1 h. (I) Representative immunoblot showing phospho AKT and β-actin in 
PAECs stimulated with BMP4 (40 ng/ml) and FK506 (15 ng/ml) for 10 min, 30 min 
and 1 h. (J) Representative immunoblot showing phospho c-Jun and -actin in PAECs 
stimulated with BMP4 (40 ng/ml) and FK506 (15ng/ml) for 10 min, 30 min and 1 h. 





Supplement Figure 3: 3-week treatment with low dose FK506 does not increase the 
systemic blood pressure in mice. Systemic blood pressure measurements via carotid 
artery in C57Bl6 mice (8-10 weeks of age) after 3 weeks treatment with vehicle or 






Supplement Figure 4 (A,B): FK506 does not induce Smad1/5 phosphorylation or 
Id1 expression inhuman pulmonary artery smooth muscle cells (hPASMCs). (A) 
Representative immunoblot and densitometric analysis of pSmad1/5/8 relative to total 
Smad-1 protein expression and (B) Id1 protein relative to ß-actin at 15 min and 60 min 
after stimulation with BMP4 (10 ng/ml),FK506 (0.2 ng/ml and 15 ng/ml) in PASMCs. 
(In A and B, for N=3, *p< 0.05 vs. CON, 1-way ANOVA,Dunnett‘s post-test). Bars are 
mean ± s.e.m. 
Supplement Figure 4 (C): Low dose FK506 does not reduce NFAT dependent INF 
expression in monocrotaline treated rats. (C) INF expression in whole lungs of rats 
21 d after MCT treatment (60 mg sconce) and ± 3 week treatment with either vehicle 





Supplement Figure 5: Low dose FK506 does not decrease NFAT dependent INF 
expression in whole lungs of SUGEN/hypoxia rats INF expression in whole lungs of 
rats in normoxia (± VEH or low-dose FK506) as well as in rats after 
hypoxia/Sugen/normoxia sacrificed at 11 w (± 3 w treatment of VEH or low dose 
FK506). (N=8, *p<0.05 VEH normoxia vs VEH hypoxia, #p<0.05 FK normoxia vs FK 
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Endoglin is a type III co-receptor of the transforming growth factor β (TGF-β) 
family. It plays a critical role in angiogenesis, and mutations in endoglin can 
lead to the vascular disease hereditary hemorrhagic telangiectasia. The soluble 
form of endoglin (sEng) has been found in human sera and enhanced levels 
correlate with the vascular disorder preeclampsia. In this study we have 
expressed and purified the extracellular domain (ECD) of human endoglin using 
human cells. This recombinant sEng was secreted in both monomeric and 
dimeric forms which could both bind to the TGF-β type receptor activin 
receptor-like kinase (ALK)1 ECD and bone morphogenetic protein (BMP)9. 
Our results indicate that monomeric sEng has multiple effects on BMP9 
induced signaling, and does not only function as a ligand trap. Further research 
on the underlying molecular mechanisms by which sEng affects BMP signaling 
might be helpful for resolving the action of sEng in preeclampsia and other 
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Introduction 
Human endoglin is present in cells as a 180 kDa homodimeric disulfide-linked 
transmembrane glycoprotein. Based on its cDNA sequence endoglin is 
predicted to have a large extracellular domain, a hydrophobic transmembrane 
domain, and a short cytoplasmic tail (1). It is mainly expressed in proliferating 
endothelial cells (ECs) and is a critical factor for vascular remodeling and 
angiogenesis (2). 
    Endoglin was initially characterized as a co-receptor for transforming 
growth factor β (TGF-β) (3). TGF-β is the prototype of a large structurally 
related cytokine family, including two other TGF-β 
bone morphogenetic proteins (BMPs), and signals via type I and type II 
transmembrane serine/threonine kinase receptors (4). Endoglin interacts with 
TGF-β1, TGF-β3, activin A, BMP2 and BMP7 in the presence of the respective 
receptors (5). Interestingly, it can interact with BMP9 and BMP10 in the 
absence of type I and type II receptors (6). 
A soluble form of endoglin (sEng) has been found in particular in the 
serum of patients with cancers and preeclampsia (7, 8). In carcinoma tissues, a 
80 kDa sEng was found to be shedded from the membrane bound endoglin 
through proteolytic cleavage by matrix metalloproteinase (MMP) 14 at position 
586, indicating that nearly the whole extracellular domain of endoglin is 
released (9). Also in the case of preeclampsia, a systemic syndrome associated 
with pregnancy hypertension and proteinuria (8, 10, 11), the detected sEng was 
postulated to be derived from the membrane bound endoglin through 
proteolysis by MMP14, but the molecular weight of preeclampsia derived sEng 
is around 65 kDa (8, 12). 
BMP9 is the only BMP family member circulating in a biological active 
concentration in the blood, and it plays an important role in human angiogenesis 
(13, 14). The vascular disorder phenotypes of patients with BMP9 mutations 
show overlap with the phenotype of HHT patients (15). BMP9 specifically 
activates the EC-specific type I receptor activin receptor-like kinase (ALK)1, 
but it can bind to three TGF-β family type II receptors: BMP type II receptor 
(BMPR2), activin A receptor type II A (ACVR2A) and ACVR2B (16-18). 
BMP9 signaling is measured by analyzing the activation/phosphorylation and 
expression of the downstream effectors of these TGF-β type I receptors, i.e. 
SMAD1/5 phosphorylation and ID1 gene expression. 
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Recently two groups reported mechanistic studies on the role of sEng. One 
group analyzed Fc chimeras containing amongst others the full-length endoglin 
extracellular domain (ECD) (sEng-Fc); the other examined recombinant sEng 
ECD without an Fc domain (6, 19). Both studies showed that endoglin ECD can 
directly bind to BMP9 and BMP10 with a high affinity. Moreover endoglin 
ECD and ALK1 were found to bind to different sites of BMP9 (6, 19). The 
recombinant sEng-Fc was found to inhibit vascular endothelial growth factor 
(VEGF) induced vessel formation in the chick chorioallantoic membrane assay 
and to reduce VEGF/ fibroblast growth factor (FGF)-induced blood vessel 
sprouting in vivo (6). It was proposed that sEng functions as a ligand trap to 
block the binding of BMP9 and BMP10 to TGF-β type II receptors to inhibit 
BMP9 and BMP10 signaling, thereby perturbing vascular homeostasis (6, 19). 
To gain further insight in the molecular mechanisms by which sEng 
regulates BMP9/SMAD signaling, we expressed and purified recombinant sEng 
containing the full-length endoglin ECD using human embryonic kidney 293 
cells stably expressing Epstein-Barr virus nuclear antigen (HEK EBNA), and 
investigated the biochemical interaction of this sEng with BMP9 and ALK1 
ECD. In addition, we investigated the effect of recombinant sEng on BMP 
signaling and examined the role of ALK1, TGFβR2 and BMPR2 therein. 
 
Results 
Expression and purification of human sEng from human cells 
The full-length extracellular region of human endoglin (Figure 1A) was cloned 
in a pCEP4 C-terminal histidine-tag (His-tag) vector and transfected into human 
HEK EBNA cells. The supernatant of the transfected cells was collected and the 
secreted endoglin was purified by column chromatography. Non-reducing 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by Western blot analysis with an anti-endoglin antibody indicates that 
both dimeric (D) and monomeric (M) forms of sEng were present in the 
supernatant, with molecular weights of around 150 kDa and 80 kDa respectively 
(Figure 1B). In addition, a higher molecular weight protein complex was 
detected that likely represents a tetrameric form of sEng, albeit in a lower ratio 
compared to the D and M forms (Figure 1B). The different forms of sEng were 
further purified by nickel nitrilotriacetic acid column chromatography. The size 
of the D form of sEng was found to be comparable with that of recombinant 
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endoglin from R&D systems (Figure 1C). Moreover, both the R&D endoglin 
and the D form of purified sEng could be dissociated into the (monomeric) M 
form upon reduction with dithiothreitol (DTT) (Figure 1C). This is consistent 
with previous reports in which endoglin was found to be a covalently dimerized 
protein with disulfide cysteine linkages at position 350 and 582 (19, 20). In 
summary, our results showed that the full-length ECD of endoglin can be 
produced as a soluble form in human cells, and that it seems to exist in a 
dimeric and monomeric configuration. 
 
 
Figure 1. Western blot analysis of recombinant sEng. A, Schematic diagrams of 
full-length membrane bound endoglin and recombinant sEng with His-tag used in this 
study with numbers indicating the amino acid residues. Full-length endoglin is cleaved 
by MMP14 at position 586 to release 80 kDa sEng with the complete extracellular 
domain. Cys350 and Cys582 may mediate the dimerization of endoglin via disulfide 
linkage. Sig, signal peptide; TM, transmembrane region; ZP, zona pellucida; C350, 
cysteine 350; C582, cysteine 582; cyto, cytoplasmic; His, histidine tag. B, sEng 
expression in dimeric and monomeric forms. Supernatant of sEng expressing cells was 
separated on non-reducing SDS-PAGE and detected with an endoglin antibody; the 
diagram on the right shows a schematic drawing of sEng. Molecular weight markers are 
indicated on the left side. C, SDS-PAGE analysis of recombinant human endoglin 
(R&D Systems) and 1.5 μg purified sEng dimers and monomers, under non-reducing 
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and reducing conditions followed by Coomassie staining. D, dimer form; M, monomer 
form. 
 
Both D and M sEng can form complexes with BMP9 and BMP9/ALK1 
To investigate whether the purified forms of sEng can interact with BMP9 and 
ALK1, we incubated it with purified recombinant BMP9 and ALK1 and 
analyzed complex formation on native PAGE. His tagged BMP9 (HBMP9) and 
ALK1 ECD were produced as described before and they can form a complex on 
native gel (21). We observed that both D and M forms of sEng can form 
complexes with HBMP9, as upon co-incubation with BMP9 the two bands of 
sEng shifted to higher molecular weight bands (Figure 2A and 2B, band 2, 3). 
sEng can form complexes in the presence of both ALK1 ECD and BMP9 (Fig. 
2A and 2B, band 4, 5), but not with ALK1 ECD alone (unpublished data). 
SDS-PAGE analysis of bands 2-5 confirmed that both the D and M forms of 
sEng formed complexes with BMP9 and BMP9/ALK1 (Figure 2B and 2C). 
 
 
Figure 2. sEng forms complexes with BMP9 and BMP9/ALK1. A, Purified proteins 
were mixed and run on 10% native PAGE at 100V for 3 hours and visualized by 
Coomassie staining. Both sEng dimer and monomer can form complexes with His 
tagged (H) BMP9 and BMP9/ALK1 in the native PAGE. B, Analysis of the complexes 
shown in panel A: bands 1-5 were cut out and boiled in loading buffer with SDS for 20 
min before loading in the non-reducing SDS-PAGE. D, dimer, M, monomer. C, 
Schematic diagram of the monomeric sEng complexed to BMP9-ALK1 ECD in the 
plasma membrane.  
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Effects of sEng on BMP9 induced signaling 
To gain more insight into how monomeric sEng regulates BMP9 signaling, we 
assessed SMAD phosphorylation in human ECs treated with BMP9 or 
BMP9/sEng complexes. Human microvascular endothelial cells (HMEC-1) 
were serum starved overnight, and (without washing) subsequently stimulated 
with BMP9 (0.1 ng/ml), or with BMP9 that was first pre-incubated with 
increasing concentrations of the purified sEng monomer (BMP9/sEng) for 15 
minutes at room temperature. Cells were stimulated for 15 minutes to detect the 
immediate signaling responses without involving new protein synthesis. The 
phosphorylation status of SMAD1/5 (pSMAD1/5) was measured by western 
blot analysis. We observed that our monomeric sEng partially inhibits BMP9 
induced pSMAD1/5 activity at the high concentration (200 ng/ml), as observed 
by others who studied the effect of recombinant sEng on BMP9 signaling (6, 
19), and unexpectedly, but reproducibly, also at low doses of sEng (4 ng/ml). 
However, at concentrations ranging from 8 to 16 ng/ml we did not find that 
monomeric sEng inhibits but weakly activates BMP9/SMAD1 signaling (Figure 
3A). The weak stimulatory effect was reproducible, but the exact dose of BMP9 
by which this was observed differed between experiments. Next, we analyzed 
BMP9 and BMP9/monomeric sEng for their ability to induce an Id1-derived 
BMP responsive element (BRE) driven luciferase reporter in C2C12 mouse 
myoblast cells. As these cells do not express ALK1, we first transfected the 
cells with a human ALK1 expression vector or control vector, and subsequently 
with the BRE reporter. After overnight serum starvation, the transfected C2C12 
cells were stimulated with increasing concentrations of BMP9 or BMP9 
pre-incubated with monomeric sEng (16 ng/ml) for 8 hours. Both BMP9 and 
BMP9/sEng induced luciferase responses in the presence of ALK1, and there 
was a trend that the preformed BMP9/sEng complex is more potent than BMP9 
to induce luciferase activity at multiple BMP concentrations (Figure 3B). Thus, 
these experiments indicate that that monomeric sEng has multiple effects on 
BMP9 induced signaling, and does not only inhibit signaling by acting as a 




Figure 3. Effects of sEng on BMP9 induced signaling. A, The effect of sEng 
monomer on BMP9 induced pSMAD1/5 in human microvascular endothelial cells. B, 
sEng promotes BMP9/ALK1 mediated signaling in a BRE-luciferase assay in C2C12 
mouse myoblast cells. All the experiments were repeated 3 times, and one of the 
representative results is shown. Values are presented as mean and SD from 3 technique 
replicates. Data are representative of three independent experiments.  
 
Both TGFβR2 and BMPR2 may mediate BMP9 regulated signaling 
BMP9 strongly binds to ALK1 and BMPR2 and weakly binds to the type II 
receptors ACVR2A and ACVR2B, but not TGFβR2 (17, 18). The role of 
full-length (membrane bound) endoglin in regulating BMP9 signaling is largely 
dependent on the type II receptors involved (22), which raises the question 
whether sEng might utilize different type II receptors than full-length endoglin 
to alter downstream SMAD signaling. To answer this question, we first knocked 
down ALK1, BMPR2, TGFβR2 and ACVR2B by siRNA in HMEC-1 cells. 
Receptor knockdown efficiency was verified by the quantitative PCR (qPCR) 
analysis (Figure 4A). HMEC-1 cells were subsequently stimulated with BMP9 
for 15 minutes. Compared to the cells treated with control siRNA the induction 
of pSMAD1/5 was impaired in the ALK1, BMPR2 and TGFβR2 knockdown 
cells but not in the ACVR2B depleted cells (Figure 4B). This suggests that 
ALK1, BMPR2 and TGFβR2 might be required for BMP9 signaling in 
HMEC-1 cells. To further study this, we performed crosslinking experiments 
with 
125
I-BMP9. COS-1 cells were transfected with expression plasmids 
encoding a mutant TGFβR2 containing a truncated intracellular domain with a 
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Myc tag (TGFβR2 Δ-Myc), HA-tagged wild-type ALK1 (ALK1-HA) and 
full-length membrane bound endoglin (Figure 4C). After incubation with 
125
I-BMP9 for 3 hours and crosslinking, the receptor and ligand complexes were 
immunoprecipitated with a Myc antibody (Figure 4C). TGFβR2 was found to 
bind to BMP9 in the presence of ALK1 or endoglin in this overexpression 
system (Figure 4C). This indicates that TGFβR2 ECD might transduce BMP9 
and endoglin controlled signaling. Additional receptor interaction experiments 
with labeled sEng need to be performed for further investigations. 
 
Discussion 
In this study we expressed and purified recombinant sEng containing a 
full-length ECD in human cells, and showed that both monomeric and dimeric 
sEng forms complexes with BMP9 and ALK1 ECD in vitro. We also showed 
that TGFβR2 ECD can bind to BMP9 in the presence of overexpressed ALK1 
or endoglin. In our experimental conditions monomeric sEng did not inhibit 
BMP9 induced signaling at a physiological concentration (around 16 ng/ml). 
This might be due to the fact that sEng together with BMP9 can bind to ALK1 
(and possibly TGFβR2) and participate in signaling itself at the cell membrane. 
Another explanation might be that dimeric sEng is a more potent scaffold than 
monomeric sEng, but this remains to be established. 
The soluble form of endoglin has been hypothesized to scavenge BMP9 
and thereby affect the delicate balance of angiogenesis (6, 19). However, our 
study indicates that it may also function in a different way, which appears to be 
concentration dependent. The studies demonstrating an inhibitory effect of sEng 
on BMP signaling were performed with relatively high concentration of sEng. 
For instance, Alt et al. showed that 10,000 ng/ml sEng blocks BMP9 induced 
ID1 gene expression in HMEC-1 (19). Castonguay et al. showed an inhibitory 
effect of human sEng-Fc on BMP9 induced luciferase activity in a human 
rhabdomyosarcoma cell line with IC50 of 83.6 ng/ml based on the molecular 
weight of sEng-Fc (6). However, it is difficult to compare their results with ours, 
since they used a different cell type and the Fc fusion protein used might bring 
about unspecific protein interactions. It is possible that excessive sEng 
scavenges BMP9 to inhibit the downstream signaling, but that at lower 
concentrations sEng might also promote downstream signaling. Importantly, the 
median value of sEng in the plasma of normal pregnant women is 5.6 ng/ml; for 
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patients with preeclampsia the median value is around 73.7 ng/ml for 
early-onset patients and 31.1 ng/ml for late-onset patients (23). 
 
 
Figure 4. TGFβR2 is possibly involved in BMP9 signaling. A, Verification of the 
knockdown efficiency of the indicated constructs by qPCR in HMEC-1 cells two days 
after the transfection. Scramble siRNA (Control) was tested in all qPCR primers set, 
which is defined as 1, and all values were accordingly adjusted to the control. B, 
Knockdown of ALK1, BMPR2, TGFβR2 in HMEC-1 impairs BMP9 induced 
BMP/SMAD signaling. C, BMP9/endoglin/TGFβR2 and BMP9/ALK1/TGFβR2 
complexes were detected on the cell surface of transfected COS-1 cells after affinity 
labeling with 
125
I-BMP9. Data are representative of three independent experiments in 
Figure 4A and 4B. 
 
The involvement of TGFβR2 might be another reason why we did not 
observe a strong inhibitory effect of sEng in our study. Upton et al. showed that 
the type II receptors are critical for balancing BMP9 signaling via ALK1, as 
BMP9 signals through BMPR2 to induce Smad1/5 phosphorylation while 
ACVR2A mediates BMP9/Smad2 activation in ECs (22). As mentioned above, 
we found that endoglin ECD forms complexes with BMP9 and ALK1 ECD, and 
that BMP9 can bind to TGFβR2 in the presence of excessive ALK1 or 
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full-length (membrane bound) endoglin. Moreover, knockdown of TGFβR2 by 
siRNA inhibited BMP9/SMAD signaling. Previous research also showed that 
endoglin, ALK1 and TGFβR2 form functional complexes to interact with 
several proteins associated with endothelial barrier maintenance and cell 
migration (24). We therefore hypothesize that BMP9 and (monomeric) sEng 
can bind TGFβR2 at physiologically relevant concentrations of sEng; these 
BMP9/sEng complexes might signal through ALK1/TGFβR2 and result in 
non-inhibitory effects on BMP signaling. However, receptor binding 
experiments with monomeric sEng need to be performed to validate binding to 
the various type II receptors involved in BMP9/sEng signaling. This might help 
to explain how sEng contributes to the pathogenesis of various vascular diseases 
like preeclampsia. 
 
Materials and Methods 
Cell culture and reagents 
Human HMEC-1 cells were maintained in MCDB 131 (Invitrogen) supplied 
with 10 ng/ml epidermal growth factor (Millipore), 1 ug/ml hydrocortisone 
(Sigma) and 15% fetal bovine serum (FBS). C2C12 mouse myoblast cells and 
COS-1 cells were grown in DMEM with 10% FBS. All cells were cultured at 5% 
CO2. The antibodies used for immunoblotting were phosphorylated SMAD1/5 
antibody (1:1000, Cell signaling Technology, Danvers, MA, USA), Endoglin 
antibody (R&D system), Myc antibody (Santa Cruz) and GAPDH antibody 
(1:40,000, Sigma).  
 
sEng expression and purification 
The human endoglin extracellular domain was cloned into pCEP4 with a 
C-terminal His-tag and verified by DNA sequencing. The endoglin ECD 
construct was transfected into HEK EBNA cells by polyethylenimine as 
described before (21). Cells were changed into CDCHO expression medium 
without serum the following day, and conditioned media was harvested after 3–
4 days. To purify sEng, the conditioned medium was run over a nickel 
nitrilotriacetic acid column (GE Healthcare), followed by a Q sepharose and 




Transfections and quantitative real-time PCR analysis  
HMEC-1 cells were transfected using DharmaFECT 1 (Thermo Scientific, 
Pittsburgh, PA, USA) according to the manufacturer‘s instructions. Total RNA 
was isolated using the RNAII isolation kit (Machery Nagel, Düren, Germany) 
according to the manufacturer‘s instructions. 1 μg RNA was reverse transcribed 
by using the RevertAid H Minus First strand cDNA synthesis kit (Fermentas, 
St.Leon-Rot, Germany) according to manufactures instructions. Quantitative 
real-time PCR (qPCR) analysis was performed using the Roche LightCycler 
480 and the relative expression levels of the genes of interest were determined 
in triplicate for each sample using the 2
-CT






I-BMP9 binding assay 
Iodination of BMP9 was performed according to the chloramine T method and 
cells were subsequently affinity-labeled with the radioactive ligand as described 
before (25). In brief, cells were pre-incubated with the radioactive BMP9 on ice 
for 3 hours. After incubation, crosslinking was performed using 0.27 uM 
disuccinimidyl suberate (DSS) and 0.07 uM bis(sulfosuccinimidyl)suberate 
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(BS3, Pierce) for 15 minutes. Cells were washed and lysed. Cell lysates were 
incubated with Myc antibody overnight and immune complexes were 
precipitated by adding protein G sepharose (GE healthcare). Samples were 
boiled and subjected to SDS-PAGE.  
 
Transcriptional reporter assay 
C2C12 cells were seeded in a 96-well plate and transiently transfected with a 
human ALK1 expression construct or empty vector using Lipofectamine 
reagent (Invitrogen) according to the manufacturer's protocol. 24 hours later, the 
cells were transfected with BRE-luciferase reporter construct. An expression 
plasmid for β-galactosidase was co-transfected and used to correct for 
transfection efficiency. Cells were serum-starved overnight and stimulated with 
the respective ligands the next day for eight hours. Cells were washed, lysed 
and luciferase and β-galactosidase activity were determined. Each transfection 
was carried out in triplicate and representative experiments are shown. 
 
Standard SDS–PAGE, non-reducing SDS–PAGE, and native PAGE 
Standard SDS-PAGE was prepared with reducing reagent DTT or 
β-mercaptoethanol and denatured by SDS. Non-reducing SDS-PAGE was 
prepared without DTT, but with SDS. For native PAGE, protein samples were 
prepared without SDS denaturation and DTT reduction, and there was no SDS 
or DTT included in the gel casting buffers or in the running buffer for 
electrophoresis. The gels were either stained by Coomassie blue or used for 
Western blotting. Immunoblotting was performed as previously described, 
using standard techniques (26).  
 
Acknowledgements 
This work was supported by the LeDucq foundation. 
 
References 
1. Gougos A, and Letarte M. Primary structure of endoglin, an RGD-containing 
glycoprotein of human endothelial cells. The Journal of biological chemistry. 
1990;265(15):8361-4. 
2. ten Dijke P, Goumans MJ, and Pardali E. Endoglin in angiogenesis and vascular 
diseases. Angiogenesis. 2008;11(1):79-89. 
CHAPTER 5 
142 
3. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, and Letarte M. 
Endoglin is a component of the transforming growth factor-beta receptor system in 
human endothelial cells. The Journal of biological chemistry. 
1992;267(27):19027-30. 
4. Wrana JL, Attisano L, Wieser R, Ventura F, and Massague J. Mechanism of 
activation of the TGF-beta receptor. Nature. 1994;370(6488):341-7. 
5. Barbara NP, Wrana JL, and Letarte M. Endoglin is an accessory protein that 
interacts with the signaling receptor complex of multiple members of the 
transforming growth factor-beta superfamily. The Journal of biological chemistry. 
1999;274(2):584-94. 
6. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, 
Sako D, Pearsall RS, Underwood KW, Seehra J, et al. Soluble endoglin specifically 
binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood 
vessel formation, and suppresses tumor growth. The Journal of biological 
chemistry. 2011;286(34):30034-46. 
7. Bernabeu C, Lopez-Novoa JM, and Quintanilla M. The emerging role of TGF-beta 
superfamily coreceptors in cancer. Biochimica et biophysica acta. 
2009;1792(10):954-73. 
8. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, 
Lim KH, Yuan HT, Libermann TA, et al. Soluble endoglin contributes to the 
pathogenesis of preeclampsia. Nature medicine. 2006;12(6):642-9. 
9. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, 
and ten Dijke P. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin 
shedding inhibits tumor angiogenesis. Cancer research. 2010;70(10):4141-50. 
10. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, and Kumar S. Plasma 
levels of soluble CD105 correlate with metastasis in patients with breast cancer. 
International journal of cancer Journal international du cancer. 2000;89(2):122-6. 
11. Valbuena-Diez AC, Blanco FJ, Oujo B, Langa C, Gonzalez-Nunez M, Llano E, 
Pendas AM, Diaz M, Castrillo A, Lopez-Novoa JM, et al. Oxysterol-induced 
soluble endoglin release and its involvement in hypertension. Circulation. 
2012;126(22):2612-24. 
12. Kaitu'u-Lino TJ, Palmer KR, Whitehead CL, Williams E, Lappas M, and Tong S. 
MMP-14 is expressed in preeclamptic placentas and mediates release of soluble 
endoglin. The American journal of pathology. 2012;180(3):888-94. 
13. Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, Subileau M, Tillet E, 
Feige JJ, and Bailly S. BMP9 is produced by hepatocytes and circulates mainly in 
an active mature form complexed to its prodomain. Cellular and molecular life 
sciences : CMLS. 2012;69(2):313-24. 
14. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, Plauchu 
H, Feige JJ, and Bailly S. Bone morphogenetic protein-9 is a circulating vascular 
quiescence factor. Circulation research. 2008;102(8):914-22. 
15. Wooderchak-Donahue WL, McDonald J, O'Fallon B, Upton PD, Li W, Roman BL, 
Young S, Plant P, Fulop GT, Langa C, et al. BMP9 mutations cause a 
vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic 
telangiectasia. American journal of human genetics. 2013;93(3):530-7. 
16. David L, Mallet C, Mazerbourg S, Feige JJ, and Bailly S. Identification of BMP9 
and BMP10 as functional activators of the orphan activin receptor-like kinase 1 
(ALK1) in endothelial cells. Blood. 2007;109(5):1953-61. 
Soluble endoglin regulates signaling by bone morphogenetic protein 
143 
17. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, 
Lowik CW, and ten Dijke P. BMP-9 signals via ALK1 and inhibits bFGF-induced 
endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of cell 
science. 2007;120(Pt 6):964-72. 
18. Brown MA, Zhao Q, Baker KA, Naik C, Chen C, Pukac L, Singh M, Tsareva T, 
Parice Y, Mahoney A, et al. Crystal structure of BMP-9 and functional interactions 
with pro-region and receptors. The Journal of biological chemistry. 
2005;280(26):25111-8. 
19. Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ, Round A, Rubio V, 
Bernabeu C, and Marina A. Structural and functional insights into endoglin ligand 
recognition and binding. PloS one. 2012;7(2):e29948. 
20. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, and Bernabeu C. 
Extracellular and cytoplasmic domains of endoglin interact with the transforming 
growth factor-beta receptors I and II. The Journal of biological chemistry. 
2002;277(32):29197-209. 
21. Wei Z, Salmon RM, Upton PD, Morrell NW, and Li W. Regulation of bone 
morphogenetic protein 9 (BMP9) by redox-dependent proteolysis. The Journal of 
biological chemistry. 2014;289(45):31150-9. 
22. Upton PD, Davies RJ, Trembath RC, and Morrell NW. Bone morphogenetic 
protein (BMP) and activin type II receptors balance BMP9 signals mediated by 
activin receptor-like kinase-1 in human pulmonary artery endothelial cells. The 
Journal of biological chemistry. 2009;284(23):15794-804. 
23. Chaiworapongsa T, Romero R, Kusanovic JP, Mittal P, Kim SK, Gotsch F, Than 
NG, Mazaki-Tovi S, Vaisbuch E, Erez O, et al. Plasma soluble endoglin 
concentration in pre-eclampsia is associated with an increased impedance to flow 
in the maternal and fetal circulations. Ultrasound in obstetrics & gynecology : the 
official journal of the International Society of Ultrasound in Obstetrics and 
Gynecology. 2010;35(2):155-62. 
24. Xu G, Barrios-Rodiles M, Jerkic M, Turinsky AL, Nadon R, Vera S, Voulgaraki D, 
Wrana JL, Toporsian M, and Letarte M. Novel protein interactions with endoglin 
and activin receptor-like kinase 1: potential role in vascular networks. Molecular & 
cellular proteomics : MCP. 2014;13(2):489-502. 
25. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, 
Heldin CH, and Miyazono K. Osteogenic protein-1 binds to activin type II 
receptors and induces certain activin-like effects. The Journal of cell biology. 
1995;130(1):217-26. 
26. Shi S, Cai J, de Gorter DJ, Sanchez-Duffhues G, Kemaladewi DU, Hoogaars WM, 
Aartsma-Rus A, t Hoen PA, and ten Dijke P. Antisense-oligonucleotide mediated 
exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is 









6.1 The regulation of the BMP signaling pathway 
 
6.2 Developing FOP therapies by targeting ALK2 
      6.2.1 FOP disease models 
      6.2.2 Strategies and challenges in the development of FOP therapies 
based on the BMP signaling pathway 
 
6.3 Restoration of BMPR2 signaling in PAH 
      6.3.1 BMPR2 in PAH 
      6.3.2 Strategies and challenges to restore BMPR2 expression 
 
6.4 Soluble endoglin modifies signaling by BMP9 
 












Bone morphogenetic proteins (BMPs) play vital roles in development and 
maintenance of adult tissue homeostasis. Due to the extensive biological 
activities they are involved in, disruptions in BMP signaling will lead to marked 
defects or severe pathologies in the body. In this thesis, I focused on the 
disturbed BMP signaling in fibrodysplasia ossificans progressiva (FOP) and 
pulmonary arterial hypertension (PAH). The aim of this thesis is to reveal how 
BMP signaling contributes to the pathology of these diseases, which might 
contribute to the development of effective therapeutic strategies for these 
diseases with unmet clinical need.  
 
6.1 The regulation of the BMP signaling pathway 
BMPs are multi-functional growth factors that are important for determining 
embryonic patterning and tissue morphogenesis (1). Dimeric BMP ligands 
initiate intracellular signaling by binding to BMP type I and type II 
serine/threonine kinase receptors on the cell surface to form a ternary complex. 
In the heteromeric complex, BMP type II receptor activates the type I receptors 
by phosphorylating specific serine and threonine residues in their 
juxtamenbrane glycine-serine-rich (GS) domains (2).  
BMP signaling is extensively regulated at multiple levels, which we have 
described in chapter 1. The most important regulators for my research are the 
12 kDa FK506 binding protein (FKBP12) and endoglin.  
FKBP12 is widely expressed throughout the body and shows a conserved 
structure among different species. It was known to mediate the effects of the 
immunosuppressant drugs FK506 and rapamycin (3, 4). Further research 
showed that FKBP12 also acts as a natural ligand to bind to the GS domain of 
transforming growth factor beta (TGF-β) type I receptors and inhibits the leaky 
activation of TGF-β type I receptors in the absence of TGF-β ligands (5-7). 
Intact TGF-β type II receptor kinase activity is necessary for the release of 
FKBP12 from the type I receptors, since a mutation in the ATP binding site of 
the kinase domain of TGF-β type II receptors prevents the dissociation of 
FKBP12 from the type I receptors (5). 
Interruption of the interaction between FKBP12 and TGF-β type I 
receptors is correlated with human diseases and could be used for drug targeting. 
The weak binding between FKBP12 and R206H mutant activin receptor-like 
kinase (ALK) 2 in FOP patients resulted in the activated response of heterotopic 
ossification progenitor cells to low concentration of BMP ligands, and finally 
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leads to ectopic bone formation in soft tissues with the involvement of other 
inflammatory factors (Figure 1) (8-10). On the other hand, FKBP12 may also be 
a drug target for curing PAH by activating BMP signaling, which we have 
discussed in chapter 4 (Figure 1).  
 
 
Figure 1. Schematic overview of the BMP signaling pathway. 1, FKBP12 binds to 
the GS domain of BMP type I receptors to prevent the signal leakage in the absence of 
BMPs; 2, The FOP mutation R206H in BMP type I receptor ALK2 inhibits the 
interaction between the ALK2 GS domain and FKBP12; 3, In PAH with dysfunctional 
BMPR2, FK506 can activate downstream SMAD signaling by binding to calcineurin in 
the presence of FKBP12, and removing FKBP12 from TGF-β/BMP type I receptor 
ALK1, ALK2 and ALK3. Adapted from the original figure in Chapter 4. 
 
    Co-receptors like endoglin that can interact with TGF-β type I and type II 
receptors add further regulation specificity to the BMP signaling pathway (11). 
Endoglin (CD105) is highly expressed in proliferating endothelial cells (ECs) 
(12). Various disease conditions, including hereditary hemorrhagic 
telangiectasia (HHT), preeclampsia and solid tumors have been associated with 
endoglin. In chapter 5, we have investigated the soluble form of endoglin and 
how it regulates the activity of BMP9. Finally, crosstalk with other signaling 
pathways could add additional layers of complexity to the BMP signaling 
pathway.  
 
6.6 Developing FOP therapies by targeting ALK2 
FOP is caused by a heterozygous mutation in the ALK2 gene. Most patients 
have the same mutation (c.617G>A; R206H) that is located in the GS domain of 
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ALK2 (13). Other mutations have been identified both in the GS domain and in 
the kinase domain of ALK2 with various phenotypes (Figure 2) (10). The 
clinical features of FOP include malformation of the great toes and progressive 
heterotopic ossification (HO) in the soft tissues. HO begins in childhood and 
can be triggered by traumas or occurs without warning (14). Researchers have 
made great progress on illustrating the molecular mechanisms of FOP since the 
identification the FOP mutant gene in 2006. However, the underlying 
mechanisms involved in the HO in FOP are still not clearly clarified, and to date 
there is no cure or even treatment for HO in FOP. 
 
 
Figure 2: Schematic overview of the ALK2 structural protein domains and the 
FOP mutations in the GS and kinase domains. Signal peptide (Sig), Ligand binding 
domain (LBD), Transmembrane domain (TM), GS domain (GS), and kinase domain 
(KD). 
 
6.2.1 FOP disease models 
It is not easy to obtain tissues from FOP patients, because physical and surgical 
injuries can induce new traumas and trigger HO. Previous research in FOP 
animal models have helped us to understand the role of BMP signaling in the 
pathology of FOP. For instance, Yu et al. showed that blocking mutant ALK2 
by an ALK2 kinase small molecule inhibitor might be a useful treatment, as 
revealed from experiments in a FOP mouse model expressing constitutively 
active ALK2 (15). Chakkalakal et al. showed the first direct evidence that the 
ALK2 R206H mutation is the cause of FOP using a chimeric mouse knock-in 
model (16). The work on animal models might also provide novel research and 
treatment targets for FOP. Recently, a FOP conditional knock-in mouse model 
was introduced by Hatsell et al.(17). This mouse model recreated FOP disease 
phenotypes by exhibiting HO progressively in various locations of the body. 
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Importantly, in this FOP mouse model the novel finding that activin A signals 
through mutant R206H ALK2 to induce FOP was verified. Blocking activin A 
activity with antibodies prevented the HO phenotype in this FOP mouse model, 
which indicates that activin A is a potential therapeutic target in FOP (17).  
Validation in human samples of disease phenotypes and molecular 
mechanisms found in animal models will facilitate us to better understand the 
pathology of human diseases. Previously, researchers obtained FOP patients‘ 
samples in the form of lymphoblastoid cell lines or connective tissue of the 
discarded milk teeth of FOP children (13, 18). Due to the rarity feature of this 
disease and limited accessibility of patient‘s tissues, we have focused on 
modeling FOP disease using human induced pluripotent stem cells (hiPSCs). 
This can provide an alternative human research model that complements the in 
vivo studies of FOP mouse models. hiPSCs can provide a large amount of cells 
for research, and, more importantly, hiPSCs have the potential to differentiate 
into various cell linages that can mimic the disease phenotypes in the 
pathological cells. There are several publications on the establishment of 
hiPSCs from FOP patients and their subsequent differentiation into 
chondrocytes and osteoblasts (19, 20). Our research on this topic is described in 
chapter 2. 
Our FOP hiPSC disease model needs to be improved on many aspects 
before applying it in high-throughput drug development. One crucial issue of 
the application of hiPSCs is to choose proper controls. Previous publications 
have shown that there are variations in different hiPSC clones and these 
variations (resulting from (epi) genetic changes) may arise during 
reprogramming and culturing (21-25). We found that the small-molecule ALK2 
kinase inhibitor LDN-212854 could rescue the excessive osteoblast 
differentiation of FOP hiPSC-pericytes (chapter 2). However, we also observed 
clone variations between FOP or wild-type hiPSCs derived from different 
donors. The further application of hiPSCs may need to use multiple control 
hiPSC lines from different donors or gene-edited hiPSCs from the same genetic 
background (19). 
 
6.2.2 Strategies and challenges in the development of FOP therapies based   
on the BMP signaling pathway 
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The identification of ALK2 mutation in FOP patients provides a specific 
druggable target for this disease. The first approach to inhibit HO progression in 
FOP was to block the activity of the mutant ALK2 receptors (14). Based on this 
principle, the small-molecule inhibitor of BMP type I receptor LDN-193189 
was used to inhibit ALK2 mediated SMAD1/5 phosphorylation and to reduce 
ectopic ossification in the FOP mouse model expressing constitutively active 
ALK2
Q207D
 and concomitant inflammation (15). Thereafter other 
small-molecule BMP type I receptor kinase inhibitors have been discovered, 
including LDN-212854, DMH1 and K02288 (26-28). 
    Targeting the overactive ALK2 by anti-sense oligonucleotides (AONs) or 
siRNAs that suppress (mutant) ALK2 expression is the other possible strategy 
for the treatment and prevention of HO in FOP patients (29-31). Previous 
researches showed that the allele specific siRNA technique can be used to target 
the disease-causing ALK2 (30, 31). The siRNAs were applied in the patient‘ 
cells to restore BMP activity and osteogenic differentiation (30, 31). In chapter 
3, we used the AON-mediated exon skipping technique to target mouse 
wild-type Alk2 to prevent the increased BMP signaling in FOP. AON-mediated 
exon skipping has been reported to reframe the mutated dystrophin mRNA and 
restore protein synthesis of dystrophin protein in skeletal muscle of Duchenne 
muscular dystrophy patients (32, 33). Systemic delivery of AONs is less 
challenging than of siRNAs. However, the application of the AON technique in 
FOP is still in the preliminary stage. We have attempted to specifically target 
the ALK2 R206H allele with human ALK2 AONs, but so far this has not been 
successful. The other problem, targeting HO progenitor cells by ALK2 AON, 
also needs to be solved. 
Recently work indicated that TGF-β type II receptors need to cooperate 
with the mutated ALK2 in FOP. BMP type II receptor (BMPR2) and activin 
receptor type IIb (ActR2B) are involved in the activation of BMP signaling by 
mutant ALK2 (R206H, G325A) (34, 35). Thus, BMPR2 could be another novel 
therapeutic target for FOP drug development, for instance development of 
AONs and siRNAs targeting BMPR2. 
    As already indicated above, a critical issue for developing effective 
therapies for FOP is to identify the target cells for the treatment. However, the 
obtained results on the identification of the HO progenitor cells are still 
inconclusive. Earlier linage tracing experiments in mouse models suggested that 
Tie2-expressing cells contribute to HO lesions (36). Research conducted by 
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Medici et al. showed that TIE2 and the endothelial marker von Willebrand 
factor (vWF) are co-expressed in FOP patient lesions, and a HO mouse model 
supported the endothelial original of HO in FOP (37). However, Wosczyna et al. 
reported that Tie2
+ 
multipotent mesenchymal cells are a predominant source of 
progenitors, but not the Tie2
+ 
ECs (38). As Tie2 is not a specific cell linage 
marker and at least expressed in ECs, hematopoietic stem cells and pericyte 
precursors, it is possible that other cell lineages may also contribute to HO in 
FOP. Other cells like circulating osteogenic precursors, skeletal myoblasts and 
vascular smooth muscle cells (SMCs) were also found in FOP lesions, and may 
contribute to HO in FOP as well (36, 39, 40). 
    Besides the activating mutations in the ALK2 gene, HO induction also 
correlates with soft tissue injury and resultant inflammation in tissue 
microenvironments (41). Anti-inflammatory glucocorticoid drugs have been 
applied for the management of early flare-ups in limited cases (42). In addition, 
anti-inflammatory and anti-angiogenic drugs like cyclo-oxygenase-2 (cox-2) 
inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) have been 
applied in clinical treatments (43). As already described above, a recent 
publication by Hatsell et al. indicates the involvement of activin A in HO in a 
FOP conditional knock-in mouse model (17). Activin A regulates both the 
innate and adaptive immune responses in response to injury and inflammation 
(44). Activin A might thus link the activated SMAD signaling and 
inflammatory flare-ups in FOP lesions, and bring a new drug target to cure FOP 
(17). It should be noted that the experimental work on FOP described in chapter 
2 and 3 was performed before the publication of the paper by Hatsell et al.(17). 
By performing chondrogenic and osteogenic differentiation of FOP hiPSCs or 
ALK2 AON transfected cells treated with Activin A in the presence or absence 
of activin inhibitors, we might not only validate the role of Activin A in HO but 
also provide a different platform for developing efficient treatments for FOP. 
 
6.3 Restoration of BMPR2 signaling in PAH 
6.3.1 BMPR2 in PAH 
PAH is a chronic and progressive disease characterized by high pulmonary 
artery pressure, which will result in failure of the right heart if left untreated. 
Heterozygous mutations in the BMPR2 gene are detected in most of the patients 
with heritable PAH (~70%) and some patients with idiopathic PAH (~20%) (45, 
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46). The majority of BMPR2 mutations (~70%) result in premature termination 





) cause disease due to the dominant negative effects 
(45). Mutations in the ALK1 or endoglin genes are also associated with the 
pathology of PAH (47, 48). Besides, reports have described mutations in other 
BMP signaling components, like SMAD1, SMAD5 and SMAD8 in PAH patients 
(49, 50). Conditional heterozygous or homozygous deleted BMPR2 gene in 
mouse pulmonary ECs results in PAH (51), as well as mice expressing 
dominant-negative BMPR2 in vascular SMCs after birth (52).  
New DNA sequencing techniques such as RNA sequencing and 
whole-exome sequencing have helped to identify more PAH related genes. 
Caveolin-1 and potassium channel subfamily K member 3 (KCNK3) were 
identified as the two mutated genes in PAH patients without BMPR2 mutation 
(53, 54), and TopBP1 was identified in idiopathic PAH without BMPR2 
mutation (55). However, these mutations are extremely rare compared to 
BMPR2 mutations (56). 
Although there is a strong correlation between mutations in BMPR2 and 
PAH, the low penetrance of BMPR2 mutations suggests that other genetic and 
environmental factors combine with the disrupted BMP signaling to contribute 
to the development of PAH. For instance, the incidence of PAH is elevated in 
women, and that alterations in estrogen metabolism are associated with the 
increased penetrance in female patients (57). Suppression of BMP signaling by 
estrogen promoted the proliferation of female pulmonary artery smooth muscle 
cells (PASMCs) and predisposed women to PAH (58).  
Loss function of BMPR2 in ECs increases pulmonary EC apoptosis and 
promotes endothelial permeability (59, 60). Hamid et al. illustrated that 
unaffected mutation carriers have higher levels of wild-type BMPR2 transcripts 
than familial PAH patients, indicating that the expression level of wild-type 
BMPR2 might be important in disease pathogenesis of familial PAH patients, 
especially patients with nonsense mediated decay mutations in BMPR2 (61). 
Furthermore, PAH patients without BMPR2 mutations showed lower 
expression levels of BMPR2, for instance PAH patients associated with human 
immunodeficiency virus (HIV) infection (62). By adenoviral transfer of 
BMPR2 into the pulmonary vascular endothelium, Reynolds et al. showed that 
upregulating BMPR2 expression in two established PAH rat models can rescue 
PAH disease phenotypes (63). Thus, these examples demonstrate the critical 
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role of BMPR2 signaling in PAH and BMPR2 might act as a potential regulator 
linking different PAH pathologies. 
 
6.3.2 Strategies and challenges to restore BMPR2 expression 
Current treatments of PAH mainly focus on reversal of pulmonary 
vasoconstriction or decrease of EC and SMC proliferation, through targeting of 
the prostacyclin, endothelin, or nitric oxide pathways (64). However, these 
treatments can relieve disease symptoms and slow down the progression of 
PAH, but cannot prevent the disease. Understanding of the molecular 
mechanism of PAH pathology has enabled us to consider several novel 
treatments by restoring BMPR2 levels. 
Strategy 1: 
One strategy is to increase BMPR2 expression on the mRNA or protein 
levels. As mentioned above, the majority of BMPR2 mutations (around 70%) 
result in the premature termination of translation of the BMPR2 transcripts (45), 
the approach to promote the read-through of premature stop codons in BMPR2 
could be beneficial for these patients. Drake et al. showed that ataluren 
normalizes full-length BMP2 protein expression level by permitting ribosomal 
read-through of premature stop codons (65). In addition, ataluren also corrected 
BMP-regulated miRNA processing and restored the hyperproliferative 
phenotype of pulmonary artery endothelial cells (PAECs) and PASMCs (65).  
NMD
-
 mutations may lead to the restoration of BMPR2 proteins in the 
endoplasmic reticulum and Golgi and fail to reach the cell surface. Chemical 
chaperones can help with the correct folding of BMPR2 protein and enhances 
the trafficking of BMPR2 to the cell surface (66). Thirdly, Durrington et al. 
demonstrated that BMPR2 is degraded through lysosomes and that the 
endogenous mammalian E3 ligase Itch may be involved in this process (67). 
The antimalarial drug chloroquine has been reported to promote cell surface 
expression of BMPR2 by blocking lysosomal degradation (68, 69).  
A recent publication indicated that BMP9 restores BMPR2 signaling in 
part by upregulating BMPR2 expression. Long et al. reported that BMP9 could 
prevent EC apoptosis and enhance monolayer integrity in vitro. Furthermore, 
BMP9 reversed the development of PAH in heterozygous knock-in mice 





Another option is using reagents that activate BMPR2 downstream signaling by 
activating either BMP type I receptors or SMAD signaling. An example of this 
using the compound FK506 has been described in chapter 4. By performing 
high throughput screening of US food and drug administration (FDA) approved 
drugs and bioactive compounds in BMP reporter cell lines, we identified FK506 
(tacrolimus) as the best BMP activator. FK506 activates BMP signaling via a 
dual mechanism. Firstly, it acts as a calcineurin inhibitor. Calcineurin is a 
calcium-dependent serine-threonine phosphatase which activates nuclear factor 
of activated T cells (NFAT) dependent transcription by dephosphorylating 
NFATs (70). Bonnet et al. demonstrated that NFAT activation is associated 
with human and experimental PAH, and inhibition of NFAT with 
calcineurin/NFAT inhibitor Cyclosporine A reverses monocrotaline induced 
PAH in rats (71). Besides, calcineurin was shown to antagonize the intensity of 
BMP signaling by directly dephosphorylating receptor-regulated SMADs 
(R-SMAD) during neural differentiation of human and mouse embryonic stem 
cells (ESCs) (72). In chapter 4, we showed that low dose of FK506 mildly 
inhibits NFAT activity and its downstream target Interleukin (IL)-2. Thus, 
inhibition of calcineurin in PAH patients could help to relief inflammatory 
responses and probably activates BMP downstream signaling by counteracting 
R-Smad dephosphorylation. The other mechanism by which FK506 can activate 
BMP signaling is by interacting with FKBP12 to prevent the binding of 
FKBP12 to the BMP type I receptors ALK1, ALK2 and ALK3, resulting in 
enhanced phosphorylation of these type I receptors and activation of 
downstream signaling (Figure 1).  
A clinical trial on the effects of low-dose FK506 reported therapeutic 
benefit for three cases of end-stage PAH (73). FK506 is a potent 
immunosuppressive drug being widely used in solid organ transplantations (74). 
It has been found that organ transplanted patients treated with FK506 are at high 
risk of renal injury, which might have happened due to the wide expression of 
calcineurin (75, 76). Thus, even though FK506 has shown significant clinical 
benefits, long-term use of this agent when treating PAH needs to be carefully 
monitored for the toxicity issue.  
Besides FK506, we have tested compounds developed by Arcarios BV 
(Netherlands) for their effects on the BMP signaling pathway. For this drug 
screening we used C2C12 cells (a mouse myoblast cell line) stably transfected 
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with a reporter construct containing a BMP-responsive element linked to the 
luciferase gene (BRE-luc). By adding 135 ng/ml BMP9, the concentration 
resulting in 20% of maximal response (EC-20) and distinguishing activators 
requiring the exogenous ligand (Figure 3A), we have identified two agents 
(compound 6 and compound 13) that could potentiate BMP9-induced luciferase 
activity in C2C12 cells (Figure 3B). In addition to BMP9, we have also 
screened Arcarios compounds with other BMP ligands (BMP2, BMP6 and 
BMP7), but none of these compounds activated luciferase activity with these 
other ligands (data not shown). The two co-activators could sustain 
BMP9-induced phospho-SMAD1/5 (pSMAD1/5) activity for about ten hours 
(Figure 3C). In a three days differentiation assay, they also could potentiate the 
BMP9 induced alkaline phosphatase activity (ALP) activity (Figure 3D). The 
above results indicate that compound 6 and 13 selectively activate BMP9 
signaling but not the signaling of other BMPs we have tested. 
BMP9 specifically signals through ALK1 signaling in ECs and ALK2 in 
myoblasts (77, 78), and it can selectively enhance endothelial BMPR2 signaling 
in established PAH animal models (60). Further in vitro and in vivo experiments 
with those co-activators are currently being conducted in our laboratory. As we 
performed the drug screening in a murine myoblast cell line, further validation 
experiments in PAH target cells (ECs and SMCs) are needed. We also need to 
verify the effects of these compounds in PAH patient cells, and finally to test 
them in PAH animal models.  
In summary, none of above treatment strategies is currently approved for 
patients; some of them are tested in clinical trials. Activating BMP signaling as 
therapeutic approach for PAH is challenging due to the complexity of BMP 
signaling. Thus, deeper understanding of the molecular mechanisms and 
regulation of the BMP signaling pathway, and also other signal pathways 
involved in PAH, are urgently needed and would be helpful for the development 




Figure 3: Compound 6 and compound 13 are coactivators of BMP signaling. A, 
BRE-luciferase activity assay testing different concentrations of BMP9 in C2C12 cells. 
135 ng/ml BMP9 (EC-20) was applied in later experiments. B, BRE-luciferase activity 
testing compound 6 (10 μM), compound 13 (10 μM) with or without BMP9 (135 ng/ml) 
in C2C12 cells. C, pSMAD1/5 analysis following the treatment with only BMP9 (135 
ng/ml), BMP9 with compound 6 (10 μM), or compound 13 (10 μM) atdifferent time 
points. D, ALP staining of C2C12 cells cultured with BMP9 (135 ng/ml) and/or 
compound 6 or 13 (10 μM) on day 3 of differentiation with 2% FBS. 
 
6.4 Soluble endoglin modifies signaling by BMP 9 
BMP9 is a TGF-β ligand mainly produced by the liver which can circulate in its 
active form (79). The activity of BMPs is modulated by co-receptors and 
soluble antagonists like noggin and other regulators that have been discussed in 
chapter 1. Crossveinless 2 (CV2 or BMPER) is the only known regulator of 
BMP9; its functions as an activator or an inhibitor of BMP signaling rely in part 
on the concentration of CV2 (80, 81). In chapter 5, we have described that the 
role of soluble endoglin (sEng) in regulating BMP9 signaling. 
    Endoglin is homodimeric transmembrane glycoprotein that functions as a 
co-receptor for TGF-β signaling (82). It is essential for cardiovascular 
development and mutations in endoglin are associated with the vascular disease 
HHT characterized by telangiectasias and arteriovenous malformations (83, 84). 
sEng sheds from the membrane bound endoglin upon proteolytic cleavage by 
matrix metalloproteinase (MMP) 14 at position 586 in carcinoma tissues (85). 
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sEng is associated with preeclampsia, a pregnancy associated vascular disorder 
characterized by hypertension and proteinuria (86). The expression level of 
sEng correlates with disease severity and dramatically falls after delivery (86). 
Rat preeclampsia models with increasing expression of sEng recapitulate the 
elevated mean arterial pressure, vascular damage in the placenta as well as other 
preeclampsia symptoms (86, 87). Besides preeclampsia, the level of sEng in 
plasma might be a marker for diagnosis of the vascular disorder PAH. Malhotra 
et al. found in PAH patients elevated sEng and soluble vascular endothelial 
growth factor receptor (VEGFR) 1, another anti-angiogenic marker (88).  
BMP9 binds to ALK1 and endoglin in ECs and activates downstream 
signaling by phosphorylating SMAD1/5 (77). Recently researches showed that 
sEng directly can bind to BMP9 and sequester its activity (11, 89). However, we 
have shown in chapter 5 that sEng may have dual effects on BMP9 at lower 
concentrations. Membrane bound endoglin can both promote and inhibit 
SMAD1/5 and SMAD2/3 downstream TGF-β signaling, which relies on the 
endoglin expression levels and the receptors (e.g. ALK1 and ALK5) involved in 
certain cellular contexts (90-92). sEng might work as a ligand trap depending on 
the dosage of sEng and TGF-β family receptors as well.  
    Endoglin is a key mediator of BMP9 induced angiogenic signaling (93, 94), 
but the molecular mechanism is still not complete clear. The role of BMP9 in 
angiogenesis largely relies on the dosage and the ECs types targeted. 
Scharpfenecker et al. found that BMP9 inhibits basic fibroblast growth factor 
(bFGF) induced ECs proliferation and migration and blocks vascular 
endothelial growth factor (VEGF) induced angiogenesis in vitro (78). However, 
in another report Suzuki et al. showed that BMP9 promotes angiogenesis in 
matrigel plug assays in vivo and also enhances tumor angiogenesis in a 
pancreatic carcinoma xenograft model (95). sEng specifically binds to BMP9 to 
inhibit VEGF-induced vessel formation in vivo (89), which indicates that sEng 
scavenges BMP9 or BMP10 ligands to disturb the balance for normal 
angiogenesis.   
 
6.5 Concluding remarks 
The studies in this thesis focused on the role of BMP signaling in disease 
contexts and identification of novel strategies for treatment of FOP and PAH 
based on the understanding of disease pathology. Despite the misregulation of 
BMP signaling in FOP (overactive) and PAH (insufficient), local inflammation 
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also plays a critical role in disease progressions. In chapter 2 and 3, a FOP 
hiPSC disease model and a mouse Alk2 AON were introduced. Although we 
found that targeting ALK2 gene is sufficient to block osteoblast differentiation 
in vitro in the studies in chapter 2 and 3, experiments to test the combination 
effects of ALK2 and inflammation inhibitors in our disease model might be 
beneficial for the development of novel treatment strategies. By screening FDA 
proved drug libraries, we have shown in chapter 4 that the chemical compound 
FK506 can activate BMP signaling via a dual mechanism of action, as a 
calcineurin inhibitor and BMP activator. FK506 has been reported to be 
beneficial for end-stage PAH patients (73). The research on PAH indicated that 
the combination of BMP signaling modulators with other modulators, especially 
of local inflammation, would be helpful for the development of efficient 
treatments for PAH and probably FOP. In chapter 5, we have demonstrated 
that sEng regulates BMP9 activity. Revealing the molecular mechanism of the 
interactions of sEng and BMP9 with other TGF-β/SMAD signaling components 
could be relevant for the development of diagnostic tools and treatment of 
human diseases, especially PAH and preeclampsia. 
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Bone morphogenetic proteins (BMPs) are multifunctional regulators in 
embryonic development and tissue homeostasis. Disruptions in BMP signaling 
lead to various diseases, such as skeletal diseases, vascular diseases and cancer. 
Studies in this thesis mainly focused on the role of BMP signaling in disease 
contexts, and the identification of possible novel treatments for fibrodysplasia 
ossificans progressiva (FOP) and pulmonary arterial hypertension (PAH) based 
on the understanding of the disease pathology.  
FOP is a rare disease which severely affects the health condition and life 
span of the patients. The majority of FOP research was conducted in murine cell 
lines or mouse models and some were conducted in human material obtained 
from blood or milk teeth. In order to mimic the disease phenotypes in human 
cells, especially in heterotopic ossification progenitor cells, we have established 
human induced pluripotent stem cell (hiPSC) lines from FOP patients samples. 
Our FOP iPSC disease model recreated disease phenotypes by showing 
enhanced mineralization in FOP pericytes and impaired endothelial cell (EC) 
differentiation ability, which might be due to activated SMAD signaling. 
Furthermore, FOP iPSC derived pericytes could be applied for drug 
development for FOP (chapter 2). The research on FOP iPSCs indicated that 
this model might be a useful tool for high-throughput screening and verification 
of new disease targets. 
The discovery in 2006 that an activating mutation in the BMP type I 
receptor activin receptor-like kinase (ALK) 2 is associated with FOP provided a 
druggable target for the development of FOP treatment. One option is to block 
the aberrant and enhanced ALK2 signaling with chemical compounds targeting 
the ALK2 kinase activity. Another possible strategy is to knockdown mutant 
ALK2 expression by anti-sense oligonucleotides (AON) or siRNAs. Our study 
in chapter 3 showed that an ALK2 AON can specifically target exon 8 of 
wild-type mouse Alk2 in vitro and decrease ALK2 expression in various ECs. 
Furthermore, the ALK2 AON could downregulate BMP/SMAD signaling and 
block osteoblast differentiation in ECs. 
    In contrast to FOP, BMP signaling is reduced in PAH. By screening an 
FDA approved drug library, we identified in chapter 4 the chemical compound 
FK506 as an activator of BMP signaling. By binding the 12-kDa 
Summary 
168 
FK506-binding protein FKBP12, FK506 was found to activate BMP signaling 
via a dual mechanism, as a calcineurin inhibitor and a derepressor of the BMP 
type I receptors. In addition, low-dose FK506 could rescue EC dysfunction and 
improve EC targets of BMP signaling, such as apelin expression, in several 
experimental animal models. Thus, FK506 is a valuable drug in treating PAH as 
well as other vascular diseases with defective BMP signaling.  
In chapter 5, we have shown that soluble endoglin (sEng) can regulate 
BMP9 activity. sEng together with BMP9 can bind to ALK1 (and possibly 
transforming growth factor β (TGF-β) receptor type 2) and participate in 
signaling itself at the cell membrane. sEng and BMP9 are two important TGF-β 
signaling pathway components for the maintenance of vascular homeostasis, 
and are also involved in inflammatory responses in healthy and pathological 
conditions. Research to reveal the molecular mechanism of the interactions of 
sEng and BMP9 with the different membrane receptors would be beneficial for 
developing novel diagnosis markers and therapeutic strategies for vascular 
disorders, especially PAH and preeclampsia.  
In summary, this thesis describes how disrupted BMP signaling is 
implicated in the pathology of FOP and PAH. In addition to BMP signaling, 
other environmental factors like local inflammatory stimuli are involved in 
disease progression, and relevant for the development of effective therapies. 
Finally, alternations in BMP signaling are involved in various other human 
diseases in addition to the diseases discussed in this thesis. Thus, research on 
developing effective treatments for FOP and PAH might have potential 
therapeutic value for other BMP signaling related disorders and help to 





Bot morfogenetische proteinen (BMPs) zijn multifunctionele regulatoren tijdens 
de embryonale ontwikkeling en bij weefselhomeostase. Verstoringen in BMP 
signaaltransductie kunnen verschillende ziektes veroorzaken, zoals 
skeletafwijkingen, vaatziekten en kanker. De studies in dit proefschrift waren 
voornamelijk gericht op de rol van BMP signalering bij een aantal ziektes, en op 
het identificeren van mogelijke nieuwe behandelingen voor fibrodysplasia 
ossificans progressiva (FOP) en pulmonaire arteriële hypertensie (PAH), door 
beter inzicht te krijgen in de pathologie van deze ziektes.  
FOP (―bindweefsel progressief omgezet in bot‖) is een zeldzame ziekte 
met ernstige effecten op de gezondheid en levensverwachting van de patiënten. 
Het merendeel van het FOP onderzoek is verricht in cellijnen afkomstig van 
muizen of in muismodellen, en slechts een aantal studies zijn gedaan m.b.v. 
humaan materiaal, afkomstig uit bloed of melktanden. Om het fenotype van de 
ziekte na te kunnen bootsen in humane cellen, met name in zogenaamde 
heterotope ossificatie voorloper cellen, hebben we humane geïnduceerde 
pluripotente stamcellen (hiPSC) gemaakt uit FOP patiënten materiaal. In dit 
FOP iPSC ziekte model hebben we diverse aspecten van de ziekte kunnen laten 
ontstaan en/of aantonen, zoals verhoogde mineralisatie in FOP pericyten en 
verstoorde differentiatie van endotheel cellen (EC), wat het gevolg zou kunnen 
zijn van geactiveerde SMAD signaaltransductie. Bovendien konden van iPSC 
afgeleide FOP pericyten gebruikt worden om drugs tegen FOP te ontwikkelen 
(hoofdstuk 2). Het onderzoek liet zien dat dit FOP iPSC model een goed 
testsysteem zou kunnen worden voor high-throughput screening en verificatie 
van nieuwe FOP targets.  
De ontdekking in 2006 dat een activerende mutatie in de BMP type I 
receptor activin receptor-like kinase (ALK) 2 geassocieerd is met FOP, leverde 
meteen een potentieel target eiwit op voor FOP drug ontwikkeling. Een 
potentiële manier om FOP aan te pakken is het remmen van de afwijkende en 
versterkte signaaloverdracht door het gemuteerde ALK2, via chemische stoffen 
gericht tegen de ALK2 kinase activiteit. Een andere mogelijke strategie is het 
om via zogenaamde knockdown technieken de expressie van het mutante ALK2 
te verlagen met behulp van anti-sense oligonucleotiden (AONs) of siRNAs. 
Onze studie in hoofdstuk 3 liet zien dat een ALK2 AON specifiek exon 8 van 
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wild-type Alk2 kan aanpakken en daarmee ALK2 expressie in verscheidene 
typen endotheelcellen (EC) kan verlagen. Bovendien kon de ALK2 AON 
signaaltransductie door BMP/SMAD remmen en osteoblast differentiatie van 
ECs blokkeren. 
In tegenstelling tot FOP is bij pulmonaire arteriële hypertensie (PAH) de 
signaaltransductie door BMP/SMAD juist verlaagd. Door het testen van 
FDA-goedgekeurde drugs, hebben we in hoofdstuk 4 de chemische stof FK506 
kunnen identificeren als een activator van BMP signaaltransductie. We vonden 
dat FK506 via binding aan het 12-kDa FK506-bindende eiwit FKBP12 op twee 
verschillende manieren BMP signalering kan activeren, als een remmer van het 
fosfatase calcineurin en als een derepressor van BMP type I receptoren. Tevens 
vonden we dat een lage dosis FK506 in een aantal experimentele 
diermodelsystemen endotheelcel dysfunctie kan herstellen en expressie van 
BMP targets, zoals bijvoorbeeld apeline, kan verhogen. Dit geeft aan dat FK506 
een waardevolle drug kan zijn voor het behandelen van PAH en andere 
vasculaire ziektes met verlaagde BMP signaaltransductie.  
In hoofdstuk 5 hebben we aangetoond dat de oplosbare variant van het 
eiwit endogline (sEng) de activiteit van BMP9 kan reguleren. sEng kan samen 
met BMP9 aan de type I receptor ALK1 binden (en mogelijk ook aan de type 2 
receptor van transforming growth factor β (TGF-β), en daarbij gebonden aan de 
celmembraan participeren in het signaleringsproces. sEng en BMP9 zijn twee 
belangrijke componenten van de TGF-β signaaltransductie cascade. BMP9 
zorgt voor handhaving van de vasculaire homeostase, en is ook betrokken bij 
inflammatoire responsen in gezonde en pathologische omstandigheden. 
Onderzoek naar de moleculaire mechanismen waarmee sEng en BMP9 aan de 
verschillende membraan receptoren binden kan daarom bijdragen aan het 
identificeren van nieuwe markers voor diagnose, en aan ontwikkeling van 
therapeutische strategiën voor vasculaire ziektes, met name PAH en 
preeclampsia.  
Samengevat beschrijft dit proefschrift hoe verstoringen in BMP 
signaaloverdracht betrokken zijn bij (de pathologie van) FOP en PAH. Naast 
BMP signalering zijn ook omgevingsfactoren zoals lokale inflammatoire stimuli 
betrokken bij de progressie van deze ziektes, en dus relevant voor het 
ontwikkelen van effectieve behandelingen. Tenslotte dient benadrukt te worden 
dat verstoringen in BMP signalering ook betrokken zijn bij verscheidene andere 
humane ziekten. Daarom kan het ontwikkelen van effectieve therapie voor FOP 
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en PAH ook van therapeutische waarde zijn voor andere BMP-gerelateerde 
ziekten, en helpen om de rol van BMP signaaloverdracht in verschillende 
cellulaire contexten te begrijpen.  
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A ActR2A Activin receptor type II A 
 ALK Activin receptor-like kinase 
 ALP Alkaline phosphatase  
 AMH Anti-müllerian hormone 
 AONs Antisense oligonucleotides 
 Apo Apolipoprotein 
 AV Aortic valve 
 AVMs Arteriovenous malformation 
B BAECs Bovine aortic endothelial cells 
 BAMBI BMP and activin membrane-bound inhibitor 
 bFGF Basic fibroblast growth factor 
 BMPs Bone morphogenetic proteins 
 BMPER BMP endothelial cell precursor derived regulator 





 BSP Bone sialoprotein 
C COL 1 COLLAGEN type I  
 cox-2 Cyclo-oxygenase-2 
 CV2 Cross-veinless 2 or BMPER 
D DAN Differential screening-selected gene aberrative in 
neuroblastoma 
 Dll4 Delta-like 4 
 DMD Duchenne muscular dystrophy  
 DSS 
DTT 
Disuccinimidyl suberate  
dithiothreitol 
E ECs Endothelial cells 
 EC-20 
ECD 
20% of maximal response  
extracellular domain 
 EndoMT Endothelial to mesenchymal transition 
 eNOS Endothelial nitric-oxide synthase 




Embryonic stem cells 
 ETV2 Early endothelial transcription factor  
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Fetal bovine serum 
US food and drug administration 
Fibroblast growth factor 
 FKBP12 FK-binding protein-12 
 FOP Fibrodysplasia ossificans progressiva 
 FPAH Hereditary or familial PAH 
G GAGs Glycosaminoglycans 
 GDFs Growth and differentiation factors 
 GS Glycine-serine-rich 
H HEK293 
hESC 
human embryonic kidney 293 cells  




Hereditary hemorrhagic telangiectasia 
histidine-tag 
Human immunodeficiency virus 
 HLH Helix-loop-helix  
 HMEC-1 Human microvascular endothelial cells  
 HO Heterotopic ossification  




Sporadic or idiopathic PAH 
 iPSCs Induced pluripotent stem cells 




Potassium channel subfamily K member 3  
L LAP Latency associated peptide 
 LBD Ligand binding domain 
 LDL Low-density lipoprotein 
 LDN LDN-193189 
 LTBP Latent TGF-β binding protein 
M MCs Mesenchymal cells 




Matrix metallo proteinse 14 
 mvPAECs Microvessel PAECs 
N NFATs Nuclear factor of activated T cells 





Non-steroidal anti-inflammatory drugs 
O OSC Osteocalcin  
P PAEC 
PAH 
Pulmonary artery endothelial cells 
Pulmonary arterial hypertension 
 PASMCs Pulmonary artery SMCs  
 PDGF-BB Platelet-derived growth factor subunit BB 
 PDGFR Platelet-derived growth factor receptor 
 PEI Polyethyleneimine  
 PKC Protein kinase C 
 PRDC 
pSMAD1/5 
Protein related to DAN and Cerberus 
Phospho-SMAD1/5 
 PTPN14 Tyrosine-protein phosphatase non-receptor type 
14 
Q qPCR Quantitative real-time PCR  
R RGM Repulsive guidance molecule 
 ROS Reactive oxygen species 
 R-Smads Receptor-regulated Smads 
 RVH Right ventricular hypertrophy  




sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
 sEng Soluble endoglin  
 SMCs Smooth muscle cells 
T TGF-β Transforming growth factor-β 
 TGFβR2 TGF-β receptor 2  
 TM Transmembrane domain 
U USAG-1 Uterine sensitization-associated gene-1 
V VEGF Vascular endothelial growth factor 
 VEGFR2 Vascular endothelial growth factor receptor 2  
 vWF Von Willebrand factor 
 
 
 
